
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-manuscript.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Structure Activity Relationship Towards Design of Cryptosporidium Specific Thymidylate Synthase Inhibitors - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F39205000046A72D6B9BDD.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="nihpa" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC6829050/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829050/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="European journal of medicinal chemistry" /><meta name="citation_title" content="Structure Activity Relationship Towards Design of Cryptosporidium Specific Thymidylate Synthase Inhibitors" /><meta name="citation_author" content="D.J. Czyzyk" /><meta name="citation_author_institution" content="Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA" /><meta name="citation_author" content="M. Valhondo" /><meta name="citation_author_institution" content="Department of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA" /><meta name="citation_author" content="L. Deiana" /><meta name="citation_author_institution" content="Department of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA" /><meta name="citation_author" content="J. Tirado-Rives" /><meta name="citation_author_institution" content="Department of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA" /><meta name="citation_author" content="W.L. Jorgensen" /><meta name="citation_author_institution" content="Department of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA" /><meta name="citation_author" content="K.S. Anderson" /><meta name="citation_author_institution" content="Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA" /><meta name="citation_author_institution" content="Department of Molecular Biophysics and Biochemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA" /><meta name="citation_publication_date" content="2019/12/12" /><meta name="citation_volume" content="183" /><meta name="citation_firstpage" content="111673" /><meta name="citation_doi" content="10.1016/j.ejmech.2019.111673" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC6829050/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC6829050/" /><meta name="citation_pmid" content="31536894" /><meta name="DC.Title" content="Structure Activity Relationship Towards Design of Cryptosporidium Specific Thymidylate Synthase Inhibitors" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="NIH Public Access" /><meta name="DC.Contributor" content="D.J. Czyzyk" /><meta name="DC.Contributor" content="M. Valhondo" /><meta name="DC.Contributor" content="L. Deiana" /><meta name="DC.Contributor" content="J. Tirado-Rives" /><meta name="DC.Contributor" content="W.L. Jorgensen" /><meta name="DC.Contributor" content="K.S. Anderson" /><meta name="DC.Date" content="2019 Dec 1" /><meta name="DC.Identifier" content="10.1016/j.ejmech.2019.111673" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Structure Activity Relationship Towards Design of Cryptosporidium Specific Thymidylate Synthase Inhibitors" /><meta property="og:type" content="article" /><meta property="og:description" content="Cryptosporidiosis is a human gastrointestinal disease caused by protozoans of the genus Cryptosporidium, which can be fatal in immunocompromised individuals. The essential enzyme, thymidylate synthase (TS), is responsible for de novo synthesis of deoxythymidine ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829050/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6829050/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC6829050
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC6829050/pdf/nihms-1051114.pdf" class="int-view">PDF (3.3M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/6829050/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/6829050/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="6829050" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6829050%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="5THP198bdnnoCitBIC56tRGDRe3AuE3nHxs3ENclSebpM8CkBA8RTiAAqIUHtaYm">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6829050%2F&amp;text=Structure%20Activity%20Relationship%20Towards%20Design%20of%20Cryptosporidium%20Specific%20Thymidylate%20Synthase%20Inhibitors" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6829050%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829050/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC6829050/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/31536894/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC6829050/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/31536894/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC6829050/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/6829050/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC6829050
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-nihpa.png" alt="Logo of nihpa" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="https://www.hhs.gov/open/public-access-guiding-principles/index.html" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div><span id="pmcmata">Eur J Med Chem.</span> Author manuscript; available in PMC 2020 Dec 1.</div><div></div><div class="final-form"><em>Published in final edited form as:</em></div><div class="final-citation"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=31536894" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Eur J Med Chem. 2019 Dec 1; 183: 111673. </a></div><span class="fm-vol-iss-date">Published online 2019 Sep 4. </span> <span class="doi"><span>doi: </span><a href="//doi.org/10.1016%2Fj.ejmech.2019.111673" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1016/j.ejmech.2019.111673</a></span></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC6829050</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS1051114</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31536894">31536894</a></div></div></div><h1 class="content-title">Structure Activity Relationship Towards Design of <em>Cryptosporidium</em> Specific Thymidylate Synthase Inhibitors</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Czyzyk%20D%5BAuthor%5D" class="affpopup" co-rid="_co_idm140246380960224" co-class="co-affbox">D.J. Czyzyk</a>,<sup>a,</sup><sup>&#x02021;</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Valhondo%20M%5BAuthor%5D" class="affpopup" co-rid="_co_idm140246377900832" co-class="co-affbox">M. Valhondo</a>,<sup>b,</sup><sup>&#x02021;</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Deiana%20L%5BAuthor%5D" class="affpopup" co-rid="_co_idm140246371293952" co-class="co-affbox">L. Deiana</a>,<sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tirado-Rives%20J%5BAuthor%5D" class="affpopup" co-rid="_co_idm140246371291968" co-class="co-affbox">J. Tirado-Rives</a>,<sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Jorgensen%20W%5BAuthor%5D" class="affpopup" co-rid="_co_idm140246371640288" co-class="co-affbox">W.L. Jorgensen</a>,<sup>b,</sup><sup>*</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Anderson%20K%5BAuthor%5D" class="affpopup" co-rid="_co_idm140246380890496" co-class="co-affbox">K.S. Anderson</a><sup>a,</sup><sup>c,</sup><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140246380960224"><h3 class="no_margin">D.J. Czyzyk</h3><p><sup>a</sup>Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Czyzyk%20D%5BAuthor%5D">D.J. Czyzyk</a></div></div><div id="_co_idm140246377900832"><h3 class="no_margin">M. Valhondo</h3><p><sup>b</sup>Department of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Valhondo%20M%5BAuthor%5D">M. Valhondo</a></div></div><div id="_co_idm140246371293952"><h3 class="no_margin">L. Deiana</h3><p><sup>b</sup>Department of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Deiana%20L%5BAuthor%5D">L. Deiana</a></div></div><div id="_co_idm140246371291968"><h3 class="no_margin">J. Tirado-Rives</h3><p><sup>b</sup>Department of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Tirado-Rives%20J%5BAuthor%5D">J. Tirado-Rives</a></div></div><div id="_co_idm140246371640288"><h3 class="no_margin">W.L. Jorgensen</h3><p><sup>b</sup>Department of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Jorgensen%20W%5BAuthor%5D">W.L. Jorgensen</a></div></div><div id="_co_idm140246380890496"><h3 class="no_margin">K.S. Anderson</h3><p><sup>a</sup>Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA</p><p><sup>c</sup>Department of Molecular Biophysics and Biochemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Anderson%20K%5BAuthor%5D">K.S. Anderson</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140246377928912_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140246377928912_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140246377928912_ai" style="display:none"><div class="fm-affl" id="A1"><sup>a</sup>Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA</div><div class="fm-affl" id="A2"><sup>b</sup>Department of Chemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA</div><div class="fm-affl" id="A3"><sup>c</sup>Department of Molecular Biophysics and Biochemistry, Yale University, 225 Prospect Street, PO Box 208107, New Haven, CT 06520, USA</div><div id="FN1"><sup>&#x02021;</sup>Authors have contributed equally to this work.</div><div id="CR1"><sup>*</sup>Corresponding authors. Tel.: +1 203 432 6278; fax: +1 203 432 6299 (W.L.J.); Tel.: +1 203 785 7670; fax: +1 203 785 7670 (K.S.A.)., <a href="mailto:dev@null" data-email="ude.elay@nesnegroj.mailliw" class="oemail">ude.elay@nesnegroj.mailliw</a> (W.L. Jorgensen), <a href="mailto:dev@null" data-email="ude.elay@nosredna.nerak" class="oemail">ude.elay@nosredna.nerak</a> (K.S. Anderson)</div></div><div class="fm-article-notes half_rhythm"></div><div class="permissions half_rhythm hide" id="idm140246377928912_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">PMC Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm" role="complementary" aria-label="Related or updated information about this article."><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=31536894" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Eur J Med Chem</a></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp.</strong></div><div><a href="/pmc/articles/PMC6829050/bin/NIHMS1051114-supplement-Supp.pdf" data-ga-action="click_feat_suppl">NIHMS1051114-supplement-Supp.pdf</a><span style="color:gray"> (3.5M)</span></div><div class="small guid">GUID: 6E4FF50D-C37E-4766-8DAE-E9325D144919</div></div></dd></dl></div><div id="ABS1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="ABS1title">Abstract</h2><!--article-meta--><div><p id="P2" class="p p-first-last">Cryptosporidiosis is a human gastrointestinal disease caused by protozoans of the genus <em>Cryptosporidium</em>, which can be fatal in immunocompromised individuals. The essential enzyme, thymidylate synthase (TS), is responsible for <em>de novo</em> synthesis of deoxythymidine monophosphate. The TS active site is relatively conserved between <em>Cryptosporidium</em> and human enzymes. In previous work, we identified compound <strong>1</strong>, (2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidin-methyl-phenyl-L-glutamic acid), as a promising selective <em>Cryptosporidium hominis</em> TS (<em>Ch</em>TS) inhibitor. In the present study, we explore the structure-activity relationship around <strong>1</strong> glutamate moiety by synthesizing and biochemically evaluating the inhibitory activity of analogues against <em>Ch</em>TS and human TS (hTS). X-Ray crystal structures were obtained for compounds bound to both <em>Ch</em>TS and hTS. We establish the importance of the 2-phenylacetic acid methylene linker in optimally positioning compounds <strong>23</strong>, <strong>24</strong>, and <strong>25</strong> within the active site. Moreover, through the comparison of structural data for <strong>5</strong>, <strong>14</strong>, <strong>15</strong>, and <strong>23</strong> bound in both <em>Ch</em>TS and hTS identified that active site rigidity is a driving force in determining inhibitor selectivity.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">SAR study, Antifolate, <em>Cryptosporidium hominis</em>, Thymidylate synthase, X-ray crystallography</span></div></div><div id="ABS2" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="ABS2title">Graphical Abstract</h2><!--article-meta--><div><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246374684832"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0001.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0001.jpg" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0001.jpg" /></div><p></p></div></div><div id="S1" class="tsec sec"><h2 class="head no_bottom_margin" id="S1title">1. Introduction</h2><p id="P4" class="p p-first">Cryptosporidiosis is a human gastrointestinal illness caused by protozoans of the genus <em>Cryptosporidium</em> and is the second leading cause of diarrheal disease and deaths in children &#x0003c;2 years old across Africa and South Asia.[<a href="#R1" rid="R1" class=" bibr popnode">1</a>&#x02013;<a href="#R3" rid="R3" class=" bibr popnode">3</a>] Additionally, outbreaks have occurred in industrialized countries, with major outbreaks occurring in Milwaukee and New York City.[<a href="#R4" rid="R4" class=" bibr popnode">4</a>, <a href="#R5" rid="R5" class=" bibr popnode">5</a>] Among the several <em>Cryptosporidium</em> species that can cause human disease, <em>Cryptosporidium hominis</em> (<em>C. hominis</em>) and <em>Cryptosporidium parvum</em> (<em>C. parvum</em>) are responsible for 90 % of the human disease and share a high sequence identity (95&#x02013;97%) at the genome level.[<a href="#R6" rid="R6" class=" bibr popnode">6</a>&#x02013;<a href="#R8" rid="R8" class=" bibr popnode">8</a>] <em>Cryptosporidium</em> is capable of surviving without a host for many months at a wide range of temperatures.[<a href="#R9" rid="R9" class=" bibr popnode">9</a>] Infection occurs when an individual ingest oocyst in contaminated food or water. Healthy individuals experience gastrointestinal distress that can last for two or more weeks. However, infection rates are higher and more severe in children, the elderly, and immunocompromised individuals, where it leads to severe and life-threatening wasting disease.[<a href="#R8" rid="R8" class=" bibr popnode">8</a>&#x02013;<a href="#R10" rid="R10" class=" bibr popnode">10</a>] Currently, nitazoxanide is the only FDA-approved drug for the treatment of cryptosporidiosis.[<a href="#R10" rid="R10" class=" bibr popnode">10</a>] However, the efficacy of nitazoxanide is variable in immunocompetent patients, limited in children, and ineffective in immunocompromised patients, indicating a pressing need for improved therapies.[<a href="#R1" rid="R1" class=" bibr popnode">1</a>, <a href="#R9" rid="R9" class=" bibr popnode">9</a>, <a href="#R10" rid="R10" class=" bibr popnode">10</a>]</p><p id="P5">The essential enzymes, thymidylate synthase (TS) and dihydrofolate reductase (DHFR), have long been chemotherapeutic targets for cancer and infectious diseases.[<a href="#R11" rid="R11" class=" bibr popnode">11</a>, <a href="#R12" rid="R12" class=" bibr popnode">12</a>] In humans and most organisms, these two enzymes exist as separate polypeptide chains, whereas in <em>Cryptosporidium</em> both activities are encoded into a single bifunctional enzyme TS-DHFR.[<a href="#R13" rid="R13" class=" bibr popnode">13</a>, <a href="#R14" rid="R14" class=" bibr popnode">14</a>] TS-DHFR has been extensively characterized and shown to be a promising target for the development of inhibitors.[<a href="#R12" rid="R12" class=" bibr popnode">12</a>, <a href="#R15" rid="R15" class=" bibr popnode">15</a>, <a href="#R16" rid="R16" class=" bibr popnode">16</a>] TS catalyzes the <em>de novo</em> synthesis of deoxythymidine monophosphate (dTMP) from deoxyuridine monophosphate (dUMP) and the cofactor 5,10-methylenetetrahydrofolate (CH<sub>2</sub>H<sub>4</sub>F).[<a href="#R11" rid="R11" class=" bibr popnode">11</a>, <a href="#R17" rid="R17" class=" bibr popnode">17</a>] The dihydrofolate produced as the other product of the TS reaction is then reduced by DHFR utilizing the cofactor NADPH, to produce tetrahydrofolate and NADP<sup>+</sup>.[<a href="#R11" rid="R11" class=" bibr popnode">11</a>, <a href="#R18" rid="R18" class=" bibr popnode">18</a>] The TS active site is highly conserved for both the <em>C. hominis</em> and the human enzymes, however there are two distinct, variant amino acids in the region of the binding pocket that interact with the glutamate moiety of folate.[<a href="#R19" rid="R19" class=" bibr popnode">19</a>] In <em>C. hominis</em> TS (<em>Ch</em>TS) these residues are A287 and S290, versus F80 and G83 in human TS (hTS), respectively.[<a href="#R11" rid="R11" class=" bibr popnode">11</a>, <a href="#R19" rid="R19" class=" bibr popnode">19</a>] Our earlier kinetic studies with bifunctional <em>Ch</em>TS-DHFR together with mutational and structural analyses identified this novel folate binding region containing the two variant residues, A287 and S290. These residues are critical to properly position the folate substrate for efficient interaction with the second substrate dUMP for methyl transfer during catalysis.[<a href="#R11" rid="R11" class=" bibr popnode">11</a>, <a href="#R20" rid="R20" class=" bibr popnode">20</a>] In other species such as human, a bulky phenylalanine residue is located in this region. These studies suggested that this region might be exploited to build in increased inhibitor specificity and affinity for the <em>Ch</em>TS-DHFR.</p><p id="P6">In previous work we identified compound <strong>1</strong> (2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidin-methylphenyl-L-glutamic acid), originally designed as an anticancer agent, that proved to be a promising <em>Ch</em>TS inhibitor (see <a href="/pmc/articles/PMC6829050/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>).[<a href="#R12" rid="R12" class=" bibr popnode">12</a>, <a href="#R16" rid="R16" class=" bibr popnode">16</a>, <a href="#R21" rid="R21" class=" bibr popnode">21</a>] We reported the X-ray crystal structure of <em>Ch</em>TS complexed with <strong>1</strong>, in combination with inhibition activity of <strong>1</strong> demonstrating a 6-fold greater selectivity for the <em>Ch</em>TS over the hTS enzyme.[<a href="#R12" rid="R12" class=" bibr popnode">12</a>] This data suggested that these two variant active site residues might play an important role in determining selectivity. This concept was further supported by our recent work in which the X-ray crystal structure of <strong>1</strong> complexed with hTS was determined.[<a href="#R19" rid="R19" class=" bibr popnode">19</a>] The variant <em>Ch</em>TS residue S290 forms a hydrogen bond with the carboxylate of the glutamate moiety of <strong>1</strong> as well as hydrophobic interactions with A287, stabilizing this portion of compound <strong>1</strong> within the TS active site. In the case of hTS, a hydrogen bond with compound <strong>1</strong> glutamate moiety does not form, but rather hydrophobic interactions with F80 or interaction with solvent.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC6829050/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246381745040"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0010.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0010.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0010.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246381745040"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1.</a></div><!--caption a7--><div class="caption"><p id="P175">Lead optimization guided by crystal structure of compound <strong>1</strong> bound to <em>Ch</em>TS. A. Compound <strong>1</strong> bound in <em>Ch</em>TS active site, hydrogen bond between &#x003b3;-carboxylate with S290 denoted by black dotted line. B. Structure of compound <strong>1</strong> and scaffolds used for lead optimization.</p></div></div></div><p id="P7" class="p p-last">In this present study, we describe a computational and structure-guided lead optimization strategy to explore the structure-activity-relationship (SAR) of compound <strong>1</strong> with the aim of identifying compounds which take advantage of the variant <em>Ch</em>TS and hTS active site residues in an effort to increase potency and selectivity. A series of 26 compounds were designed and synthesized for this effort. The compounds were tested for inhibitory activity against both <em>Ch</em>TS and hTS enzymes. A total of 12 X-ray crystal structures were determined for a number of these compounds bound in the <em>Ch</em>TS active site to evaluate interactions that may be important for inhibitor potency. Additionally, we compare the X-ray crystal structures of four compounds bound in both <em>Ch</em>TS and hTS active sites to understand inhibitor selectivity.</p></div><div id="S2" class="tsec sec"><h2 class="head no_bottom_margin" id="S2title">2. Results and Discussion</h2><div id="S3" class="sec sec-first"><h3 id="S3title">2.1. Lead optimization guided by computational and structural analyses</h3><p id="P8" class="p p-first-last">The three-dimensional structure of compound <strong>1</strong> bound the <em>Ch</em>TS active site is shown in <a href="/pmc/articles/PMC6829050/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1(A)</span></a> along with several scaffolds showing potential regions of the molecule to be targeted in the lead optimization efforts (B). Analysis of the crystal structure of compound <strong>1</strong> indicates that the accommodation of the pyrrolo[2,3-d]pyrimidine fragment of <strong>1</strong> in the <em>Ch</em>TS active site is nearly ideal. The pyrrolo[2,3-d]pyrimidine &#x003c0;-stackes with the uracil ring of the FdUMP, with hydrogen bonds of normal lengths for all of the heteroatoms except N3 (its closest contact is 4.32 &#x000c5; with the side-chain N of N319), and the central benzyl ring is well situated in a hydrophobic region and has an edge-to-face aryl-aryl interaction with F433. However, the amide linker moiety and its attachments are not making notable contacts. The &#x003b1;&#x02013;carboxylate of the glutamate moiety has one oxygen 4.30 &#x000c5; from the ammonium group of K284, while the &#x003b3;&#x02013;carboxylate forms a hydrogen bond with S290 (<a href="/pmc/articles/PMC6829050/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>). Thus, our initial focus for analogues was on the eastern region of compound <strong>1</strong>. Several possibilities were suggested by initial modeling based on the <em>Ch</em>TS crystal structure with <strong>1</strong> (PDB: 40QE).[<a href="#R12" rid="R12" class=" bibr popnode">12</a>] These include modifications which would retain the &#x003b3;&#x02013;carboxylate to preserve the hydrogen bond with S290 while substituting the &#x003b1;&#x02013;carboxylic acid with an aryl ring to interact with hydrophobic pocket, changes to the amide linker, and additional functionalization of the aryl ring (Scaffold A, <a href="/pmc/articles/PMC6829050/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1B</span></a>). Modeling suggests that further elaboration of the aryl ring to substituted biphenyl compounds would also be viable (Scaffold B, <a href="/pmc/articles/PMC6829050/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1B</span></a>). Moreover, it has been shown that biphenyls are twisted 30&#x000b0; to provide some conformational variety.[<a href="#R22" rid="R22" class=" bibr popnode">22</a>] This substitution pattern would feature a smaller group that projects towards K284, and a larger one for the opening between A287 and S290. The larger group could be used to control properties such as solubility as its terminus can project into the aqueous solvent. An example of a computed biphenyl structure is illustrated in <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S1</a>.</p></div><div id="S4" class="sec"><h3 id="S4title">2.2. Chemistry</h3><p id="P9" class="p p-first-last">A general outline of our synthetic strategy for the preparation of 2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidin-methyl-phenyl-L-glutamic acid derivatives <strong>2</strong>&#x02013;<strong>26</strong> is summarized in <a href="/pmc/articles/PMC6829050/figure/F11/" target="figure" class="fig-table-link figpopup" rid-figpopup="F11" rid-ob="ob-F11" co-legend-rid="lgnd_F11"><span>Schemes 1</span></a>&#x02013;<a href="/pmc/articles/PMC6829050/figure/F13/" target="figure" class="fig-table-link figpopup" rid-figpopup="F13" rid-ob="ob-F13" co-legend-rid="lgnd_F13"><span>3</span></a> and Experimental Section. A complete description of synthetic routes for the synthesis of the non-commercial amines is summarized in the <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Information</a>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F11" co-legend-rid="lgnd_F11"><a href="/pmc/articles/PMC6829050/figure/F11/" target="figure" rid-figpopup="F11" rid-ob="ob-F11"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246378115936"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0020.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0020.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0020.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246378115936"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F11/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F11"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F11/" target="figure" rid-figpopup="F11" rid-ob="ob-F11">Scheme 1.</a></div><!--caption a7--><div class="caption"><p id="P501">General scheme for the synthesis of compounds <strong>2&#x02013;9</strong> and <strong>11&#x02013;25</strong>.</p><p id="P185"><sup><em>a</em></sup>Reagents, conditions: (<em>a</em>) Et<sub>3</sub>N, DCM, r.t., o.n.; (<em>b</em>) MeI, NaH, DMF, r.t., o.n.; (<em>c</em>) Allyl alcohol, NaHCO<sub>3</sub>, Pd(OAc)<sub>2</sub>, Bu<sub>4</sub>NCl, 70&#x0202f;&#x000b0;C, o.n.; (<em>d</em>) 5,5-dibromo meldrum&#x02019;s acid, HCl, THF, r.t., 18h; (<em>e</em>) 2,6-diaminopyrimidin-4-ol, NaOAc, MeOH/H<sub>2</sub>O, 45 &#x000b0;C, 2h; (<em>f</em>) 2N NaOH, MeOH/H<sub>2</sub>O, 60&#x0202f;&#x000b0;C, 1h; (<em>g</em>) NaN<sub>3</sub>, DMSO, 100&#x0202f;&#x000b0;C, o.n.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F13" co-legend-rid="lgnd_F13"><a href="/pmc/articles/PMC6829050/figure/F13/" target="figure" rid-figpopup="F13" rid-ob="ob-F13"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246371072160"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0022.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0022.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0022.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246371072160"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F13/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F13"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F13/" target="figure" rid-figpopup="F13" rid-ob="ob-F13">Scheme 3.</a></div><!--caption a7--><div class="caption"><p id="P187">General scheme for the synthesis of compounds <strong>26</strong> and <strong>27</strong>.</p></div></div></div></div><div id="S5" class="sec"><h3 id="S5title">2.3. SAR Profiling using biochemical assays</h3><p id="P10" class="p p-first">A series of antifolate compounds were prepared to explore SAR based upon compound <strong>1</strong> and Scaffolds A and B (<a href="/pmc/articles/PMC6829050/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1B</span></a>). The synthesized series of 26 antifolate compounds were biochemically evaluated against purified <em>Ch</em>TS and hTS enzymes by monitoring the conversion of dUMP and CH<sub>2</sub>H<sub>4</sub>F to dTMP and H<sub>2</sub>F. Compound <strong>1</strong> was utilized as a positive antifolate control. TS inhibitory activity is summarized in (<a href="/pmc/articles/PMC6829050/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Tables 1</span></a> and <a href="/pmc/articles/PMC6829050/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and2</span></span><span>2</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Table S1</a>), and the SAR of these compounds with <em>Ch</em>TS was investigated.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T1"><h3>Table 1.</h3><!--caption a7--><div class="caption"><p id="P188">Compound 2&#x02013;8 and 14&#x02013;27 IC<sub>50</sub> (&#x003bc;M) for <em>Ch</em>TS</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr style="border-bottom: solid 1px"><th align="center" valign="middle" rowspan="1" colspan="1"></th><th align="center" valign="middle" rowspan="1" colspan="1"></th><th colspan="4" align="center" valign="middle" rowspan="1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246364418048"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0002.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0002.jpg" src="/pmc/articles/PMC6829050/bin/nihms-1051114-t0002.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140246364418048"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T1/?report=objectonly">Open in a separate window</a></div></th><th align="center" valign="middle" rowspan="1" colspan="1"></th><th align="center" valign="middle" rowspan="1" colspan="1"></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" rowspan="1" colspan="1">R<sub>1</sub></th><th align="center" valign="middle" rowspan="1" colspan="1">R<sub>2</sub></th><th align="center" valign="middle" rowspan="1" colspan="1">R<sub>3</sub></th><th align="center" valign="middle" rowspan="1" colspan="1">R<sub>4</sub></th><th align="center" valign="middle" rowspan="1" colspan="1">R<sub>5</sub></th><th align="center" valign="middle" rowspan="1" colspan="1"><em>Ch</em>TS IC<sub>50</sub> (&#x003bc;M)</th><th align="center" valign="middle" rowspan="1" colspan="1">ClogP</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">20 &#x000b1; 12</td><td align="center" valign="middle" rowspan="1" colspan="1">2.63</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">96 &#x000b1; 10</td><td align="center" valign="middle" rowspan="1" colspan="1">2.47</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" rowspan="1" colspan="1">2.49</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">16 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.96</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">(CH<sub>2</sub>)<sub>2</sub>COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">114 &#x000b1; 21</td><td align="center" valign="middle" rowspan="1" colspan="1">2.48</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Tetrazole</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">159 &#x000b1; 19</td><td align="center" valign="middle" rowspan="1" colspan="1">1.96</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">CN</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">123 &#x000b1; 7</td><td align="center" valign="middle" rowspan="1" colspan="1">2.29</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">Cl</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">28 &#x000b1; 6</td><td align="center" valign="middle" rowspan="1" colspan="1">3.28</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">18 &#x000b1; 2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.51</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">OCH<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">50 &#x000b1; 8</td><td align="center" valign="middle" rowspan="1" colspan="1">2.66</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">CN</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">11 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">2.36</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>OH</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">181 &#x000b1; 32</td><td align="center" valign="middle" rowspan="1" colspan="1">1.94</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>OCH<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">68 &#x000b1; 12</td><td align="center" valign="middle" rowspan="1" colspan="1">2.56</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">CONH<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">20 &#x000b1; 4</td><td align="center" valign="middle" rowspan="1" colspan="1">1.42</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>OCH<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">OCH<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">222 &#x000b1; 77</td><td align="center" valign="middle" rowspan="1" colspan="1">2.66</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">OCH<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">11 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">CN</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">9.1 &#x000b1; 0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1.69</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">10 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.85</td></tr><tr style="border-bottom: solid 1px;border-top: solid 1px"><td align="center" valign="middle" rowspan="1" colspan="1"></td><td align="center" valign="middle" rowspan="1" colspan="1"></td><td colspan="4" align="center" valign="middle" rowspan="1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246378159888"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0003.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0003.jpg" src="/pmc/articles/PMC6829050/bin/nihms-1051114-t0003.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140246378159888"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T1/?report=objectonly">Open in a separate window</a></div></td><td align="center" valign="middle" rowspan="1" colspan="1"></td><td align="center" valign="middle" rowspan="1" colspan="1"></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">O(CH<sub>2</sub>)<sub>2</sub>OCH<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">OCH<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">~ ~</td><td align="center" valign="middle" rowspan="1" colspan="1">~ ~</td><td align="center" valign="middle" rowspan="1" colspan="1">~ ~</td><td align="center" valign="middle" rowspan="1" colspan="1">97 &#x000b1; 44</td><td align="center" valign="middle" rowspan="1" colspan="1">3.42</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">COO<sup>&#x02212;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">OCH<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">~ ~</td><td align="center" valign="middle" rowspan="1" colspan="1">~ ~</td><td align="center" valign="middle" rowspan="1" colspan="1">~ ~</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;500</td><td align="center" valign="middle" rowspan="1" colspan="1">3.38</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140246371068224"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T1/?report=objectonly">Open in a separate window</a></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T2"><h3>Table 2.</h3><!--caption a7--><div class="caption"><p id="P189">Compound 9&#x02013;13 IC<sub>50</sub> (&#x003bc;M) for <em>Ch</em>TS</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr style="border-bottom: solid 1px"><th align="center" valign="middle" rowspan="1" colspan="1"></th><th colspan="2" align="center" valign="middle" rowspan="1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246374554560"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0004.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0004.jpg" src="/pmc/articles/PMC6829050/bin/nihms-1051114-t0004.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140246374554560"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T2/?report=objectonly">Open in a separate window</a></div></th><th align="center" valign="middle" rowspan="1" colspan="1"></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" rowspan="1" colspan="1"></th><th align="center" valign="middle" rowspan="1" colspan="1"><em>Ch</em>TS IC<sub>50</sub> (&#x003bc;M)</th><th align="center" valign="middle" rowspan="1" colspan="1">ClogP</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246381885536"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0005.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0005.jpg" src="/pmc/articles/PMC6829050/bin/nihms-1051114-t0005.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140246381885536"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T2/?report=objectonly">Open in a separate window</a></div></td><td align="center" valign="top" rowspan="1" colspan="1">210 &#x000b1; 81</td><td align="center" valign="top" rowspan="1" colspan="1">2.87</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246381879536"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0006.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0006.jpg" src="/pmc/articles/PMC6829050/bin/nihms-1051114-t0006.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140246381879536"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T2/?report=objectonly">Open in a separate window</a></div></td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="top" rowspan="1" colspan="1">3.60</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246370627952"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0007.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0007.jpg" src="/pmc/articles/PMC6829050/bin/nihms-1051114-t0007.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140246370627952"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T2/?report=objectonly">Open in a separate window</a></div></td><td align="center" valign="top" rowspan="1" colspan="1">119 &#x000b1; 13</td><td align="center" valign="top" rowspan="1" colspan="1">1.81</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246370621952"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0008.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0008.jpg" src="/pmc/articles/PMC6829050/bin/nihms-1051114-t0008.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140246370621952"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T2/?report=objectonly">Open in a separate window</a></div></td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;500</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0. 66</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1"><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246370615952"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0009.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-t0009.jpg" src="/pmc/articles/PMC6829050/bin/nihms-1051114-t0009.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140246370615952"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T2/?report=objectonly">Open in a separate window</a></div></td><td align="center" valign="top" rowspan="1" colspan="1">63 &#x000b1; 8</td><td align="center" valign="top" rowspan="1" colspan="1">1.90</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140246374562048"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/table/T2/?report=objectonly">Open in a separate window</a></div></div><p id="P11">As shown in <a href="/pmc/articles/PMC6829050/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a> and <a href="/pmc/articles/PMC6829050/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>, the first compound synthesized, <strong>2</strong>, involved replacement of the &#x003b1;-carboxylate of the glutamic acid moiety with an aryl ring containing a carboxyl acid at the ortho position to mimic the &#x003b3;-carboxylate. Compound <strong>2</strong> had an IC<sub>50</sub> = 20 &#x003bc;M. There was a ~ 5-fold loss of potency, when the carboxylate was in either the meta or para positions of the aryl ring, compounds <strong>3</strong> and <strong>4</strong>, demonstrating a preference for the ortho position. The three-dimensional crystal structure for <strong>2</strong> in complex with the ChTS-DHFR protein was solved (see <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S2A</a>). The structural analysis revealed that the ortho carboxylic acid was oriented toward S290, however the distance was too short to allow a hydrogen bond (see <a href="/pmc/articles/PMC6829050/figure/F7/" target="figure" class="fig-table-link figpopup" rid-figpopup="F7" rid-ob="ob-F7" co-legend-rid="lgnd_F7"><span>Figure 7</span></a>, below). Accordingly, incorporation of a methylene linker to extend the ortho-carboxylate by one carbon unit from the aryl ring, in order to replicate the hydrogen bond observed in the crystal structure between <strong>1</strong> and S290, resulted in compound <strong>5</strong>, which did result in a small increase in potency. The increased linker length allowed formation of the hydrogen bond with S290 as verified by the determination of the crystal structure of <strong>5</strong> bound to the ChTS active site (see <a href="/pmc/articles/PMC6829050/figure/F7/" target="figure" class="fig-table-link figpopup" rid-figpopup="F7" rid-ob="ob-F7" co-legend-rid="lgnd_F7"><span>Figure 7</span></a>, below, and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S2B</a>). However, the addition of the longer ethylene linker resulted in a ~ 6-fold loss of potency for <strong>6</strong>. Isosteric replacement of the carboxylate moiety with other functional groups that could form a hydrogen bond, such as a tetrazole or a cyano, also resulted in an ~ 8-fold and ~ 6-fold loss of potency, respectively, compound <strong>7</strong> and <strong>8</strong>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC6829050/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246379604320"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0011.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0011.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0011.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246379604320"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2.</a></div><!--caption a7--><div class="caption"><p id="P176">Structure and <em>Ch</em>TS IC<sub>50</sub> values for compounds <strong>2&#x02013;8</strong>, modifications made to carboxylate (red). Coloration of compound <strong>2</strong> denotes modifications made during SAR, amide linker moiety (blue), aromaticity (pink), carboxylate (red), and substitutions to C-3, C-4, and C-5 positions (purple, green, and gold, respectively).</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F7" co-legend-rid="lgnd_F7"><a href="/pmc/articles/PMC6829050/figure/F7/" target="figure" rid-figpopup="F7" rid-ob="ob-F7"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246370559888"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0016.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0016.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0016.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246370559888"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F7/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F7"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F7/" target="figure" rid-figpopup="F7" rid-ob="ob-F7">Figure 7.</a></div><!--caption a7--><div class="caption"><p id="P181">Comparison of <em>Ch</em>TS bound to <strong>2</strong> (light green/warm pink), <em>Ch</em>TS bound to <strong>5</strong> (green/tan) and <em>Ch</em>TS bound to <strong>6</strong> (dark green/cyan) with dUMP (yellow) (PDB: 6PF7, 6PF9, and 6PFB). A. Comparison of <strong>2</strong>, <strong>5</strong>, and <strong>6</strong> bound in <em>Ch</em>TS active site, hydrogen bonds to <strong>5</strong> in black and to <strong>6</strong> in gray. B. Top view of benzoic acid, 2-phenylacetic acid, and 3-phenylpropanoic acid moiety for <strong>2</strong>, <strong>5</strong>, and <strong>6</strong>, respectively.</p></div></div></div><p id="P12">As illustrated in <a href="/pmc/articles/PMC6829050/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a> and <a href="/pmc/articles/PMC6829050/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3</span></a>, in general modifications made to the amide linker moiety resulted in substantial decrease in potency. The addition of a methyl group to produce a tertiary amine resulted in an ~11-fold decrease in potency, compound <strong>9</strong>. Removing the amide linker and replacing with an ethylene linker resulted in a greater than 5-fold decrease in potency, compound <strong>10</strong>. Increasing the length of the linker region by inserting a methylene to elongate the linker region by one carbon unit resulted in a 6-fold loss in potency, compound <strong>11</strong>. Compound <strong>12</strong> demonstrated a greater than 25-fold decrease in potency. Here the loss of aromaticity is combined with the creation of a piperidine ring, which shortens the amide linker moiety by insertion of a secondary amine into the ring structure. However, the loss of aromaticity alone resulted in a 3-fold loss of potency, compound <strong>13</strong>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC6829050/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246379599904"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0012.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0012.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0012.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246379599904"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3.</a></div><!--caption a7--><div class="caption"><p id="P177">Structures and <em>Ch</em>TS IC<sub>50</sub> values for compounds <strong>9&#x02013;13</strong>, modifications made to the amide linker moiety (blue), and aromaticity (pink).</p></div></div></div><p id="P13">Based on the ortho substituted compound <strong>2</strong>, a series of substituents were added to the C-4 position of the aryl ring to take advantage of the pocket surrounding K284 to improve potency as shown in <a href="/pmc/articles/PMC6829050/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a> and <a href="/pmc/articles/PMC6829050/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4</span></a>. Hydrophilic substituents in general were well tolerated, compounds <strong>15</strong>, <strong>17</strong> and <strong>20</strong>. While the addition of a carboxamide or carboxylate at C-4 maintained potency compared to <strong>2,</strong> where the addition of a cyano at this position enhanced potency 2-fold in compound <strong>17</strong>. This is confirmed by the crystal structure (<a href="/pmc/articles/PMC6829050/figure/F9/" target="figure" class="fig-table-link figpopup" rid-figpopup="F9" rid-ob="ob-F9" co-legend-rid="lgnd_F9"><span>Figure 9</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S3D</a>), described below. However, the addition of a methoxy group or a hydroxymethyl group at the C-4 position resulted in a ~ 2.5-fold and ~ 9-fold decrease in potency, respectively, compound <strong>16</strong> and <strong>18</strong>. The addition of a chloride substituent to the C-4 position resulted in a small loss of potency, compound <strong>14</strong>. The addition of a methoxymethyl substituent to the C-4 position resulted in ~ 3.5-fold loss in potency for compound <strong>19</strong>. Additionally, the addition of methoxymethyl or methoxy substituents to the aryl moiety at the C-3 and C-5 positions were not well tolerated, with a greater than 5-fold loss of potency, compound <strong>21</strong> and <strong>22.</strong></p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F4" co-legend-rid="lgnd_F4"><a href="/pmc/articles/PMC6829050/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246371166192"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0013.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0013.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0013.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246371166192"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Figure 4.</a></div><!--caption a7--><div class="caption"><p id="P178">Structures and <em>Ch</em>TS IC<sub>50</sub> values for compounds <strong>14&#x02013;22</strong>, modifications made to the C-3 (purple), C-4 (green), and C-5 (gold) positions.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F9" co-legend-rid="lgnd_F9"><a href="/pmc/articles/PMC6829050/figure/F9/" target="figure" rid-figpopup="F9" rid-ob="ob-F9"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246423996368"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0018.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0018.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0018.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246423996368"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F9/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F9"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F9/" target="figure" rid-figpopup="F9" rid-ob="ob-F9">Figure 9.</a></div><!--caption a7--><div class="caption"><p id="P183">Comparison of <em>Ch</em>TS bound to <strong>17</strong> (green/navy) and <em>Ch</em>TS bound to <strong>24</strong> (dark green/teal) with dUMP (yellow) (PDB: 6PFF, and 6PFH). A. Comparison of <strong>17</strong> and <strong>24</strong> bound in <em>Ch</em>TS active site, hydrogen bonds to <strong>17</strong> in gray and to <strong>24</strong> in black. B. Zoom in view rotation of <strong>24</strong> 2-phenylacetic acid moiety with respect to <strong>17</strong> benzoic acid moiety. C. Zoom in view of shift of pyrrolo[2,3-d]pyrimidine moiety of <strong>17</strong> and <strong>24</strong>.</p></div></div></div><p id="P14">As shown in <a href="/pmc/articles/PMC6829050/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a> and <a href="/pmc/articles/PMC6829050/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Figure 5</span></a>, the combination of an ortho-phenylacetic acid moiety with a substituent at the C-4 position of the aryl ring resulted in ~ 2-fold increase in potency, compounds <strong>23&#x02013;25</strong>. These compounds were designed to form a hydrogen bond with S290 as well as interact with the pocket surrounding K284. These interactions are supported by the crystal structure (<a href="/pmc/articles/PMC6829050/figure/F9/" target="figure" class="fig-table-link figpopup" rid-figpopup="F9" rid-ob="ob-F9" co-legend-rid="lgnd_F9"><span>Figure 9</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figures S5</a> and <a href="#SD1" rid="SD1" class=" supplementary-material">S6</a>), as described below.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F5" co-legend-rid="lgnd_F5"><a href="/pmc/articles/PMC6829050/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246371161776"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0014.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0014.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0014.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246371161776"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F5"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5">Figure 5.</a></div><!--caption a7--><div class="caption"><p id="P179">Structures and <em>Ch</em>TS IC<sub>50</sub> values for compounds <strong>23&#x02013;25</strong>, modifications made carboxylate (red), and C-4 (green) positions.</p></div></div></div><p id="P15" class="p p-last">Finally, as illustrated in <a href="/pmc/articles/PMC6829050/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table1</span></a> and <a href="/pmc/articles/PMC6829050/figure/F6/" target="figure" class="fig-table-link figpopup" rid-figpopup="F6" rid-ob="ob-F6" co-legend-rid="lgnd_F6"><span>Figure 6</span></a>, elaboration of the aryl ring to a biphenyl, suggested by modeling to be favorable, resulted in a substantial drop in potency. The biphenyl moiety was poorly tolerated resulting in a loss of potency ~ 5-fold and greater than 25-fold for compounds <strong>26</strong> and <strong>27</strong> respectively.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F6" co-legend-rid="lgnd_F6"><a href="/pmc/articles/PMC6829050/figure/F6/" target="figure" rid-figpopup="F6" rid-ob="ob-F6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246371157360"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0015.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0015.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0015.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246371157360"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F6"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F6/" target="figure" rid-figpopup="F6" rid-ob="ob-F6">Figure 6.</a></div><!--caption a7--><div class="caption"><p id="P180">Structures and <em>Ch</em>TS IC<sub>50</sub> values for compounds <strong>26&#x02013;27</strong>.</p></div></div></div></div><div id="S6" class="sec"><h3 id="S6title">2.4. X-ray crystal structures of antifolates complexed with ChTS</h3><p id="P16" class="p p-first">All 26 antifolate compounds were evaluated by biochemical assays to assess inhibition of <em>Ch</em>TS catalytic activity. The compounds were then further evaluated with structural analyses. Co-crystal structures were obtained for 12 antifolate compounds: <strong>2</strong>, <strong>5</strong>, <strong>6</strong>, <strong>11</strong>, <strong>14</strong>, <strong>15</strong>, <strong>16</strong>, <strong>17</strong>, <strong>20</strong>, <strong>23</strong>, <strong>24</strong>, and <strong>25</strong> with <em>Ch</em>TS-DHFR. As further described in the Experimental section, structures of <em>Ch</em>TS-DHFR complexed with antifolate compounds were obtained utilizing the same procedures. The resolution of the structures range from 2.5 to 3.3 &#x000c5; and all twelve structures have been deposited in the Protein Data Bank. The co-crystal structures contained five protein molecules within the asymmetric subunit and crystallized as a C2 space group with a similar crystal lattice as reported for <em>Ch</em>TS-DHFR complexed with <strong>1</strong>.[<a href="#R12" rid="R12" class=" bibr popnode">12</a>]</p><p id="P17">The antifolate compounds bind into the 5,10-methylenetetrahydrofolate (CH<sub>2</sub>H<sub>4</sub>F) pocket where the pyrrolo[2,3-d]pyrimidine and centralbenzyl moieties form similar interactions with <em>Ch</em>TS active site as previously described for <strong>1</strong> (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figures S2</a>&#x02013;<a href="#SD1" rid="SD1" class=" supplementary-material">4</a>).[<a href="#R12" rid="R12" class=" bibr popnode">12</a>] However, the pyrrolo[2,3-d]pyrimidine of compounds <strong>2</strong>, <strong>6</strong>, <strong>15</strong>, <strong>17,</strong> and <strong>20</strong> form fewer hydrogen bonding interactions with the <em>Ch</em>TS active site (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S2A</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S2C</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S3B</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S3D</a>, and <a href="#SD1" rid="SD1" class=" supplementary-material">S4A</a>). Compounds <strong>6</strong>, <strong>15</strong> and <strong>17</strong> do not form hydrogen bonding interactions with the backbone N of G430. Additionally, <strong>15</strong> and <strong>17</strong> do not form hydrogen bonding interactions with D426. All five compounds do not form a hydrogen bond with Y466.</p><p id="P18">The carboxylate group of the benzoic acid, 2-phenylacetic acid, and 3-phenylpropanoic acid moieties are directed towards S290. With an average distance of ~ 3.9 &#x000c5;, the carboxylate group for compounds containing a benzoic acid moiety were not within hydrogen bonding distance to S290. The carboxylate group for compounds containing either 2-phenylacetic acid, or 3-phenylpropanoic acid moieties, with an average distance of ~3.3 &#x000c5;, were within hydrogen bonding distance to S290. Compounds <strong>2</strong>, <strong>5</strong>, and <strong>6</strong>, which contain a benzoic acid, 2-phenylacetic acid, and 3-phenylpropanoic acid moiety, respectively, illustrates the importance of linker length on inhibitor potency. Comparing the three compounds it is observed that the carboxylate of <strong>2</strong> is ~4.0 &#x000c5; from S290, while the methylene linker of <strong>5</strong> extends the carboxylate within hydrogen bonding distance, ~ 3.3 &#x000c5;, to S290 (<a href="/pmc/articles/PMC6829050/figure/F7/" target="figure" class="fig-table-link figpopup" rid-figpopup="F7" rid-ob="ob-F7" co-legend-rid="lgnd_F7"><span>Figure 7</span></a>). The longer linker used in <strong>6</strong> enables the carboxylate to hydrogen bond with S290, however there is greater disorder due to the linker length resulting in the loss of two hydrogen bonds to the pyrrolo[2,3-d]pyrimidine moiety (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S2C</a>).</p><p id="P19">Compound <strong>11</strong> differs from <strong>2</strong> by the addition of a methylene to the amide linker moiety, which resulted in a 6-fold loss of potency. Comparing the two structures of <strong>2</strong> and <strong>11</strong>, the carboxylate of both compounds is ~ 4.0 &#x000c5; from S290 (<a href="/pmc/articles/PMC6829050/figure/F8/" target="figure" class="fig-table-link figpopup" rid-figpopup="F8" rid-ob="ob-F8" co-legend-rid="lgnd_F8"><span>Figure 8A</span></a>). In <a href="/pmc/articles/PMC6829050/figure/F8/" target="figure" class="fig-table-link figpopup" rid-figpopup="F8" rid-ob="ob-F8" co-legend-rid="lgnd_F8"><span>Figure 8B</span></a>, we observe the benzoic acid moiety shifts 1.4 &#x000c5; into the pocket, while shifting the amide linker towards M519 by ~ 0.9 &#x000c5;. The addition of the methylene to this region destabilizes the binding of <strong>11</strong> by increasing the compounds flexibility within the binding pocket.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F8" co-legend-rid="lgnd_F8"><a href="/pmc/articles/PMC6829050/figure/F8/" target="figure" rid-figpopup="F8" rid-ob="ob-F8"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246370552448"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0017.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0017.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0017.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246370552448"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F8/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F8"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F8/" target="figure" rid-figpopup="F8" rid-ob="ob-F8">Figure 8.</a></div><!--caption a7--><div class="caption"><p id="P182">Comparison of <em>Ch</em>TS bound to <strong>2</strong> (green/warm pink) and <em>Ch</em>TS bound to <strong>11</strong> (dark green/lavender) with dUMP (yellow) (PDB: 6PF7, and 6PFA). A. Comparison of <strong>2</strong> and <strong>11</strong> bound in <em>Ch</em>TS active site, carboxylate group for both compounds are similar distance from S290 B. Zoom in view of <strong>11</strong> benzoic acid moiety compared to <strong>2</strong>.</p></div></div></div><p id="P20" class="p p-last">C-4 substituents to either benzoic acid or 2-phenylacetic acid moieties were directed into a small pocket adjacent to K284. Cyano, carboxylate, or carboxamide C-4 substituents, <strong>15</strong> and <strong>25</strong>, <strong>17</strong> and <strong>24</strong>, or <strong>20</strong>, respectively, where within hydrogen bonding distance of the ammonium of K284, while the C-4 substituent of <strong>20</strong> was also within hydrogen bonding distance of the backbone carbonyl of I515 (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S3B</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S3D</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S4A</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S4C</a> and <a href="#SD1" rid="SD1" class=" supplementary-material">S4D</a>). Compounds <strong>23</strong>, <strong>24</strong>, and <strong>25</strong>, which combine a C-4 substituent, in this case a methoxy, cyano or carboxylate, respectively, with the 2-phenylacetic acid moiety, demonstrate the greatest <em>Ch</em>TS potency for this series of compounds. A structural comparison of compounds <strong>23</strong>, <strong>24</strong>, and <strong>25</strong> with the benzoic acid moiety counterparts <strong>16</strong>, <strong>17</strong>, and <strong>15</strong>, respectively, reveals subtle differences in the way these compounds interact with the <em>Ch</em>TS active site. First the carboxylate group of compounds <strong>23</strong>, <strong>24</strong>, and <strong>25</strong> is within hydrogen bonding distance of S290, while the carboxylate of the benzoic acid counterparts is an average ~ 3.8 &#x000c5; away from this residue (<a href="/pmc/articles/PMC6829050/figure/F9/" target="figure" class="fig-table-link figpopup" rid-figpopup="F9" rid-ob="ob-F9" co-legend-rid="lgnd_F9"><span>Figure 9A</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S5A</a> and <a href="#SD1" rid="SD1" class=" supplementary-material">S6A</a>). This hydrogen bond with S290 coupled with the C-4 substituents interactions within the pocket containing K284 stabilizes the 2-phenylacetic acid moiety within the <em>Ch</em>TS active site. Secondly, the addition of the methylene linker in the 2-phenylacetic acid moiety of compounds <strong>23</strong>, <strong>24</strong>, and <strong>25</strong> produces ~ 22.0&#x000b0; clockwise rotation of this moiety with respect to their benzoic acid moiety counter parts (<a href="/pmc/articles/PMC6829050/figure/F9/" target="figure" class="fig-table-link figpopup" rid-figpopup="F9" rid-ob="ob-F9" co-legend-rid="lgnd_F9"><span>Figure 9B</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S5B</a> and <a href="#SD1" rid="SD1" class=" supplementary-material">S6B</a>). This small rotation appears to transfer to the pyrrolo[2,3-d]pyrimidine moiety resulting in an average shift of ~ 0.3 &#x000c5; into the pocket, stabilizing the hydrogen bonding interactions between the pyrrolo[2,3-d]pyrimidine and <em>Ch</em>TS active site (<a href="/pmc/articles/PMC6829050/figure/F9/" target="figure" class="fig-table-link figpopup" rid-figpopup="F9" rid-ob="ob-F9" co-legend-rid="lgnd_F9"><span>Figure 9C</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S5C</a> and <a href="#SD1" rid="SD1" class=" supplementary-material">S6C</a>).</p></div><div id="S7" class="sec sec-last"><h3 id="S7title">2.5. X-ray crystal structures of antifolates complexed with hTS</h3><p id="P21" class="p p-first">All antifolate compounds where evaluated for structural analysis with hTS, however, co-crystal structures were obtained for antifolate compounds <strong>5</strong>, <strong>14</strong>, <strong>15</strong>, and <strong>23</strong>. A full description of the procedures used to obtain structures of hTS complexed with the antifolate compounds can be found in the Experimental section. The resolution of the structures range from 2.39 to 2.84 &#x000c5; and all four structures have been deposited in the Protein Data Bank. The co-crystal structures contained four protein molecules within the asymmetric subunit, with <strong>14</strong> and <strong>23</strong>, <strong>5</strong>, and <strong>15</strong> crystalizing in a C2, P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, and P4<sub>1</sub>2<sub>1</sub>2 space groups, respectively. In all structures, density for the antifolate compounds was observed in all four chains of the asymmetric unit except for the structure for <strong>15</strong>, where density was only observed in chains B and C.</p><p id="P22">The antifolate compounds bind into the CH<sub>2</sub>H<sub>4</sub>F pocket where the pyrrolo[2,3-d]pyrimidine and central benzyl moieties form similar interactions with the hTS active site as previously described for <strong>1.</strong>[<a href="#R19" rid="R19" class=" bibr popnode">19</a>] However, the pyrrolo[2,3-d]pyrimidine of compounds <strong>5</strong>, <strong>14</strong>, and <strong>23</strong> form fewer hydrogen bonding interactions with the hTS active site (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S7A</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S7B</a>, and <a href="#SD1" rid="SD1" class=" supplementary-material">S7D</a>). Compound <strong>5</strong> does not form hydrogen bonding interactions with the backbone carbonyl of A312, but this could be an artifact due to a lack of density to visualize the neighboring residue V313. Compound <strong>14</strong> and <strong>23</strong> do not form hydrogen bonding interactions with Q112. The carboxylate group of the benzoic acid, and 2-phenylacetic acid moieties are directed towards solvent, while C-4 substituents are directed towards the pocket containing residue K77. Additionally, the aryl ring of both the benzoic acid, and 2-phenylacetic acid moieties formed hydrophobic interactions with F80 (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S7</a>). Interestingly, unlike the positioning of the amide linker moiety for these compounds bound in <em>Ch</em>TS, the amide linker moiety for all four compounds bound in the opposite orientation where the carbonyl points into the pocket near F225 (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S7</a>).</p><p id="P23" class="p p-last">Comparing the structures of <strong>5</strong>, <strong>14</strong>, <strong>15</strong>, and <strong>23</strong> in both the ChTS and hTS active sites provides a possible explanation for the observed trend in inhibitory selectivity the antifolate compounds display for both enzymes (<a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Table S1</a>). As previously reported in our work with R-and S- enantiomers of <strong>1</strong>, we observed that the <em>Ch</em>TS active site is more rigid than the hTS active site.[<a href="#R19" rid="R19" class=" bibr popnode">19</a>] Similarly here the hTS residue F225 rotates ~ 75&#x000b0; clockwise, as compared to its corresponding <em>Ch</em>TS residue F433 for all four compound structures (<a href="/pmc/articles/PMC6829050/figure/F10/" target="figure" class="fig-table-link figpopup" rid-figpopup="F10" rid-ob="ob-F10" co-legend-rid="lgnd_F10"><span>Figure 10A</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S8A</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S9A</a>, and <a href="#SD1" rid="SD1" class=" supplementary-material">S10A</a>). The space afforded by the rotation of F225 allows the central benzyl moiety to shift back into the pocket towards F225 by ~ 0.8 &#x000c5;, while providing space for the compound&#x02019;s amide linker moiety carbonyl (<a href="/pmc/articles/PMC6829050/figure/F10/" target="figure" class="fig-table-link figpopup" rid-figpopup="F10" rid-ob="ob-F10" co-legend-rid="lgnd_F10"><span>Figure 10B</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S8B</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S9B</a>, and <a href="#SD1" rid="SD1" class=" supplementary-material">S10B</a>). The reverse orientation of the amide linker moiety appears to position the benzoic acid, and 2-phenylacetic acid moieties aryl rings towards F80, allowing for a more optimal position to hydrophobically interact with F80. The positioning of the compounds towards F80 provides space for the sidechain of L221 to rotate ~180&#x000b0; into the pocket as compared to its <em>Ch</em>TS counterpart L429 (<a href="/pmc/articles/PMC6829050/figure/F10/" target="figure" class="fig-table-link figpopup" rid-figpopup="F10" rid-ob="ob-F10" co-legend-rid="lgnd_F10"><span>Figure 10C</span></a> and <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Figure S8C</a>, <a href="#SD1" rid="SD1" class=" supplementary-material">S9C</a>, and <a href="#SD1" rid="SD1" class=" supplementary-material">S10C</a>). Taken together, hTS structural data and IC<sub>50</sub> values indicate that with few exceptions the hTS active site is capable of accommodating most alterations in the compounds used in this SAR.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F10" co-legend-rid="lgnd_F10"><a href="/pmc/articles/PMC6829050/figure/F10/" target="figure" rid-figpopup="F10" rid-ob="ob-F10"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246423989872"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0019.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0019.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0019.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246423989872"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F10/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F10"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F10/" target="figure" rid-figpopup="F10" rid-ob="ob-F10">Figure 10.</a></div><!--caption a7--><div class="caption"><p id="P184">Comparison of hTS bound to <strong>14</strong> (blue/dark red) and <em>Ch</em>TS bound to <strong>14</strong> (green/purple) with dUMP (yellow) (PDB: 6PF8, and 6PF3). A. Comparison of <strong>14</strong> bound in hTS and <em>Ch</em>TS active site. B. Zoom in view hTS residue F225 and ChTS residue F433 position upon binding <strong>14</strong>. C. Zoom in view hTS residue L221 and ChTS residue L429 position upon binding <strong>14</strong>.</p></div></div></div></div></div><div id="S8" class="tsec sec"><h2 class="head no_bottom_margin" id="S8title">3. Conclusions</h2><p id="P24" class="p p-first-last">We have designed, synthesized and evaluated a series of anti-cryptosporidium agents based on the chemical structure of lead compound <strong>1,</strong> where the glutamate moiety is replaced by a benzoic acid. Structure-activity relationship analysis indicates (1) <em>Ch</em>TS prefers an ortho-phenylacetic acid moiety over an ortho-benzoic acid or ortho-phenylpropanoic acid moieties (2) hydrophilic C-4 substituents on the 2-phenylacetic acid moieties increase potency (3) changes to the amide linker moiety are not tolerated. X-ray crystal structures of compounds <strong>23</strong>, <strong>24</strong>, and <strong>25</strong> bound to the <em>Ch</em>TS active site reveal the key interactions that are necessary for compound potency, as well as the role that the 2-phenylacetic acid methylene linker plays in optimally positioning these compounds into the active site. Comparison of structural data for compounds <strong>5</strong>, <strong>14</strong>, <strong>15</strong>, and <strong>23</strong> bound in both <em>Ch</em>TS and hTS identified that active site structural rigidity is a driving factor in determining inhibitor selectivity. In summary, the results presented here provide a platform for further efforts to develop new anti-cryptosporidium agents.</p></div><div id="S9" class="tsec sec"><h2 class="head no_bottom_margin" id="S9title">4. Experimental section</h2><div id="S10" class="sec sec-first"><h3 id="S10title">4.1. General Information</h3><p id="P25" class="p p-first-last">NMR spectra were recorded on Agilent DD2 600 (600 MHz), DD2 500 (500 MHz) and DD2 400 (400 MHz) instruments. Column chromatography was carried out using CombiFlash over redisep column cartridges employing Merck silica gel (Kieselgel 60, 63&#x02013;200 &#x003bc;m). Pre-coated silica gel plates F-254 were used for thinlayer analytical chromatography. Mass determinations were performed using electrospray ionization on a Waters Micromass ZQ (LC-MS) and on an Agilent Technologies 6890N (GC-MS). HRMS (ESI-TOF) analyses were performed on Waters Xevo QTOF equipped with Z-spray electrospray ionization source. HRMS values agree within &#x000b1; 0.4 % of the theoretical values. The purity of all final synthesized compounds was determined by reverse phase HPLC, using Waters 2487 dual &#x003bb; absorbance detector with a Waters 1525 binary pump and a Phenomenex Luna 5&#x003bc; C18(2) 250 &#x000d7; 4.6 mm column. Samples were run at 1mL/min using gradient mixtures of 5&#x02013;100% of water with 0.1% trifluoroacetic acid (TFA) (A) and 10:1 acetonitrile:water with 0.1% TFA (B) for 22 min followed by 3 min at 100% B. Additional details are provided in <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Information</a>.</p></div><div id="S11" class="sec"><h3 id="S11title">4.2. General procedure for the synthesis of intermediates 29a-u. Method a.</h3><p id="P26" class="p p-first">Intermediates <strong>29a-u</strong> have been obtained through general method <em>a</em>. To a solution of corresponding amine (<strong>28a-u</strong>) (1eq) in anhydrous dichloromethane (3.16 mL/eq) and dry triethylamine (1.10 eq), was added 4-iodobenzoylchloride (1.10 eq). The reaction was stirred overnight at room temperature. Solvent was evaporated under reduced pressure and the desired intermediates purified by flash column chromatography.[<a href="#R23" rid="R23" class=" bibr popnode">23</a>]</p><div id="S12" class="sec"><p></p><h4 id="S12title" class="inline">4.2.1.  <em>methyl 1-(4-iodobenzoyl)piperidine-2-carboxylate</em> (29a) </h4><p id="P27" class="p p-first-last">(hexanes to ethyl acetate). White powder, 0.54 g, 1.44 mmol, 37% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 7.79 &#x02013; 7.73 (m, 2H), 7.21 &#x02013; 7.16 (m, 2H), 5.51 &#x02013; 5.44 (m, 1H), 3.78 (s, 3H), 3.62 &#x02013; 3.56 (m, 1H), 3.31 &#x02013; 3.18 (m, 1H), 2.37 &#x02013; 2.31 (m, 1H), 1.78 &#x02013; 1.74 (m, 3H), 1.43 &#x02013; 1.35 (m, 2H). LC-MS (ESI) m/z 374.1 [M+H]<sup>+</sup>.</p></div><div id="S13" class="sec"><p></p><h4 id="S13title" class="inline">4.2.2.  <em>methyl 2-(4-iodobenzamido)cyclohexane-1-carboxylate</em> (29b) </h4><p id="P28" class="p p-first-last">(hexanes to hexanes/ dichloromethane 1:1). White powder, 0.54 g, 1.39 mmol, 32% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 7.80 &#x02013; 7.74 (m, 2H), 7.52 &#x02013; 7.46 (m, 2H), 7.29 (s, 1H), 4.30 (qd, <em>J</em> = 9.0, 7.9, 4.4 Hz, 1H), 3.72 (s, 3H), 2.91 (q, <em>J</em> = 4.6 Hz, 1H), 2.24 &#x02013; 2.13 (m, 1H), 1.83 &#x02013; 1.51 (m, 5H), 1.51 &#x02013; 1.40 (m, 1H), 1.33 &#x02013; 1.20 (m, 1H). LC-MS (ESI) m/z 388.1 [M+H]<sup>+</sup>.</p></div><div id="S14" class="sec"><p></p><h4 id="S14title" class="inline">4.2.3.  <em>methyl 2-(4-iodobenzamido)benzoate</em> (29c) </h4><p id="P29" class="p p-first-last">(hexanes/dichloromethane 8:2 to dichloromethane). White powder, 0.66 g, 1.73 mmol, 87% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.07 (s, 1H), 8.90 (d, <em>J</em> = 8.5 Hz, 1H), 8.12 &#x02013; 8.06 (m, 1H), 7.91 &#x02013; 7.86 (m, 2H), 7.80 &#x02013; 7.74 (m, 2H), 7.65 &#x02013; 7.58 (m, 1H), 7.17 &#x02013; 7.11 (m, 1H), 3.97 (s, 3H). LC-MS (ESI) m/z 382.0 [M+H]<sup>+</sup>.</p></div><div id="S15" class="sec"><p></p><h4 id="S15title" class="inline">4.2.4.  <em>methyl 3-(4-iodobenzamido)benzoate</em> (29d) </h4><p id="P30" class="p p-first-last">(hexanes to ethyl acetate). White powder, 0.97 g, 2.55 mmol, 68% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 8.16 &#x02013; 8.09 (m, 1H), 8.05 &#x02013; 8.01 (m, 1H), 7.92 (s, 1H), 7.88 &#x02013; 7.80 (m, 3H), 7.63 &#x02013; 7.58 (m, 2H), 7.46 (t, <em>J</em> = 7.9 Hz, 1H), 3.92 (s, 3H). LC-MS (ESI) m/z 382.1 [M+H]<sup>+</sup>.</p></div><div id="S16" class="sec"><p></p><h4 id="S16title" class="inline">4.2.5.  <em>methyl 4-(4-iodobenzamido)benzoate</em> (29e) </h4><p id="P31" class="p p-first-last">(hexanes to ethyl acetate). White powder, 0.29 g, 0.76 mmol, 20% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 8.09 &#x02013; 8.05 (m, 2H), 7.88 &#x02013; 7.85 (m, 2H), 7.75 &#x02013; 7.70 (m, 2H), 7.63 &#x02013; 7.59 (m, 2H), 3.92 (s, 3H). LC-MS (ESI) m/z 382.1 [M+H]<sup>+</sup>.</p></div><div id="S17" class="sec"><p></p><h4 id="S17title" class="inline">4.2.6.  <em>methyl 2-(2-(4-iodobenzamido)phenyl)acetate</em> (29f) </h4><p id="P32" class="p p-first-last">(hexanes/dichloromethane 8:2 to dichloromethane). White powder, 1.15 g, 2.91 mmol, 78% yield. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.78 (s, 1H), 8.02 (d, <em>J</em> = 8.1 Hz, 1H), 7.90 &#x02013; 7.84 (m, 2H), 7.80 &#x02013; 7.74 (m, 2H), 7.39 &#x02013; 7.35 (m, 1H), 7.27 &#x02013; 7.22 (m, 1H), 7.18 &#x02013; 7.13 (m, 1H), 3.76 (s, 3H), 3.68 (s, 2H). LC-MS (ESI) m/z 396.0 [M+H]<sup>+</sup>.</p></div><div id="S18" class="sec"><p></p><h4 id="S18title" class="inline">4.2.7.  <em>methyl 3-(2-(4-iodobenzamido)phenyl)propanoate</em> (29g) </h4><p id="P33" class="p p-first-last">(hexanes to ethyl acetate). White powder, 6.54 g, 15.99 mmol, 84% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.75 (s, 1H), 7.93 &#x02013; 7.80 (m, 5H), 7.31 &#x02013; 7.24 (m, 1H), 7.23 &#x02013; 7.13 (m, 2H), 3.67 (s, 3H), 2.91 (dd, <em>J</em> = 7.1, 4.7 Hz, 2H), 2.79 (dd, <em>J</em> = 7.1, 4.6 Hz, 2H) LC-MS (ESI) m/z 410.1 [M+H]<sup>+</sup>.</p></div><div id="S19" class="sec"><p></p><h4 id="S19title" class="inline">4.2.8.  <em>N-(2-cyanophenyl)-4-iodobenzamide</em> (29h) </h4><p id="P34" class="p p-first-last">(hexanes to ethyl acetate). White powder, 5.82 g, 16.7 mmol, 84% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 8.56 (d, <em>J</em> = 8.4 Hz, 1H), 8.35 (s, 1H), 7.93 &#x02013; 7.87 (m, 2H), 7.70 &#x02013; 7.61 (m, 4H), 7.26 &#x02013; 7.20 (m, 1H). LC-MS (ESI) m/z 349.1 [M+H]<sup>+</sup>.</p></div><div id="S20" class="sec"><p></p><h4 id="S20title" class="inline">4.2.9.  <em>methyl 2-((4-iodobenzamido)methyl)benzoate</em> (29i) </h4><p id="P35" class="p p-first-last">(hexanes to hexanes/ethyl acetate 6:4). White powder, 0.53 g, 1.35 mmol, 75% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 7.99 (dd, <em>J</em> = 7.8, 1.4 Hz, 1H), 7.77 &#x02013; 7.71 (m, 2H), 7.64 (dd, <em>J</em> = 7.7, 1.4 Hz, 1H), 7.60 (t, <em>J</em> = 6.8 Hz, 1H), 7.56 &#x02013; 7.46 (m, 3H), 7.37 (td, <em>J</em> = 7.6, 1.4 Hz, 1H), 4.78 (d, <em>J</em> = 6.5 Hz, 2H), 3.95 (s, 3H). LC-MS (ESI) m/z 396.1 [M+H]<sup>+</sup>.</p></div><div id="S21" class="sec"><p></p><h4 id="S21title" class="inline">4.2.10.  <em>methyl 4-chloro-2-(4-iodobenzamido)benzoate</em> (29j) </h4><p id="P36" class="p p-first-last">(hexanes/dichloromethane 8:2 to dichloromethane). White powder, 0.96 g, 2.31 mmol, 62% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.10 (s, 1H), 9.01 (d, <em>J</em> = 2.0 Hz, 1H), 8.02 (d, <em>J</em> = 8.6 Hz, 1H), 7.93 &#x02013; 7.84 (m, 2H), 7.80 &#x02013; 7.71 (m, 2H), 7.11 (dd, <em>J</em> = 8.6, 2.1 Hz, 1H), 3.97 (s, 3H). LC-MS (ESI) m/z 416.1 [M+H]<sup>+</sup>.</p></div><div id="S22" class="sec"><p></p><h4 id="S22title" class="inline">4.2.11.  <em>dimethyl 2-(4-iodobenzamido)terephthalate</em> (29k) </h4><p id="P37" class="p p-first-last">(hexanes to hexanes/ethyl acetate 8:2). White powder, 0.43 g, 0.98 mmol, 98% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.03 (s, 1H), 9.52 (d, <em>J</em> = 1.6 Hz, 1H), 8.15 (d, <em>J</em> = 8.3 Hz, 1H), 7.92 &#x02013; 7.87 (m, 2H), 7.81 &#x02013; 7.75 (m, 3H), 4.00 (s, 3H), 3.96 (s, 3H). LC-MS (ESI) m/z 440.1 [M+H]<sup>+</sup>.</p></div><div id="S23" class="sec"><p></p><h4 id="S23title" class="inline">4.2.12.  <em>methyl 2-(4-iodobenzamido)-4-methoxybenzoate</em> (29l) </h4><p id="P38" class="p p-first-last">(hexanes to hexanes/ethyl acetate 8:2). White powder, 0.59 g, 1.43 mmol, 95% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.93 (s, 1H), 8.32 (s, 1H), 8.02 &#x02013; 7.99 (m, 2H), 7.87 (d, <em>J</em> = 7.9 Hz, 1H), 7.76 &#x02013; 7.68 (m, 2H), 6.82 (d, <em>J</em> = 7.9 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H). LC-MS (ESI) m/z 412.1 [M+H]<sup>+</sup>.</p></div><div id="S24" class="sec"><p></p><h4 id="S24title" class="inline">4.2.13.  <em>methyl 4-cyano-2-(4-iodobenzamido)benzoate</em> (29m) </h4><p id="P39" class="p p-first-last">(hexanes to hexanes/ethyl acetate 8:2). White powder, 0.56 g, 1.34 mmol, 92% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.41 (s, 1H), 8.72 (d, <em>J</em> = 1.6 Hz, 1H), 8.10 (d, <em>J</em> = 8.1 Hz, 1H), 8.02 &#x02013; 8.00 (m, 2H), 7 7.74 &#x02013; 7.71 (m, 3H), 3.89 (s, 3H). LC-MS (ESI) m/z 407.1 [M+H]<sup>+</sup>.</p></div><div id="S25" class="sec"><p></p><h4 id="S25title" class="inline">4.2.14.  <em>methyl 4-(hydroxymethyl)-2-(4-iodobenzamido)benzoate</em> (29n) </h4><p id="P40" class="p p-first-last">(hexanes to hexanes/ethyl acetate 8:2). White powder, 0.95 g, 2.31 mmol, 45% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.11 (s, 1H), 9.03 (d, <em>J</em> = 1.7 Hz, 1H), 8.10 (d, <em>J</em> = 8.2 Hz, 1H), 7.91 &#x02013; 7.86 (m, 2H), 7.78 &#x02013; 7.74 (m, 2H), 7.18 (dd, <em>J</em> = 8.2, 1.7 Hz, 1H), 5.41 (s, 2H), 3.97 (s, 3H). LC-MS (ESI) m/z 412.1 [M+H]<sup>+</sup>.</p></div><div id="S26" class="sec"><p></p><h4 id="S26title" class="inline">4.2.15.  <em>methyl 2-(4-iodobenzamido)-4-(methoxymethyl)benzoate</em> (29o) </h4><p id="P41" class="p p-first-last">(hexanes to hexanes/ethyl acetate 8:2). White powder, 0.26 g, 0.62 mmol, 61% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.60 (s, 1H), 8.52 (d, <em>J</em> = 1.6 Hz, 1H), 8.02 &#x02013; 7.98 (m, 3H), 7.75 &#x02013; 7.71 (m, 2H), 7.19 (dd, <em>J</em> = 8.1, 1.6 Hz, 1H), 4.51 (s, 2H), 3.89 (s, 3H), 3.35 (s, 3H). LC-MS (ESI) m/z 426.1 [M+H]<sup>+</sup>.</p></div><div id="S27" class="sec"><p></p><h4 id="S27title" class="inline">4.2.16.  <em>methyl 4-carbamoyl-2-(4-iodobenzamido)benzoate</em> (29p) </h4><p id="P42" class="p p-first-last">(hexanes to dichloromethane). White powder, 0.25 g, 0.58 mmol, 13% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.39 (bs, 1H), 8.80 (d, <em>J</em> = 1.7 Hz, 1H), 8.16 (bs, 1H), 8.05 &#x02013; 7.98 (m, 3H), 7.77 &#x02013; 7.72 (m, 2H), 7.69 (dd, <em>J</em> = 8.2, 1.7 Hz, 1H), 7.60 (bs, 1H), 3.88 (s, 3H). LC-MS (ESI) m/z 425.1 [M+H]<sup>+</sup>.</p></div><div id="S28" class="sec"><p></p><h4 id="S28title" class="inline">4.2.17.  <em>methyl 2-((4-iodophenyl)amino)-3-(methoxymethyl)benzoate</em> (29q) </h4><p id="P43" class="p p-first-last">(hexanes to hexanes/ethyl acetate 1:1). White powder, 0.48 g, 1.18 mmol, 62% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.39 (bs, 1H), 8.80 (d, <em>J</em> = 1.7 Hz, 1H), 8.16 (bs, 1H), 8.05 &#x02013; 7.98 (m, 3H), 7.77 &#x02013; 7.72 (m, 2H), 7.69 (dd, <em>J</em> = 8.2, 1.7 Hz, 1H), 7.60 (bs, 1H), 3.88 (s, 3H). LC-MS (ESI) m/z 425.1 [M+H]<sup>+</sup>.</p></div><div id="S29" class="sec"><p></p><h4 id="S29title" class="inline">4.2.18.  <em>methyl 2-(4-iodobenzamido)-5-methoxybenzoate</em> (29r) </h4><p id="P44" class="p p-first-last">(hexanes to ethyl acetate). White powder, 1.17 g, 2.85 mmol, 86% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 11.80 (s, 1H), 8.82 (d, <em>J</em> = 9.3 Hz, 1H), 7.88 &#x02013; 7.84 (m, 2H), 7.77 &#x02013; 7.72 (m, 2H), 7.57 (d, <em>J</em> = 3.1 Hz, 1H), 7.18 (dd, <em>J</em> = 9.3, 3.1 Hz, 1H), 3.97 (s, 3H), 3.84 (s, 3H). LC-MS (ESI) m/z 412.1 [M+H]<sup>+</sup>.</p></div><div id="S30" class="sec"><p></p><h4 id="S30title" class="inline">4.2.19.  <em>methyl 2-(2-(4-iodobenzamido)-4-methoxyphenyl)acetate</em> (29s) </h4><p id="P45" class="p p-first-last">(hexanes to hexanes/ethyl acetate 8:2). White powder, 0.26 g, 0.6 mmol, 30% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.83 (s, 1H), 7.91 &#x02013; 7.84 (m, 2H), 7.80 &#x02013; 7.73 (m, 2H), 7.71 (d, <em>J</em> = 2.6 Hz, 1H), 7.12 (d, <em>J</em> = 8.5 Hz, 1H), 6.70 (dd, <em>J</em> = 8.5, 2.7 Hz, 1H), 3.83 (s, 3H), 3.75 (s, 3H), 3.61 (s, 2H). LC-MS (ESI) m/z 426.1 [M+H]<sup>+</sup>.</p></div><div id="S31" class="sec"><p></p><h4 id="S31title" class="inline">4.2.20.  <em>methyl 2-(4-cyano-2-(4-iodobenzamido)phenyl)acetate</em> (29t) </h4><p id="P46" class="p p-first-last">(hexanes to ethyl acetate). White powder, 2.38 g, 5.66 mmol, 82% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.96 (s, 1H), 8.45 (d, <em>J</em> = 1.2 Hz, 1H), 7.90 &#x02013; 7.87 (m, 2H), 7.77 &#x02013; 7.74 (m, 2H), 7.42 (dd, <em>J</em> = 7.9, 1.5 Hz, 1H), 7.35 (d, <em>J</em> = 7.9 Hz, 1H), 3.79 (s, 3H), 3.74 (s, 2H). LC-MS (ESI) m/z 421.1 [M+H]<sup>+</sup>.</p></div><div id="S32" class="sec sec-last"><p></p><h4 id="S32title" class="inline">4.2.21.  <em>methyl 3-(4-iodobenzamido)-4-(2-methoxy-2-oxoethyl)benzoate</em> (29u) </h4><p id="P47" class="p p-first-last">(hexanes to ethyl acetate). White powder, 2.38 g, 5.66 mmol, 82% yield. <sup>1</sup>H NMR (500 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em>
<sup>1</sup>H NMR (500 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.17 (s, 1H), 7.99 (d, <em>J</em> = 1.9 Hz, 1H), 7.96 &#x02013; 7.92 (m, 2H), 7.82 (dd, <em>J</em> = 8.0, 1.8 Hz, 1H), 7.73 &#x02013; 7.69 (m, 2H), 7.50 (d, <em>J</em> = 8.0 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 2H), 3.51 (s, 3H). LC-MS (ESI) m/z 454.1 [M+H]<sup>+</sup>.</p></div></div><div id="S33" class="sec"><h3 id="S33title">4.3. General procedure for the synthesis of intermediate 29c. Method b.</h3><p id="P48" class="p p-first">A mixture of methyl 2-(4-iodobenzamido)benzoate (<strong>29c</strong>). (0.823 mg, 2.16 mmol) and NaH (121 mg, 3 mmol, 60% in oil) in anhydrous DMF (20 mL) was stirred at 0 &#x000b0;C for 15 minutes. Then, MeI (366 mg, 2.6 mmol) was added and the reaction was stirred at room temperature until completion. Then reaction was quenched by addition of MeOH and concentrated under reduced pressure. Desired intermediate was purified by flash column chromatography (0&#x02013;50 % EtOAc in hexanes) to provide 551 mg (1.39 mmol, 65% yield) of <em>methyl 2-(4-iodo-N-methylbenzamido)benzoate</em>
<strong>(29&#x00107;)</strong> as yellow oil.</p><div id="S34" class="sec sec-last"><p></p><h4 id="S34title" class="inline">4.3.1.  <em>methyl 2-(4-iodo-N-methylbenzamido)benzoate</em> (29&#x00107;) </h4><p id="P49" class="p p-first-last"><sup>1</sup>H NMR (400 MHz, Methanol-<em>d</em><sub>4</sub>) <em>&#x003b4;</em> 7.79 (d, <em>J</em> = 7.9 Hz, 1H), 7.58 (t, <em>J</em> = 7.6 Hz, 1H), 7.55 &#x02013; 7.49 (m, 2H), 7.45 (d, <em>J</em> = 8.0 Hz, 1H), 7.36 (t, <em>J</em> = 7.6 Hz, 1H), 7.01 &#x02013; 6.93 (m, 2H), 3.85 (s, 3H), 3.40 (s, 3H). LC-MS (ESI) m/z 396.0 [M+H]<sup>+</sup>.</p></div></div><div id="S35" class="sec"><h3 id="S35title">4.4. General procedure for the synthesis of intermediates 30a-u. Method c.</h3><p id="P50" class="p p-first">The syntheses of compounds <strong>30a-u</strong> have been carried out according to general method <em>c</em>. To a solution of <strong>29a-u</strong> (1 eq) in anhydrous DMF (11 mL/mmol) allyl alcohol (1.10 eq), NaHCO<sub>3</sub> (2.5 eq), Pd(OAc)<sub>2</sub> (0.06 eq) and tetrabutylammonium chloride (0.5 eq) were added and the mixture was stirred at 70 &#x000b0;C overnight. The reaction was cooled to room temperature and then ethyl acetate (50 mL/mmol) was added and the solution washed with saturated aqueous NH<sub>4</sub>Cl (3 &#x000d7; 100 mL/mmol). The organic phase was dried over anhydrous Na<sub>2</sub>SO4, filtered and concentrated under reduced pressure. The desired product was obtained as a brown solid and was used in subsequent reaction without purification.[<a href="#R12" rid="R12" class=" bibr popnode">12</a>]</p><div id="S36" class="sec"><p></p><h4 id="S36title" class="inline">4.4.1.  <em>methyl 1-(4-(3-oxopropyl)benzoyl)piperidine-2-carboxylate</em> (30a) </h4><p id="P51" class="p p-first-last">(390 mg, 1.29 mmol, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.83 (t, <em>J</em> = 1.3 Hz, 1H), 7.40 &#x02013; 7.35 (m, 2H), 7.26 &#x02013; 7.21 (m, 2H), 5.54 &#x02013; 5.45 (m, 1H), 3.78 (s, 3H), 3.70 &#x02013; 3.62 (m, 1H), 3.27 &#x02013; 3.18 (m, 1H), 2.98 (t, <em>J</em> = 7.2 Hz, 2H), 2.80 (t, <em>J</em> = 7.5 Hz, 3H), 2.38 &#x02013; 2.30 (m, 1H), 1.82 &#x02013; 1.73 (m, 3H), 1.48 &#x02013; 1.37 (m, 2H). LC-MS (ESI) m/z 304.1 [M+H]<sup>+</sup>.</p></div><div id="S37" class="sec"><p></p><h4 id="S37title" class="inline">4.4.2.  <em>methyl 2-(4-(3-oxopropyl)benzamido)cyclohexane-1-carboxylate</em> (30b) </h4><p id="P52" class="p p-first-last">(406 mg, 1.28 mmol, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em>
<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 1H NMR (400 MHz, Chloroform-d) &#x003b4; 9.82 (t, <em>J</em> = 1.3 Hz, 1H), 7.73 &#x02013; 7.68 (m, 2H), 7.27 &#x02013; 7.23 (m, 3H), 4.32 (qd, <em>J</em> = 9.4, 4.5, 3.8 Hz, 2H), 3.71 (s, 3H), 2.99 (t, <em>J</em> = 7.4 Hz, 2H), 2.95 &#x02013; 2.88 (m, 2H), 2.84 &#x02013; 2.75 (m, 2H), 2.23 &#x02013; 2.18 (m, 2H), 1.80 &#x02013; 1.41 (m, 4H). LC-MS (ESI) m/z 318.1 [M+H]<sup>+</sup>.</p></div><div id="S38" class="sec"><p></p><h4 id="S38title" class="inline">4.4.3.  <em>methyl 2-(4-(3-oxopropyl)benzamido)benzoate</em> (30c) </h4><p id="P53" class="p p-first-last">(338 mg, 1.09 mmol, 58% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.02 (s, 1H),) , 9.85 (t, <em>J</em> = 1.2 Hz, 1H), 8.93 (d, <em>J</em> = 8.5 Hz, 1H), 8.12 &#x02013; 8.07 (m, 1H), 8.01 &#x02013; 7.96 (m, 2H), 7.61 (t, <em>J</em> = 8.3 Hz, 1H), 7.38 &#x02013; 7.32 (m, 2H), 7.12 (t, <em>J</em> = 7.5 Hz, 1H), 3.97 (d, <em>J</em> = 1.4 Hz, 3H), 3.04 (t, <em>J</em> = 7.5 Hz, 2H), 2.84 (t, <em>J</em> = 7.5 Hz, 2H). LC-MS (ESI) m/z 312.1 [M+H]<sup>+</sup>.</p></div><div id="S39" class="sec"><p></p><h4 id="S39title" class="inline">4.4.4.  <em>methyl 2-(N-methyl-4-(3-oxopropyl)benzamido)benzoate</em> (30&#x00107;) </h4><p id="P54" class="p p-first-last">(414 mg, 1.16 mmol, 53% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.73 (s, 1H), 7.76 (d, <em>J</em> = 8.0 Hz, 1H), 7.45 (t, <em>J</em> = 7.8 Hz, 1H), 7.32 &#x02013; 7.20 (m, 2H), 7.17 &#x02013; 7.12 (m, 2H), 6.96 &#x02013; 6.90 (m, 2H), 3.86 (s, 3H), 3.42 (s, 3H), 2.82 (t, <em>J</em> = 7.5 Hz, 2H), 2.66 (t, <em>J</em> = 7.5 Hz, 2H). LC-MS (ESI) m/z 326.1 [M+H]<sup>+</sup>.</p></div><div id="S40" class="sec"><p></p><h4 id="S40title" class="inline">4.4.5.  <em>methyl 3-(4-(3-oxopropyl)benzamido)benzoate</em> (30d) </h4><p id="P55" class="p p-first-last">(404 mg, 1.29 mmol, 51% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.84 (s, 1H), 8.13 (t, <em>J</em> = 2.0 Hz, 1H), 8.05 (dd, <em>J</em> = 8.0, 2.3 Hz, 1H), 7.92 (s, 1H), 7.83 &#x02013; 7.80 (m, 3H), 7.46 (t, <em>J</em> = 7.9 Hz, 1H), 7.33 (d, <em>J</em> = 7.9 Hz, 2H), 3.92 (s, 3H), 3.03 (t, <em>J</em> = 7.4 Hz, 2H), 2.84 (t, <em>J</em> = 7.4 Hz, 2H). LC-MS (ESI) m/z 312.1 [M+H]<sup>+</sup>.</p></div><div id="S41" class="sec"><p></p><h4 id="S41title" class="inline">4.4.6.  <em>methyl 4-(4-(3-oxopropyl)benzamido)benzoate</em> (30e) </h4><p id="P56" class="p p-first-last">(45 mg, 0.15 mmol, 39% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.84 (t, <em>J</em> = 1.3 Hz, 1H), 8.15 (s, 1H), 7.97 &#x02013; 7.94 (m, 2H), 7.72 &#x02013; 7.68 (m, 2H), 7.47 &#x02013; 7.44 (m, 2H), 7.35 &#x02013; 7.31 (m, 2H), 3.93 (s, 3H), 3.04 (t, <em>J</em> = 7.5 Hz, 2H), 2.84 (t, <em>J</em> = 7.5 Hz, 2H). LC-MS (ESI) m/z 312.1 [M+H]<sup>+</sup>.</p></div><div id="S42" class="sec"><p></p><h4 id="S42title" class="inline">4.4.7.  <em>methyl 2-(2-(4-(3-oxopropyl)benzamido)phenyl)acetate</em> (30f) </h4><p id="P57" class="p p-first-last">(0.78 g, 2.4 mmol, 83% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.84 (t, <em>J</em> = 1.2 Hz, 1H), 9.68 (bs, 1H), 8.02 (d, <em>J</em> = 7.9 Hz, 1H), 7.99 &#x02013; 7.95 (m, 2H), 7.39 &#x02013; 7.32 (m, 3H), 7.25 &#x02013; 7.22 (m, 1H), 7.14 (t, <em>J</em> = 7.7 Hz, 1H), 3.76 (s, 3H), 3.69 (s, 2H), 3.04 (t, <em>J</em> = 7.4 Hz, 2H), 2.87 &#x02013; 2.81 (m, 2H). LC-MS (ESI) m/z 326.1[M+H]<sup>+</sup>.</p></div><div id="S43" class="sec"><p></p><h4 id="S43title" class="inline">4.4.8.  <em>methyl 3-(2-(4-(3-oxopropyl)benzamido)phenyl)propanoate</em> (30g) </h4><p id="P58" class="p p-first-last">(3.93 g, 11.59 mmol, 72% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.84 (t, <em>J</em> = 1.3 Hz, 1H), 9.57 (s, 1H), 8.05 &#x02013; 8.01 (m, 2H), 7.83 (d, <em>J</em> = 8.1 Hz, 1H), 7.37 &#x02013; 7.32 (m, 2H), 7.30 &#x02013; 7.26 (m, 1H), 7.21 &#x02013; 7.13 (m, 2H), 3.67 (s, 3H), 3.04 (t, <em>J</em> = 7.5 Hz, 2H), 2.94 &#x02013; 2.89 (m, 2H), 2.87 &#x02013; 2.81 (m, 2H), 2.80 &#x02013; 2.75 (m, 2H). LC-MS (ESI) m/z 326.1[M+H]<sup>+</sup>.</p></div><div id="S44" class="sec"><p></p><h4 id="S44title" class="inline">4.4.9.  <em>N-(2-cyanophenyl)-4-(3-oxopropyl)benzamide</em> (30h) </h4><p id="P59" class="p p-first-last">(1.09 g, 3.93 mmol, 83% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.84 (t, <em>J</em> = 1.1 Hz, 1H), 8.59 (d, <em>J</em> = 8.5 Hz, 1H), 8.38 (s, 1H), 7.89 &#x02013; 7.84 (m, 2H), 7.68 &#x02013; 7.61 (m, 2H), 7.39 &#x02013; 7.33 (m, 2H), 7.25 &#x02013; 7.18 (m, 1H), 3.04 (t, <em>J</em> = 7.5 Hz, 2H), 2.84 (t, <em>J</em> = 7.5 Hz, 2H). LC-MS (ESI) m/z 279.1 [M+H]<sup>+</sup>.</p></div><div id="S45" class="sec"><p></p><h4 id="S45title" class="inline">4.4.10.  <em>methyl 2-((4-(3-oxopropyl)benzamido)methyl)benzoate</em> (30i) </h4><p id="P60" class="p p-first-last">(0.44 g, 1.34 mmol, 99 % yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.80 (t, <em>J</em> = 1.3 Hz, 1H), 8.02 &#x02013; 7.95 (m, 1H), 7.85 &#x02013; 7.80 (m, 1H), 7.72 &#x02013; 7.68 (m, 2H), 7.62 &#x02013; 7.58 (m, 1H), 7.54 &#x02013; 7.49 (m, 1H), 7.39 &#x02013; 7.33 (m, 1H), 7.25 &#x02013; 7.49 (m, 2H), 4.79 (d, <em>J</em> = 6.4 Hz, 2H), 3.95 (s, 3H), 3.01 &#x02013; 2.95 (m, 2H), 2.78 (t, <em>J</em> = 7.5 Hz, 2H). LC-MS (ESI) m/z 326.1[M+H]<sup>+</sup>.</p></div><div id="S46" class="sec"><p></p><h4 id="S46title" class="inline">4.4.11.  <em>methyl 4-chloro-2-(4-(3-oxopropyl)benzamido)benzoate</em> (30j) </h4><p id="P61" class="p p-first-last">(0.4 g, 1.16 mmol, 53% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.06 (bs, 1H), 9.85 (t, <em>J</em> = 1.2 Hz, 1H), 9.05 (d, <em>J</em> = 2.0 Hz, 1H), 8.01 (d, <em>J</em> = 8.6 Hz, 1H), 7.99 &#x02013; 7.94 (m, 2H), 7.39 &#x02013; 7.34 (m, 2H), 7.10 (dd, <em>J</em> = 8.6, 2.1 Hz, 1H), 3.97 (s, 3H), 3.04 (t, <em>J</em> = 7.5 Hz, 2H), 2.87 &#x02013; 2.81 (m, 2H). LC-MS (ESI) m/z 346.1 [M+H]<sup>+</sup>.</p></div><div id="S47" class="sec"><p></p><h4 id="S47title" class="inline">4.4.12.  <em>dimethyl 2-(4-(3-oxopropyl)benzamido)terephthalate</em> (30k) </h4><p id="P62" class="p p-first-last">(326 mg, 0.88 mmol, 92% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 11.98 (s, 1H), 9.85 (t, <em>J</em> = 1.2 Hz, 1H), 9.55 (d, <em>J</em> = 1.7 Hz, 1H), 8.15 (d, <em>J</em> = 8.3 Hz, 2H), 8.02 &#x02013; 7.97 (m, 2H), 7.77 (dd, <em>J</em> = 8.3, 1.8 Hz, 2H), 7.40 &#x02013; 7.34 (m, 2H), 4.00 (s, 3H), 3.96 (s, 3H), 3.04 (t, <em>J</em> = 7.5 Hz, 2H), 2.88 &#x02013; 2.81 (m, 2H). LC-MS (ESI) m/z 370.1 [M+H]<sup>+</sup>.</p></div><div id="S48" class="sec"><p></p><h4 id="S48title" class="inline">4.4.13.  <em>methyl 4-methoxy-2-(4-(3-oxopropyl)benzamido)benzoate</em> (30l) </h4><p id="P63" class="p p-first-last">(330 mg, 0.97 mmol, 79% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.96 (s, 1H), 9.73 (t, <em>J</em> = 1.2 Hz, 1H), 8.38 (d, <em>J</em> = 2.7 Hz, 1H), 8.00 (d, <em>J</em> = 9.0 Hz, 1H), 7.89 &#x02013; 7.86 (m, 2H), 7.50 &#x02013; 7.44 (m, 2H), 6.80 (dd, <em>J</em> = 9.0, 2.6 Hz, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 2.95 (t, <em>J</em> = 7.0 Hz, 2H), 2.88 &#x02013; 2.82 (m, 2H). LC-MS (ESI) m/z 342.1 [M+H]<sup>+</sup>.</p></div><div id="S49" class="sec"><p></p><h4 id="S49title" class="inline">4.4.14.  <em>methyl 4-cyano-2-(4-(3-oxopropyl)benzamido)benzoate</em> (30m) </h4><p id="P64" class="p p-first-last">(381 mg, 1.13 mmol, 92% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.44 (s, 1H), 9.71 (t, <em>J</em> = 1.2 Hz, 1H), 8.79 (d, <em>J</em> = 1.6 Hz, 1H), 8.10 (d, <em>J</em> = 8.1 Hz, 1H), 7.88 &#x02013; 7.84 (m, 2H), 7.68 (dd, <em>J</em> = 8.2, 1.7 Hz, 1H), 7.47 &#x02013; 7.43 (m, 2H), 3.88 (s, 3H), 2.94 (t, <em>J</em> = 7.0 Hz, 2H), 2.83 (t, <em>J</em> = 7.2 Hz, 2H). LC-MS (ESI) m/z 337.1 [M+H]<sup>+</sup>.</p></div><div id="S50" class="sec"><p></p><h4 id="S50title" class="inline">4.4.15.  <em>methyl 4-(hydroxymethyl)-2-(4-(3-oxopropyl)benzamido)benzoate</em> (30n) </h4><p id="P65" class="p p-first-last">(400 mg, 1.17 mmol, 96% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.05 (s, 1H), 9.83 (t, <em>J</em> = 1.2 Hz, 1H), 9.06 (d, <em>J</em> = 1.6 Hz, 1H), 8.12 &#x02013; 8.07 (m, 1H), 8.06 &#x02013; 8.02 (m, 1H), 8.01 &#x02013; 7.95 (m, 2H), 7.38 &#x02013; 7.33 (m, 2H), 7.18 (dd, <em>J</em> = 8.4, 2.0 Hz, 1H), 5.41 (s, 2H), 3.97(s, 3H), 3.07 &#x02013; 2.98 (m, 2H), 2.86 &#x02013; 2.79 (m, 2H). LC-MS (ESI) m/z 342.1 [M+H]<sup>+</sup>.</p></div><div id="S51" class="sec"><p></p><h4 id="S51title" class="inline">4.4.16.  <em>methyl 4-(methoxymethyl)-2-(4-(3-oxopropyl)benzamido)benzoate</em> (30o) </h4><p id="P66" class="p p-first-last">(150 mg, 0.422 mmol, 69% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.05 (s, 1H), 9.85 (t, <em>J</em> = 1.0 Hz, 1H), 8.89 (s, 1H), 8.14 &#x02013; 8.06 (m, 1H), 8.01 &#x02013; 7.96 (m, 2H), 7.38 &#x02013; 7.33 (m, 2H), 7.18 &#x02013; 7.13 (m, 1H), 4.54 (s, 2H), 3.96 (s, 3H), 3.44 (s, 3H), 3.04 (t, <em>J</em> = 7.4 Hz, 2H), 2.84 (t, <em>J</em> = 7.5 Hz, 2H). LC-MS (ESI) m/z 356.1 [M+H]<sup>+</sup>.</p></div><div id="S52" class="sec"><p></p><h4 id="S52title" class="inline">4.4.17.  <em>methyl 4-carbamoyl-2-(4-(3-oxopropyl)benzamido)benzoate</em> (30p) </h4><p id="P67" class="p p-first-last">(206 mg, 0.56 mmol, 96% yield). <sup>1</sup>H NMR (400 MHz, CDCl3) &#x003b4; 12.05 (s, 1H), 9.83 (t, <em>J</em> = 1.2 Hz, 1H), 9.06 (d, <em>J</em> = 1.6 Hz, 1H), 8.12 &#x02013; 8.07 (m, 1H), 8.06 &#x02013; 8.02 (m, 1H), 8.01 &#x02013; 7.95 (m, 2H), 7.38 &#x02013; 7.33 (m, 2H), 7.18 (dd, <em>J</em> = 8.4, 2.0 Hz, 1H), 5.41 (s, 2H), 3.97(s, 3H), 3.07 &#x02013; 2.98 (m, 2H), 2.86 &#x02013; 2.79 (m, 2H). LC-MS (ESI) m/z 342.1 [M+H]<sup>+</sup>.</p></div><div id="S53" class="sec"><p></p><h4 id="S53title" class="inline">4.4.18.  <em>methyl 3-(methoxymethyl)-2-(4-(3-oxopropyl)benzamido)benzoate</em> (30q) </h4><p id="P68" class="p p-first-last">(313 mg, 0.88 mmol, 75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 10.32 (s, 1H), 9.85 (t, <em>J</em> = 1.2 Hz, 1H), 7.97 &#x02013; 7.90 (m, 3H), 7.78 &#x02013; 7.74 (m, 1H), 7.37 &#x02013; 7.33 (m, 2H), 7.30 (t, <em>J</em> = 7.8 Hz, 1H), 4.48 (s, 2H), 3.87 (s, 3H), 3.37 (s, 3H), 3.04 (t, <em>J</em> = 7.5 Hz, 2H), 2.87 &#x02013; 2.81 (m, 2H). LC-MS (ESI) m/z 356.1 [M+H]<sup>+</sup>.</p></div><div id="S54" class="sec"><p></p><h4 id="S54title" class="inline">4.4.19.  <em>methyl 5-methoxy-2-(4-(3-oxopropyl)benzamido)benzoate</em> (30r) </h4><p id="P69" class="p p-first-last">(835 mg, 2.45 mmol, 86% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 11.75 (s, 1H), 9.84 (d, <em>J</em> = 1.3 Hz, 1H), 8.85 (d, <em>J</em> = 9.2 Hz, 1H), 7.99 &#x02013; 7.94 (m, 2H), 7.57 (d, <em>J</em> = 3.1 Hz, 1H), 7.36 &#x02013; 7.32 (m, 2H), 7.18 (dd, <em>J</em> = 9.3, 3.1 Hz, 1H), 3.97 (s, 3H), 3.84 (s, 3H), 3.03 (t, <em>J</em> = 7.5 Hz, 2H), 2.86 &#x02013; 2.80 (m, 2H).. LC-MS (ESI) m/z 342.1 [M+H]<sup>+</sup>.</p></div><div id="S55" class="sec"><p></p><h4 id="S55title" class="inline">4.4.20.  <em>methyl 2-(4-methoxy-2-(4-(3-oxopropyl)benzamido)phenyl)acetate</em> (30s) </h4><p id="P70" class="p p-first-last">(189 mg, 0.53 mmol, 88% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) &#x003b4; 12.05 (s, 1H), 9.73 (t, <em>J</em> = 1.2 Hz, 1H), 8.18 (d, <em>J</em> = 2.7 Hz, 1H), 7.98 &#x02013; 7.90 (m, 2H), 7.85 &#x02013; 7.78 (m, 3H), 7.50 &#x02013; 7.44 (m, 2H), 6.98 (dd, <em>J</em> = 8.7, 2.0 Hz, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 2.98 (t, <em>J</em> = 7.0 Hz, 2H), 2.88 &#x02013; 2.82 (m, 2H). LC-MS (ESI) m/z 356.1 [M+H]<sup>+</sup>.</p></div><div id="S56" class="sec"><p></p><h4 id="S56title" class="inline">4.4.21.  <em>methyl 2-(4-cyano-2-(4-(3-oxopropyl)benzamido)phenyl)acetate</em> (30t) </h4><p id="P71" class="p p-first-last">(625 mg, 1.78 mmol, 45% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.84 (t, <em>J</em> = 1.2 Hz, 1H), 8.45 (d, <em>J</em> = 1.7 Hz, 1H), 7.98 &#x02013; 7.94 (m, 2H), 7.41 (dd, <em>J</em> = 7.9, 1.7 Hz, 1H), 7.38 &#x02013; 7.33 (m, 3H), 3.79 (s, 3H), 3.74 (s, 2H), 3.05 (t, <em>J</em> = 7.4 Hz, 2H), 2.88 &#x02013; 2.82 (m, 2H). LC-MS (ESI) m/z 351.1 [M+H]<sup>+</sup>.</p></div><div id="S57" class="sec sec-last"><p></p><h4 id="S57title" class="inline">4.4.22.  <em>methyl 4-(2-methoxy-2-oxoethyl)-3-(4-(3-oxopropyl)benzamido)benzoate</em> (30u) </h4><p id="P72" class="p p-first-last">(2.05 g, 5.35 mmol, 94% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.74 (t, <em>J</em> = 1.3 Hz, 1H), 9.09 (s, 1H), 8.21 (d, <em>J</em> = 1.9 Hz, 1H), 7.91 &#x02013; 7.85 (m, 2H), 7.77 (dd, <em>J</em> = 8.0, 1.9 Hz, 1H), 7.48 &#x02013; 7.41(m, 3H), 3.81 (s, 3H), 3.75 (s, 2H), 3.55 (s, 3H), 3.02 &#x02013; 2.94 (m, 2H), 2.70 &#x02013; 2.61 (m, 2H). LC-MS (ESI) m/z 384.1 [M+H]<sup>+</sup>.</p></div></div><div id="S58" class="sec"><h3 id="S58title">4.5. General procedure for the synthesis of intermediates 31a-u. Method d.</h3><p id="P73" class="p p-first">Intermediates <strong>31a-u</strong> have been obtained through general method <em>d</em>. To a solution of 3-oxopropyl derivates 30a-u (1 eq) in anhydrous THF (5mL/mmol) 5,5-dibromo-2,2-dimethyl-1,3-dioxane-4,6-dione (0.5 eq) and HCl (35%) (8.15 &#x003bc;L/mmol) were added. The mixture reaction was stirred at room temperature for 18 h. 5% NaHCO<sub>3</sub> solution (20 mL/mmol) was added and the organic layer washed with H<sub>2</sub>O (3 &#x000d7; 20 mL/mmol) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration solvent was evaporated under reduced pressure and the desired intermediates, obtained as a orange solid, were used in subsequent reaction without purification.[<a href="#R12" rid="R12" class=" bibr popnode">12</a>]</p><div id="S59" class="sec"><p></p><h4 id="S59title" class="inline">4.5.1.  <em>methyl 1-(4-(2-bromo-3-oxopropyl)benzoyl)piperidine-2-carboxylate</em> (31a) </h4><p id="P74" class="p p-first-last">(275 mg, 0.72 mmol, 49% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.53 (d, <em>J</em> = 2.1 Hz, 1H), 7.40 &#x02013; 7.35 (m, 2H), 7.26 &#x02013; 7.21 (m, 2H), 5.54 &#x02013; 5.45 (m, 1H), 4.49 (ddd, <em>J</em> = 14.5, 6.4, 2.2 Hz, 1H), 3.78 (s, 3H), 3.70 &#x02013; 3.62 (m, 1H), 3.58 (dd, <em>J</em> = 14.7, 6.3 Hz, 1H), 3.27 &#x02013; 3.18 (m, 2H), 2.38 &#x02013; 2.30 (m, 1H), 1.82 &#x02013; 1.73 (m, 3H), 1.48 &#x02013; 1.37 (m, 2H). LC-MS (ESI) m/z 383.1 [M+H]<sup>+</sup>.</p></div><div id="S60" class="sec"><p></p><h4 id="S60title" class="inline">4.5.2.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)cyclohexane-1-carboxylate</em> (31b) </h4><p id="P75" class="p p-first-last">(362 mg, 0.91 mmol, 60% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.50 (d, <em>J</em> = 2.2 Hz, 1H), 7.76 &#x02013; 7.72 (m, 2H), 7.31 &#x02013; 7.27 (m, 3H), 4.48 &#x02013; 4.42 (m, 1H), 4.38 &#x02013; 4.27 (m, 2H), 3.73 (s, 3H), 3.53 (dd, <em>J</em> = 14.5, 6.3 Hz, 1H), 3.23 &#x02013; 3.15 (m, 1H), 2.95 &#x02013; 2.89 (m, 2H), 2.23 &#x02013; 2.14 (m, 2H), 1.85 &#x02013; 1.63 (m, 3H), 1.52 &#x02013; 1.42 (m, 1H). LC-MS (ESI) m/z 397.1 [M+H]<sup>+</sup>.</p></div><div id="S61" class="sec"><p></p><h4 id="S61title" class="inline">4.5.3.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)benzoate</em> (31c) </h4><p id="P76" class="p p-first-last">(93 mg, 0.24 mmol, 31% yield).<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em>
<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 12.05 (s, 1H), 9.53 (d, <em>J</em> = 2.1 Hz, 1H), 8.93 (d, <em>J</em> = 7.5 Hz, 1H), 8.12 &#x02013; 8.07 (m, 2H), 8.03 (d, <em>J</em> = 8.4 Hz, 1H), 7.62 (t, <em>J</em> = 8.2 Hz, 1H), 7.43 &#x02013; 7.36 (m, 2H), 7.14 (t, <em>J</em> = 7.8 Hz, 1H), 4.53 &#x02013; 4.46 (m, 1H), 3.98 (s, 3H), 3.58 (dd, <em>J</em> = 14.8, 6.3 Hz, 1H), 3.24 (dd, <em>J</em> = 14.7, 8.0 Hz, 1H). LC-MS (ESI) m/z 391.1 [M+H]<sup>+</sup>.</p></div><div id="S62" class="sec"><p></p><h4 id="S62title" class="inline">4.5.4.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)-N-methylbenzamido)benzoate</em> (31&#x00107;) </h4><p id="P77" class="p p-first-last">(313 mg, 0.78 mmol, 61% yield).<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.40 (s, 1H), 9.23 (s, 1H), 7.76 (d, <em>J</em> = 8.1 Hz, 1H), 7.45 (t, <em>J</em> = 7.7 Hz, 1H), 7.25 &#x02013; 7.16 (m, 2H), 7.15 &#x02013; 7.10 (m, 2H), 6.96 (d, <em>J</em> = 7.6 Hz, 1H), 4.35 &#x02013; 4.28 (m, 1H), 3.86 (s, 3H), 3.43 (t, <em>J</em> = 4.9 Hz, 3H), 3.33 (dd, <em>J</em> = 14.8, 6.3 Hz, 1H), 3.03 (dd, <em>J</em> = 14.7, 8.0 Hz, 1H). LC-MS (ESI) m/z 406.0 [M+H]<sup>+</sup>.</p></div><div id="S63" class="sec"><p></p><h4 id="S63title" class="inline">4.5.5.  <em>methyl 3-(4-(2-bromo-3-oxopropyl)benzamido)benzoate</em> (31d) </h4><p id="P78" class="p p-first-last">(450 mg, 1.15 mmol, 88% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.53 (d, <em>J</em> = 2.1 Hz, 1H), 8.15 &#x02013; 8.13 (m, 1H), 8.06 &#x02013; 8.03 (m, 1H), 7.90 (s, 1H), 7.87 &#x02013; 7.82 (m, 3H), 7.49 &#x02013; 7.45 (m, 1H), 7.40 &#x02013; 7.35 (m, 2H), 4.48 (ddd, <em>J</em> = 8.3, 6.3, 2.1 Hz, 1H), 3.93 (s, 3H), 3.57 (dd, <em>J</em> = 14.7, 6.3 Hz, 1H), 3.24 (dd, <em>J</em> = 14.7, 8.1 Hz, 1H). LC-MS (ESI) m/z 391.1 [M+H]<sup>+</sup>.</p></div><div id="S64" class="sec"><p></p><h4 id="S64title" class="inline">4.5.6.  <em>methyl 4-(4-(2-bromo-3-oxopropyl)benzamido)benzoate</em> (31e) </h4><p id="P79" class="p p-first-last">(53 mg, 0.14 mmol, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.53 (d, <em>J</em> = 2.1 Hz, 1H), 8.15 (s, 1H), 7.97 &#x02013; 7.94 (m, 2H), 7.72 &#x02013; 7.68 (m, 2H), 7.47 &#x02013; 7.44 (m, 2H), 7.35 &#x02013; 7.31 (m, 2H), 4.48 (ddd, <em>J</em> = 8.3, 6.3, 2.1 Hz, 1H), 3.93 (s, 3H), 3.57 (dd, <em>J</em> = 14.7, 6.3 Hz, 1H), 3.24 (dd, <em>J</em> = 14.7, 8.1 Hz, 1H). LC-MS (ESI) m/z 391.1 [M+H]<sup>+</sup>.</p></div><div id="S65" class="sec"><p></p><h4 id="S65title" class="inline">4.5.7.  <em>methyl 2-(2-(4-(2-bromo-3-oxopropyl)benzamido)phenyl)acetate</em> (31f) </h4><p id="P80" class="p p-first-last">(386.7 mg, 0.96 mmol, 40% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.73 (bs, 1H), 9.53 (d, <em>J</em> = 2.2 Hz, 1H), 8.04 &#x02013; 7.98 (m, 3H), 7.41 &#x02013; 7.33 (m, 3H), 7.26 &#x02013; 7.22 (m, 1H), 7.16 (t, <em>J</em> = 7.7 Hz, 1H), 4.49 (ddd, <em>J</em> = 8.3, 6.4, 2.2 Hz, 1H), 3.76 (s, 3H), 3.69 (s, 2H), 3.57 (dd, <em>J</em> = 14.6, 6.4 Hz, 1H), 3.24 (dd, <em>J</em> = 14.7, 8.1 Hz, 1H). LC-MS (ESI) m/z 406.0 [M+H]<sup>+</sup>.</p></div><div id="S66" class="sec"><p></p><h4 id="S66title" class="inline">4.5.8.  <em>methyl 3-(2-(4-(2-bromo-3-oxopropyl)benzamido)phenyl)propanoate</em> (31g) </h4><p id="P81" class="p p-first-last">(2.23 g, 5.33 mmol, 46% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.63 (s, 1H), 9.53 (d, <em>J</em> = 2.2 Hz, 1H), 8.11 &#x02013; 8.07 (m, 2H), 7.84 (d, <em>J</em> = 8.0 Hz, 1H), 7.40 &#x02013; 7.37 (m, 2H), 7.30 &#x02013; 7.27 (m, 1H), 7.21 &#x02013; 7.17 (m, 2H), 4.50 (ddd, <em>J</em> = 8.5, 6.6, 2.3 Hz, 1H), 3.97 (s, 3H), 3.58 (dd, <em>J</em> = 14.6, 6.5 Hz, 1H), 3.25 (dd, <em>J</em> = 14.7, 8.0 Hz, 1H), 2.95 &#x02013; 2.92 (m, 2H), 2.81 &#x02013; 2.79 (m, 2H). LC-MS (ESI) m/z 418.1 [M+H]<sup>+</sup>.</p></div><div id="S67" class="sec"><p></p><h4 id="S67title" class="inline">4.5.9.  <em>4-(2-bromo-3-oxopropyl)-N-(2-cyanophenyl)benzamide</em> (31h) </h4><p id="P82" class="p p-first-last">(830 mg, 2.32 mmol, 59% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.53 (d, <em>J</em> = 2.1 Hz, 1H), 8.57 (d, <em>J</em> = 8.5 Hz, 1H), 8.41 (s, 1H), 7.90 &#x02013; 7.85 (m, 2H), 7.69 &#x02013; 7.62 (m, 2H), 7.40 &#x02013; 7.34 (m, 2H), 7.24 &#x02013; 7.17 (m, 1H), 4.53 &#x02013; 4.46 (m, 1H), 3.58 (dd, <em>J</em> = 14.8, 6.3 Hz, 1H), 3.24 (dd, <em>J</em> = 14.7, 8.0 Hz, 1H). LC-MS (ESI) m/z 358.1 [M+H]<sup>+</sup>.</p></div><div id="S68" class="sec"><p></p><h4 id="S68title" class="inline">4.5.10.  <em>methyl 2-((4-(2-bromo-3-oxopropyl)benzamido)methyl)benzoate</em> (31i) </h4><p id="P83" class="p p-first-last">(183 mg, 0.56 mmol, 42% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.71 (s, 1H), 9.48 (d, <em>J</em> = 2.2 Hz, 1H), 8.04 &#x02013; 7.97 (m, 3H), 7.76 &#x02013; 7.71 (m, 2H), 7.68 &#x02013; 7.64 (m, 1H), 7.55 &#x02013; 7.51 (m, 1H), 7.39 &#x02013; 7.36 (m, 1H), 4.82 (s, 2H), 4.43 (ddd, <em>J</em> = 8.4, 6.4, 2.3 Hz, 1H), 3.97 (s, 3H), 3.55 &#x02013; 3.48 (m, 1H), 3.17 (dd, <em>J</em> = 14.7, 8.1 Hz, 1H). LC-MS (ESI) m/z 406.1 [M+H]<sup>+</sup>.</p></div><div id="S69" class="sec"><p></p><h4 id="S69title" class="inline">4.5.11.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)-4-chlorobenzoate</em> (31j) </h4><p id="P84" class="p p-first-last">(234.2 mg, 0.554 mmol, 48% yield).<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.08 (s, 1H), 9.53 (d, <em>J</em> = 2.1 Hz, 1H), 9.04 (d, <em>J</em> = 2.2 Hz, 1H), 8.02 &#x02013; 7.99 (m, 3H), 7.42 &#x02013; 7.38 (m, 2H), 7.10 (dd, <em>J</em> = 8.5, 2.1 Hz, 1H), 4.49 (ddd, <em>J</em> = 8.3, 6.4, 2.1 Hz, 1H), 3.97 (s, 3H), 3.58 (dd, <em>J</em> = 14.6, 6.5 Hz, 1H), 3.24 (dd, <em>J</em> = 14.7, 8.1 Hz, 1H). LC-MS (ESI) m/z 424.1 [M+H]<sup>+</sup>.</p></div><div id="S70" class="sec"><p></p><h4 id="S70title" class="inline">4.5.12.  <em>dimethyl 2-(4-(2-bromo-3-oxopropyl)benzamido)terephthalate</em> (31k) </h4><p id="P85" class="p p-first-last">(285 mg, 0.64 mmol, 73% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.04 (s, 1H), 9.52 (d, <em>J</em> = 2.1 Hz, 1H), 8.18 &#x02013; 8.14 (m, 1H), 8.07 &#x02013; 8.03 (m, 1H), 7.81 &#x02013; 7.76 (m, 2H), 7.59 &#x02013; 7.55 (m, 2H), 7.40 (d, <em>J</em> = 7.9 Hz, 1H), 4.50 (ddd, <em>J</em> = 8.3, 6.3, 2.1 Hz, 1H), 4.01 (s, 3H), 3.97 (s, 3H), 3.58 (dd, <em>J</em> = 14.7, 6.2 Hz, 1H), 3.24 (dd, <em>J</em> = 14.7, 8.2 Hz, 1H). LC-MS (ESI) m/z 448.1 [M+H]<sup>+</sup>.</p></div><div id="S71" class="sec"><p></p><h4 id="S71title" class="inline">4.5.13.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)-4-methoxybenzoate</em> (31l) </h4><p id="P86" class="p p-first-last">(324 mg, 0.88 mmol, 91% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.96 (s, 1H), 9.54 (d, <em>J</em> = 1.8 Hz, 1H), 8.36 (d, <em>J</em> = 2.8 Hz, 1H), 8.00 (d, <em>J</em> = 9.1 Hz, 1H), 7.95 &#x02013; 7.88 (m, 2H), 7.62 &#x02013; 7.58 (m, 2H), 6.80 (dd, <em>J</em> = 8.9, 2.7 Hz, 1H), 5.06 (ddd, <em>J</em> = 9.0, 5.7, 1.9 Hz, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.60 (dd, <em>J</em> = 14.7, 5.7 Hz, 1H), 3.21 (dd, <em>J</em> = 14.8, 9.0 Hz, 1H). LC-MS (ESI) m/z 422.1 [M+H]<sup>+</sup>.</p></div><div id="S72" class="sec"><p></p><h4 id="S72title" class="inline">4.5.14.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)-4-cyanobenzoate</em> (31m) </h4><p id="P87" class="p p-first-last">(357 mg, 0.98 mmol, 87% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.50 (s, 1H), 9.54 (d, <em>J</em> = 1.9 Hz, 1H), 8.81 (d, <em>J</em> = 1.6 Hz, 1H), 8.13 &#x02013; 8.09 (m, 1H), 8.03 &#x02013; 7.99 (m, 2H), 7.74 &#x02013; 7.71 (m, 2H), 7.54 (d, <em>J</em> = 8.1 Hz, 1H), 5.07 (ddd, <em>J</em> = 9.0, 5.6, 1.8 Hz, 1H), 3.89 (s, 3H), 3.61 (dd, <em>J</em> = 14.7, 5.6 Hz, 1H), 3.23 (dd, <em>J</em> = 14.6, 5.6 Hz, 1H). LC-MS (ESI) m/z 416.1 [M+H]<sup>+</sup>.</p></div><div id="S73" class="sec"><p></p><h4 id="S73title" class="inline">4.5.15.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)-4-(hydroxymethyl)benzoate</em> (31n) </h4><p id="P88" class="p p-first-last">(77 mg, 0.17 mmol, 15% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.62 (s, 1H), 9.57 (m, 1H), 8.70 (s, 1H), 8.04 &#x02013; 7.87 (m, 6H), 7.51 (d, <em>J</em> = 8.0 Hz, 1H), 5.45 (s, 2H), 5.05 (ddd, <em>J</em> = 14.5, 6.4, 2.2 Hz, 1H), 3.90 (s, 3H), 3.63 &#x02013; 3.56 (m, 1H), 3.25 &#x02013; 3.19 (m, 1H). LC-MS (ESI) m/z 434.1 [M+H]<sup>+</sup>.</p></div><div id="S74" class="sec"><p></p><h4 id="S74title" class="inline">4.5.16.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)-4-(methoxymethyl)benzoate</em> (31o) </h4><p id="P89" class="p p-first-last">(137 mg, 0.315 mmol, 77% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 12.08 (s, 1H), 9.53 (d, <em>J</em> = 2.1 Hz, 1H), 8.89 (s, 1H), 8.10 &#x02013; 8.00 (m, 3H), 7.57 &#x02013; 7.54 (m, 1H), 7.39 (dd, <em>J</em> = 8.5, 2.1 Hz, 1H), 7.18 &#x02013; 7.14 (m, 1H), 4.54 (s, 2H), 4.49 (ddd, <em>J</em> = 14.5, 6.4, 2.2 Hz, 1H), 3.97 (s, 3H), 3.58 (dd, <em>J</em> = 14.7, 6.3 Hz, 1H), 3.44 (s, 3H), 3.24 (dd, <em>J</em> = 14.7, 8.1 Hz, 1H). LC-MS (ESI) m/z 434.1 [M+H]<sup>+</sup>.</p></div><div id="S75" class="sec"><p></p><h4 id="S75title" class="inline">4.5.17.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)-4-carbamoylbenzoate</em> (31p) </h4><p id="P90" class="p p-first-last">(167 mg, 0.39 mmol, 67% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.45 (s, 1H), 9.53 (d, <em>J</em> = 2.1 Hz, 1H), 8.13 &#x02013; 8.07 (m, 1H), 8.05 &#x02013; 8.02 (m, 1H), 7.94 &#x02013; 7.88 (m, 2H), 7.51 &#x02013; 7.44 (m, 2H), 7.33 &#x02013; 7.27 (m, Hz, 1H), 5.45 (s, 2H), 4.59 (ddd, <em>J</em> = 14.5, 6.4, 2.2 Hz, 1H), 3.89 (s, 3H), 3.62 &#x02013; 3.55 (m, 1H), 3.25 &#x02013; 3.19 (m, 1H). LC- MS (ESI) m/z 434.1 [M+H]<sup>+</sup>.</p></div><div id="S76" class="sec"><p></p><h4 id="S76title" class="inline">4.5.18.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)-3-(methoxymethyl)benzoate</em> (31q) </h4><p id="P91" class="p p-first-last">(289 mg, 0.66 mmol, 75% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.03 (s, 1H), 9.42 (d, <em>J</em> = 1.5 Hz, 1H), 7.93 &#x02013; 7.91 (m, 2H), 7.75 (d, <em>J</em> = 8.1 Hz, 1H), 7.67 (d, <em>J</em> = 7.6 Hz, 1H), 7.46 &#x02013; 7.39 (m, 3H), 4.62 &#x02013; 4.56 (m, 1H), 4.42 (s, 2H), 3.96 (s, 3H), 3.70 (s, 3H), 3.57 (dd, <em>J</em> = 14.7, 5.9 Hz, 1H), 3.19 (dd, <em>J</em> = 14.7, 8.9 Hz, 1H). LC-MS (ESI) m/z 435.1 [M+H]<sup>+</sup>.</p></div><div id="S77" class="sec"><p></p><h4 id="S77title" class="inline">4.5.19.  <em>methyl 2-(4-(2-bromo-3-oxopropyl)benzamido)-5-methoxybenzoate</em> (31r) </h4><p id="P92" class="p p-first-last">(888 mg, 2.11 mmol, 86% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 11.78 (s, 1H), 9.52 (d, <em>J</em> = 2.2 Hz, 1H), 8.85 (d, <em>J</em> = 9.4 Hz, 1H), 8.01 &#x02013; 7.98 (m, 2H), 7.57 (d, <em>J</em> = 3.1 Hz, 1H), 7.40 &#x02013; 7.36 (m, 2H), 7.18 (dd, <em>J</em> = 9.2, 3.2 Hz, 1H), 4.53 &#x02013; 4.44 (m, 1H), 3.97 (s, 3H), 3.84 (s, 3H), 3.57 (dd, <em>J</em> = 14.7, 6.4 Hz, 1H), 3.23 (dd, <em>J</em> = 14.7, 8.1 Hz, 1H). LC-MS (ESI) m/z 421.1 [M+H]<sup>+</sup>.</p></div><div id="S78" class="sec"><p></p><h4 id="S78title" class="inline">4.5.20.  <em>methyl 2-(2-(4-(2-bromo-3-oxopropyl)benzamido)-4-methoxyphenyl)acetate</em> (31s) </h4><p id="P93" class="p p-first-last">(141 mg, 0.32 mmol, 63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 10.98 (s, 1H), 9.56 (d, <em>J</em> = 2.1 Hz, 1H), 8.16 (d, <em>J</em> = 2.7 Hz, 1H), 7.91 &#x02013; 7.86 (m, 2H), 7.41 (dd, <em>J</em> = 7.9, 2.7 Hz, 1H), 7.40 &#x02013; 7.35 (m, 2H), 7.09 &#x02013; 7.05 (m, 1H), 4.49 (ddd, <em>J</em> = 14.5, 6.4, 2.2 Hz, 1H), 3.95 (s, 3H), 3.80 (s, 3H), 3.74 (s, 2H), 3.58 (dd, J = 14.5, 6.3 Hz, 1H), 3.27 &#x02013; 3.19 (m, 1H). LC-MS (ESI) m/z 435.1 [M+H]<sup>+</sup>.</p></div><div id="S79" class="sec"><p></p><h4 id="S79title" class="inline">4.5.21.  <em>methyl 2-(2-(4-(2-bromo-3-oxopropyl)benzamido)-4-cyanophenyl)acetate</em> (31t) </h4><p id="P94" class="p p-first-last">(688 mg, 1.60 mmol, 90% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.90 (s, 1H), 9.53 (d, <em>J</em> = 2.1 Hz, 1H), 8.45 &#x02013; 8.42 (m, 1H), 8.03 &#x02013; 7.98 (m, 2H), 7.42 &#x02013; 7.33 (m, 4H), 4.50 (ddd, <em>J</em> = 8.3, 6.4, 2.1 Hz, 1H), 3.79 (s, 3H), 3.74 (s, 2H), 3.55 (dd, J = 14.7, 6.4 Hz, 1H), 3.25 (dd, <em>J</em> = 14.7, 8.0 Hz, 1H). LC-MS (ESI) m/z 429.0 [M+H]<sup>+</sup>.</p></div><div id="S80" class="sec sec-last"><p></p><h4 id="S80title" class="inline">4.5.22.  <em>methyl 3-(4-(2-bromo-3-oxopropyl)benzamido)-4-(2-methoxy-2-oxoethyl)benzoate</em> (31u) </h4><p id="P95" class="p p-first-last">(1.05 g, 2.27 mmol, 42% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.89 (s, 1H), 9.72 (d, <em>J</em> = 1.9 Hz, 1H), 8.25 &#x02013; 8.19 (m, 1H), 7.91 &#x02013; 7.86 (m, 2H), 7.64 &#x02013; 7.58 (m, 2H), 7.00 &#x02013; 6.96 (m, 2H), 4.45 (ddd, <em>J</em> = 14.5, 6.4, 2.2 Hz, 1H), 3.80 (s, 3H), 3.74 (s, 2H), 3.65 (s, 3H), 3.55 (ddd, <em>J</em> = 14.5, 6.3 Hz, 1H), 3.23 (ddd, <em>J</em> = 14.5, 7.9, 1H). LC-MS (ESI) m/z 462.1 [M+H]<sup>+</sup>.</p></div></div><div id="S81" class="sec"><h3 id="S81title">4.6. General procedure for the synthesis of final compound 7 and intermediates 32a-g, 32i-32u. Method e.</h3><p id="P96" class="p p-first">Intermediates <strong>31a-u</strong> (1 eq) were added to solution of 2,6-diaminopyrimidin-4-ol (1.1 eq) and sodium acetate (2 eq) in water (3.13 mL/eq) and methanol (3.13 mL/eq). The reaction mixture was stirred at 45 &#x000b0;C for 2 hours. After solvent evaporation, intermediates were purified by flash column chromatography eluted initially with dichloromethane followed by 20% methanol in dichloromethane.[<a href="#R12" rid="R12" class=" bibr popnode">12</a>]</p><div id="S82" class="sec"><p></p><h4 id="S82title" class="inline">4.6.1.  <em>4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)-N-(2-cyanophenyl)benzamide</em> (7) </h4><p id="P97" class="p p-first-last">(101 mg, 0.26 mmol, 11% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.27 (s, 1H), 10.72 (s, 1H), 10.27 (s, 1H), 8.80 &#x02013; 8.75 (m, 1H), 8.20 (dd, <em>J</em> = 7.8, 1.7 Hz, 1H), 8.05 &#x02013; 8.01 (m, 2H), 7.52 &#x02013; 7.46 (m, 2H), 7.30 &#x02013; 7.25 (m, 1H), 7.14 (td, <em>J</em> = 7.5, 1.3 Hz, 1H), 6.35 (d, <em>J</em> = 1.8 Hz, 1H), 6.04 (s, 2H), 4.02 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 166.4, 162.2, 157.8, 152.2, 147.3, 139.5, 134.5, 132.1, 128.1, 127.5, 127.1, 127.0, 126.6, 126.3, 123.5, 122.6, 122.1, 118.5, 48.2. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>17</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> 385.1408, found 385.1414.</p></div><div id="S83" class="sec"><p></p><h4 id="S83title" class="inline">4.6.2.  <em>methyl 1-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzoyl)piperidine-2-carboxylate</em> (32a) </h4><p id="P98" class="p p-first-last">(60 mg, 0.147 mmol, yield 20% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.72 (d, <em>J</em> = 2.1 Hz, 1H), 10.11 (s, 1H), 7.39 &#x02013; 7.32 (m, 2H), 7.28 &#x02013; 7.21 (m, 2H), 6.35 (d, <em>J</em> = 2.2 Hz, 1H), 5.99 (s, 2H), 4.47 &#x02013; 4.36 (m, 1H), 3.96 (s, 2H), 3.71 (s, 3H), 3.59 &#x02013; 3.50 (m, 1H), 3.13 &#x02013; 3.02 (m, 1H), 2.20 &#x02013; 2.12 (m, 1H), 1.71 &#x02013; 1.63 (m, 1H), 1.58 &#x02013; 1.48 (m, 1H), 1.44 &#x02013; 1.36 (m, 1H), 1.30 &#x02013; 1.23 (m, 1H), 1.20 &#x02013; 1.13 (m, 1H). LC-MS (ESI) m/z 410.1 [M+H]<sup>+</sup>.</p></div><div id="S84" class="sec"><p></p><h4 id="S84title" class="inline">4.6.3.  <em>Methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido) cyclohexane-1-carboxylate</em> (32b) </h4><p id="P99" class="p p-first-last">(82.6 mg, 0.195 mmol, 20% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.72 (s, 1H), 10.12 (s, 1H), 7.89 (d, <em>J</em> = 8.3 Hz, 1H), 7.65 &#x02013; 7.59 (m, 2H), 7.37 &#x02013; 7.31 (m, 2H), 6.32 (d, <em>J</em> = 2.1 Hz, 1H), 6.00 (s, 2H), 4.34 &#x02013; 4.27 (m, 1H), 4.14 &#x02013; 4.05 (m, 1H), 3.96 (s, 2H), 3.53 (s, 3H), 3.19 &#x02013; 3.15 (m, 1H), 2.85 &#x02013; 2.80 (m, 1H), 1.99 &#x02013; 1.91 (m, 1H), 1.83 &#x02013; 1.74 (m, 1H), 1.73 &#x02013; 1.50 (m, 2H), 1.43 &#x02013; 1.29 (m, 2H). LC-MS (ESI) m/z 424.1 [M+H]<sup>+</sup>.</p></div><div id="S85" class="sec"><p></p><h4 id="S85title" class="inline">4.6.4.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)benzoate</em> (32c) </h4><p id="P100" class="p p-first-last">(27 mg, 0.06 mmol, 25% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.68 (s, 1H), 10.76 (d, <em>J</em> = 1.9 Hz, 1H), 10.14 (s, 1H), 8.72 (d, <em>J</em> = 2.1 Hz, 1H), 8.02 (d, <em>J</em> = 8.6 Hz, 1H), 7.85 &#x02013; 7.80 (m, 2H), 7.53 &#x02013; 7.49 (m, 2H), 7.30 (dd, <em>J</em> = 8.6, 2.1 Hz, 1H), 6.39 (d, <em>J</em> = 1.7 Hz, 1H), 6.02 (s, 2H), 4.03 (s, 2H), 3.90 (s, 3H). LC-MS (ESI) m/z 418.1 [M+H]<sup>+</sup>.</p></div><div id="S86" class="sec"><p></p><h4 id="S86title" class="inline">4.6.5.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)-N-methyl benzamido)benzoate</em> (32&#x00107;) </h4><p id="P101" class="p p-first-last">(50 mg, 0.116 mmol, 15% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.68 (s, 1H), 10.76 (d, <em>J</em> = 1.9 Hz, 1H), 10.14 (s, 1H), 8.72 (d, <em>J</em> = 2.1 Hz, 1H), 8.02 (d, <em>J</em> = 8.6 Hz, 1H), 7.85 &#x02013; 7.80 (m, 2H), 7.53 &#x02013; 7.49 (m, 2H), 7.30 (dd, <em>J</em> = 8.6, 2.1 Hz, 1H), 6.39 (d, <em>J</em> = 1.7 Hz, 1H), 6.02 (s, 2H), 4.03 (s, 2H), 3.90 (s, 3H). LC-MS (ESI) m/z 433.0 [M+H]<sup>+</sup>.</p></div><div id="S87" class="sec"><p></p><h4 id="S87title" class="inline">4.6.6.  <em>methyl 3-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)benzoate</em> (32d) </h4><p id="P102" class="p p-first-last">(57 mg, 0.13 mmol, 13 % yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.74 (d, <em>J</em> = 1.8 Hz, 1H), 10.33 (s, 1H), 10.14 (s, 1H), 8.45 (t, <em>J</em> = 2.0 Hz, 1H), 8.07 &#x02013; 8.03 (m, 1H), 7.87 &#x02013; 7.84 (m, 2H), 7.70 &#x02013; 7.66 (m, 1H), 7.49 (t, <em>J</em> = 7.9 Hz, 1H), 7.46 &#x02013; 7.43 (m, 2H), 6.36 (d, <em>J</em> = 2.2 Hz, 1H), 6.01 (s, 2H), 4.01 (s, 2H), 3.87 (s, 3H). LC-MS (ESI) m/z 418.1 [M+H]<sup>+</sup>.</p></div><div id="S88" class="sec"><p></p><h4 id="S88title" class="inline">4.6.7.  <em>methyl 4-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)benzoate</em> (32e) </h4><p id="P103" class="p p-first-last">(12 mg, 0.027 mmol, 20 % yield). <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.74 (d, <em>J</em> = 1.8 Hz, 1H), 10.44 (s, 1H), 10.14 (s, 1H), 7.95 &#x02013; 7.92 (m, 4H), 7.85 &#x02013; 7.82 (m, 2H), 7.46 &#x02013; 7.43 (m, 2H), 6.37 (d, <em>J</em> = 2.3 Hz, 1H), 6.01 (s, 2H), 4.01 (s, 2H), 3.83 (s, 3H). LC-MS (ESI) m/z 418.1 [M+H]<sup>+</sup>.</p></div><div id="S89" class="sec"><p></p><h4 id="S89title" class="inline">4.6.8.  <em>methyl 2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)phenyl)acetate</em> (32f) </h4><p id="P104" class="p p-first-last">(194 mg, 0.45 mmol, 47% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.71 (d, <em>J</em> = 1.9 Hz, 1H), 9.87 (s, 1H), 7.81 &#x02013; 7.77 (m, 2H), 7.44 &#x02013; 7.40 (m, 2H), 7.39 &#x02013; 7.36 (m, 1H), 7.34 &#x02013; 7.29 (m, 2H), 7.21 (t, <em>J</em> = 7.4 Hz, 1H), 6.54 (s, 1H), 6.40 (s, 2H), 6.33 (d, <em>J</em> = 2.0 Hz, 1H), 4.00 (s, 2H), 3.72 (s, 3H), 3.50 (s, 2H). LC-MS (ESI) m/z 432.2 [M+H]<sup>+</sup>.</p></div><div id="S90" class="sec"><p></p><h4 id="S90title" class="inline">4.6.9.  <em>methyl 3-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido) phenyl)propanoate</em> (32g) </h4><p id="P105" class="p p-first-last">(300 mg, 0.67 mmol, 13% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.76 (d, <em>J</em> = 1.6 Hz, 1H), 10.14 (s, 1H), 9.84 (s, 1H), 7.90 &#x02013; 7.80 (m, 2H), 7.48 &#x02013; 7.38 (m, 2H), 7.32 &#x02013; 7.17 (m, 4H), 6.37 (d, <em>J</em> = 1.8 Hz, 1H), 6.02 (s, 2H), 4.01 (s, 2H), 3.54 (s, 3H), 2.85 (t, <em>J</em> = 7.7 Hz, 2H), 2.59 (t, <em>J</em> = 7.7 Hz, 2H). LC-MS (ESI) m/z 446.1 [M+H]<sup>+</sup>.</p></div><div id="S91" class="sec"><p></p><h4 id="S91title" class="inline">4.6.10.  <em>methyl 2-((4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido) methyl)benzoate</em> (32i) </h4><p id="P106" class="p p-first-last">(91 mg, 0.21 mmol, 47% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.74 (d, <em>J</em> = 2.1 Hz, 1H), 10.16 (s, 1H), 8.86 (t, <em>J</em> = 6.0 Hz, 1H), 7.86 (d, <em>J</em> = 7.7 Hz, 1H), 7.80 &#x02013; 7.74 (m, 2H), 7.55 (t, <em>J</em> = 7.5 Hz, 1H), 7.42 &#x02013; 7.33 (m, 4H), 6.35 (d, <em>J</em> = 2.1 Hz, 1H), 6.02 (s, 2H), 4.77 (d, <em>J</em> = 5.9 Hz, 2H), 3.98 (s, 2H), 3.85 (s, 3H). LC-MS (ESI) m/z 432.2 [M+H]<sup>+</sup>.</p></div><div id="S92" class="sec"><p></p><h4 id="S92title" class="inline">4.6.11.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-chlorobenzoate</em> (32j) </h4><p id="P107" class="p p-first-last">(140 mg, 0.31 mmol, 44% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.68 (s, 1H), 10.76 (d, <em>J</em> = 1.9 Hz, 1H), 10.14 (s, 1H), 8.72 (d, <em>J</em> = 2.1 Hz, 1H), 8.02 (d, <em>J</em> = 8.6 Hz, 1H), 7.85 &#x02013; 7.80 (m, 2H), 7.53 &#x02013; 7.49 (m, 2H), 7.30 (dd, <em>J</em> = 8.6, 2.1 Hz, 1H), 6.39 (d, <em>J</em> = 1.7 Hz, 1H), 6.02 (s, 2H), 4.03 (s, 2H), 3.90 (s, 3H). LC-MS (ESI) m/z 452.1 [M+H]<sup>+</sup>.</p></div><div id="S93" class="sec"><p></p><h4 id="S93title" class="inline">4.6.12.  <em>dimethyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido) terephthalate</em> (32k) </h4><p id="P108" class="p p-first-last">(19 mg, 0.039 mmol, 6% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.49 (s, 1H), 10.77 (d, <em>J</em> = 1.9 Hz, 1H), 10.15 (s, 1H), 9.11 (d, <em>J</em> = 1.7 Hz, 1H), 8.10 (d, <em>J</em> = 8.2 Hz, 1H), 7.88 &#x02013; 7.83 (m, 2H), 7.77 (dd, <em>J</em> = 8.3, 1.7 Hz, 1H), 7.54 &#x02013; 7.47 (m, 2H), 6.39 (d, <em>J</em> = 2.2 Hz, 1H), 6.03 (s, 2H), 4.02 (s, 2H), 3.91 (s, 6H). LC-MS (ESI) m/z 476.1 [M+H]<sup>+</sup>.</p></div><div id="S94" class="sec"><p></p><h4 id="S94title" class="inline">4.6.13.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-methoxybenzoate</em> (32l) </h4><p id="P109" class="p p-first-last">(60 mg, 0.13 mmol, 15% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.95 (s, 1H), 10.77 (d, <em>J</em> = 2.3 Hz, 1H), 10.14 (s, 1H), 8.38 (d, <em>J</em> = 2.6 Hz, 1H), 8.00 (d, <em>J</em> = 9.0 Hz, 1H), 7.86 &#x02013; 7.81 (m, 2H), 7.54 &#x02013; 7.48 (m, 2H), 6.79 (dd, <em>J</em> = 9.0, 2.6 Hz, 1H), 6.39 (d, <em>J</em> = 2.2 Hz, 1H), 6.02 (s, 2H), 4.02 (s, 2H), 3.88 (s, 3H), 3.86 (s, 3H). LC-MS (ESI) m/z 449.1 [M+H]<sup>+</sup>.</p></div><div id="S95" class="sec"><p></p><h4 id="S95title" class="inline">4.6.14.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-cyanobenzoate</em> (32m) </h4><p id="P110" class="p p-first-last">(60 mg, 0.14 mmol, 14% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.45 (s, 1H), 10.77 (d, <em>J</em> = 2.3 Hz, 1H), 10.15 (s, 1H), 8.82 (d, <em>J</em> = 1.7 Hz, 1H), 8.11 (d, <em>J</em> = 8.2 Hz, 1H), 7.86 &#x02013; 7.82 (m, 2H), 7.70 (dd, <em>J</em> = 8.1, 1.7 Hz, 1H), 7.53 &#x02013; 7.49 (m, 2H), 6.39 (d, <em>J</em> = 2.2 Hz, 1H), 6.03 (s, 2H), 4.03 (s, 2H), 3.90 (s, 3H). LC-MS (ESI) m/z 443.1 [M+H]<sup>+</sup>.</p></div><div id="S96" class="sec"><p></p><h4 id="S96title" class="inline">4.6.15.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido) -4- (hydroxymethyl)benzoate</em> (32n) </h4><p id="P111" class="p p-first-last">(77 mg, 0.172 mmol, 19% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.63 (s, 1H), 10.77 (d, <em>J</em> = 2.1 Hz, 1H), 10.15 (s, 1H), 8.70 (s, 1H), 8.08 &#x02013; 7.80 (m, 5H), 7.51 &#x02013; 7.44 (m, 2H), 6.37 (d, <em>J</em> = 2.1 Hz, 1H), 6.02 (s, 2H), 5.44 (s, 2H), 4.01 (s, 2H), 3.89 (s, 3H). LC-MS (ESI) m/z 448.1 [M+H]+.</p></div><div id="S97" class="sec"><p></p><h4 id="S97title" class="inline">4.6.16.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-(methoxymethyl)benzoate</em> (32o) </h4><p id="P112" class="p p-first-last">(13 mg, 0.028 mmol, 8% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.63 (s, 1H), 10.76 (d, <em>J</em> = 2.1 Hz, 1H), 10.13 (s, 1H), 8.61 (d, <em>J</em> = 1.5 Hz, 1H), 8.00 (d, <em>J</em> = 8.2 Hz, 1H), 7.86 &#x02013; 7.82 (m, 2H), 7.52 &#x02013; 7.48 (m, 2H), 7.16 (dd, <em>J</em> = 8.2, 1.6 Hz, 1H), 6.38 (d, <em>J</em> = 2.1 Hz, 1H), 6.02 (s, 2H), 4.51 (s, 2H), 4.02 (s, 2H), 3.90 (s, 3H), 3.35 (s, 3H). LC-MS (ESI) m/z 462.1 [M+H]<sup>+</sup>.</p></div><div id="S98" class="sec"><p></p><h4 id="S98title" class="inline">4.6.17.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-carbamoylbenzoate</em> (32p) </h4><p id="P113" class="p p-first-last">(22.7 mg, 0.049 mmol, 13% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.44 (s, 1H), 10.78 (d, <em>J</em> = 2.1 Hz, 1H), 10.15 (s, 1H), 8.90 (d, <em>J</em> = 2.3 Hz, 1H), 8.17 (s, 1H), 8.03 &#x02013; 8.01 (m, 1H), 7.87 &#x02013; 7.83 (m, 2H), 7.61 &#x02013; 7.58 (m, 2H), 7.53 &#x02013; 7.48 (m, 2H), 6.39 (d, <em>J</em> = 2.1 Hz, 1H), 6.04 (s, 2H), 4.02 (s, 2H), 3.89 (s, 3H). LC-MS (ESI) m/z 461.1 [M+H]<sup>+</sup>.</p></div><div id="S99" class="sec"><p></p><h4 id="S99title" class="inline">4.6.18.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-3-(methoxymethyl)benzoate</em> (32q) </h4><p id="P114" class="p p-first-last">(81.9 mg, 0.177 mmol, 27% yield). (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.77 (d, <em>J</em> = 2.2 Hz, 1H), 10.15 (s, 1H), 9.93 (s, 1H), 7.86 &#x02013; 7.81 (m, 2H), 7.75 (dd, <em>J</em> = 7.6, 1.6 Hz, 1H), 7.68 (dd, <em>J</em> = 7.7, 1.6 Hz, 1H), 7.46 &#x02013; 7.39 (m, 3H), 6.39 (d, <em>J</em> = 2.2 Hz, 1H), 6.03 (s, 2H), 4.45 (s, 2H), 4.01 (s, 2H), 3.69 (s, 3H), 3.29 (s, 3H). LC-MS (ESI) m/z 462.1 [M+H]<sup>+</sup>.</p></div><div id="S100" class="sec"><p></p><h4 id="S100title" class="inline">4.6.19.  <em>methyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-5-methoxybenzoate</em> (32r) </h4><p id="P115" class="p p-first-last">(192.8 mg, 0.43 mmol, 20% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.19 (s, 1H), 10.75 (d, <em>J</em> = 2.1 Hz, 1H), 10.13 (s, 1H), 8.39 (d, <em>J</em> = 9.1 Hz, 1H), 7.83 &#x02013; 7.79 (m, 2H), 7.49 &#x02013; 7.45 (m, 3H), 7.29 (dd, <em>J</em> = 9.2, 3.1 Hz, 1H), 6.37 (d, <em>J</em> = 2.1 Hz, 1H), 6.01 (s, 2H), 4.02 (s, 2H), 3.87 (s, 2H), 3.80 (s, 3H). LC-MS (ESI) m/z 448.1 [M+H]<sup>+</sup>.</p></div><div id="S101" class="sec"><p></p><h4 id="S101title" class="inline">4.6.20.  <em>methyl 2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl) benzamido)-4-methoxyphenyl)acetate</em> (32s) </h4><p id="P116" class="p p-first-last">(49 mg, 0.011 mmol, 34 % yield). <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.74 (d, <em>J</em> = 1.9 Hz, 2H), 10.15 (s, 1H), 9.80 (s, 1H), 7.81 &#x02013; 7.76 (m, 2H), 7.45 &#x02013; 7.39 (m, 2H), 7.22 (d, <em>J</em> = 8.5 Hz, 1H), 7.02 (d, <em>J</em> = 2.6 Hz, 1H), 6.80 (dd, <em>J</em> = 8.4, 2.7 Hz, 1H), 6.36 (d, <em>J</em> = 2.1 Hz, 1H), 6.02 (s, 2H), 4.00 (s, 2H), 3.74 (s, 3H), 3.65 (s, 2H), 3.50 (s, 3H). LC-MS (ESI) m/z 462.1 [M+H]<sup>+</sup>.</p></div><div id="S102" class="sec"><p></p><h4 id="S102title" class="inline">4.6.21.  <em>methyl 2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-cyanophenyl)acetate</em> (32t) </h4><p id="P117" class="p p-first-last">(316 mg, 0.691 mmol, 45% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.74 (d, <em>J</em> = 2.2 Hz, 1H), 10.13 (s, 1H), 10.04 (s, 1H), 7.88 (d, <em>J</em> = 1.7 Hz, 1H), 7.82 &#x02013; 7.77 (m, 2H), 7.69 (dd, <em>J</em> = 7.9, 1.8 Hz, 1H), 7.56 (d, <em>J</em> = 8.0 Hz, 1H), 7.46 &#x02013; 7.42 (m, 2H), 6.37 (d, <em>J</em> = 2.1 Hz, 1H), 6.01 (s, 2H), 4.01 (s, 2H), 3.87 (s, 2H), 3.51 (s, 3H). LC-MS (ESI) m/z 457.1 [M+H]<sup>+</sup>.</p></div><div id="S103" class="sec sec-last"><p></p><h4 id="S103title" class="inline">4.6.22.  <em>methyl 3-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-(2-methoxy-2-oxoethyl)benzoate</em> (32u) </h4><p id="P118" class="p p-first-last">(295 mg, 0.603 mmol, 47% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 10.72 (d, <em>J</em> = 2.1 Hz, 1H), 10.13 (s, 1H), 10.05 (s, 1H), 8.07 (s, 1H), 7.82 &#x02013; 7.77 (m, 2H), 7.78 (dd, <em>J</em> = 8.0, 1.7 Hz, 1H), 7.48 &#x02013; 7.41 (m, 3H), 6.35 (d, <em>J</em> = 2.2 Hz, 1H), 6.01 (s, 2H), 4.02 (s, 2H), 3.86 (s, 3H), 3.74 (s, 2H), 3.60 (s, 3H). LC-MS (ESI) m/z 490.1 [M+H]<sup>+</sup>.</p></div></div><div id="S104" class="sec"><h3 id="S104title">4.7. General procedure for the synthesis of final compounds 2&#x02013;6, 9 and 11&#x02013;25. Method f.</h3><p id="P119" class="p p-first">The synthesis of compounds <strong>2&#x02013;6</strong>, <strong>9</strong> and <strong>11&#x02013;25</strong> has been carried out following general method <em>f</em>. The corresponding derivate <strong>32a-g or 32h-u</strong> (1 eq) was dissolved in a mixture MeOH (33 mL/mmol) and 2N NaOH (33 mL/mmol) was added. The resulting mixture was stirred at 60 &#x000b0;C for 1h. The resulting solution was cooled in an ice bath, and the pH was adjusted to 3&#x02013;4 using 1 N HCl. The resulting suspension was chilled in a dry ice/acetone bath and thawed to 4 &#x000b0;C overnight in a refrigerator. The precipitate was filtered, washed with cold water, and dried under reduced pressure.[<a href="#R12" rid="R12" class=" bibr popnode">12</a>]</p><div id="S105" class="sec"><p></p><h4 id="S105title" class="inline">4.7.1.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)benzoic acid</em> (2) </h4><p id="P120" class="p p-first-last">(4.4 mg, 0.011 mmol, 17% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.18 (s, 1H), 10.75 (s, 1H), 10.13 (s, 1H), 8.71 (d, <em>J</em> = 8.3 Hz, 1H), 8.05 (d, <em>J</em> = 7.7 Hz, 1H), 7.86 &#x02013; 7.77 (m, 2H), 7.64 (t, <em>J</em> = 7.8 Hz, 1H), 7.56 &#x02013; 7.43 (m, 2H), 7.19 (t, <em>J</em> = 7.5 Hz, 1H), 6.37 (s, 1H), 6.01 (s, 2H), 4.02 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 169.9, 164.7, 159.2, 152.2, 151.2, 147.0, 141.2, 134.2, 131.8, 131.3, 129.0, 126.9, 122.7, 119.7, 116.6, 116.5, 114.2, 98.6, 31.6. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 404.1353, found 404.1359.</p></div><div id="S106" class="sec"><p></p><h4 id="S106title" class="inline">4.7.2.  <em>3-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)benzoic acid</em> (3) </h4><p id="P121" class="p p-first-last">(13 mg, 0.032 mmol, 24% yield) as a green pale solid. <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.94 (s, 1H), 11.05 (s, 1H), 10.71 (s, 1H), 10.32 (s, 1H), 8.40 (t, <em>J</em> = 1.9 Hz, 1H), 8.02 (ddd, <em>J</em> = 8.2, 2.2, 1.0 Hz, 1H), 7.88 &#x02013; 7.84 (m, 2H), 7.66 (dt, <em>J</em> = 7.7, 1.2 Hz, 1H), 7.46 (t, <em>J</em> = 7.9 Hz, 1H), 7.44 &#x02013; 7.42 (m, 2H), 6.69 (s, 2H), 6.47 &#x02013; 6.44 (m, 1H), 4.02 (s, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 168.6, 166.0, 162.9, 152.6, 149.0, 134.9, 133.1, 131.4, 127.0, 126.9, 126.5, 126.1, 124.0, 119.1, 117.4, 116.8, 116.7, 111.3, 30.8. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 404.1353, found 404.1341.</p></div><div id="S107" class="sec"><p></p><h4 id="S107title" class="inline">4.7.3.  <em>4-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)benzoic acid</em> (4) </h4><p id="P122" class="p p-first-last">(1.6 mg, 0.004 mmol, 15% yield) as a yellow-green solid. <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.73 (s, 1H), 10.78 (s, 1H), 10.41 (s, 1H), 10.23 (s, 1H), 7.97 &#x02013; 7.86 (m, 4H), 7.83 (d, <em>J</em> = 8.1 Hz, 2H), 7.44 (d, <em>J</em> = 8.0 Hz, 2H), 6.38 (d, <em>J</em> = 2.2 Hz, 1H), 6.10 (s, 2H), 4.01 (s, 1H).<sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 170.3, 166.3, 162.9, 152.6, 149.0, 138.9, 133.1, 131.4, 129.5, 126.7, 126.0, 122.6, 121.5, 119.7, 116.5, 111.3, 31.8. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 404.1353, found 404.1348.</p></div><div id="S108" class="sec"><p></p><h4 id="S108title" class="inline">4.7.4.  <em>2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)phenyl) acetic acid</em> (5) </h4><p id="P123" class="p p-first-last">(71.1 mg, 0.17 mmol, 73% yield) as a pink solid. <sup>1</sup>H NMR (500 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.34 (s, 1H), 10.75 (d, <em>J</em> = 1.9 Hz, 1H), 10.16 (s, 1H), 9.86 (s, 1H), 7.85 &#x02013; 7.78 (m, 2H), 7.48 &#x02013; 7.44 (m, 1H), 7.43 &#x02013; 7.40 (m, 2H), 7.33 &#x02013; 7.27 (m, 2H), 7.22 &#x02013; 7.16 (m, 1H), 6.37 (d, <em>J</em> = 1.9 Hz, 1H), 6.04 (s, 2H), 4.00 (s, 2H), 3.65 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 172.8, 165.2, 159.2, 152.2, 151.1, 146.3, 136.8, 131.8, 131.0, 130.5, 128.5, 127.5, 127.2, 126.2, 125.6, 116.9, 114.2, 98.6, 37.6, 31.6. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 418.1510, found 418.1515.</p></div><div id="S109" class="sec"><p></p><h4 id="S109title" class="inline">4.7.5.  <em>3-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)phenyl) propanoic acid</em> (6) </h4><p id="P124" class="p p-first-last">(257 mg, 0.595 mmol, 89% yield) as a green pale solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.22 (s, 1H), 10.76 (d, <em>J</em> = 1.6 Hz, 1H), 10.15 (s, 1H), 9.89 (s, 1H), 7.91 &#x02013; 7.78 (m, 2H), 7.48 &#x02013; 7.39 (m, 2H), 7.34 (d, <em>J</em> = 7.2 Hz, 1H),7.30 (dd, <em>J</em> = 7.6, 1.7 Hz, 1H), 7.27 &#x02013; 7.16 (m, 2H), 6.37 (d, <em>J</em> = 1.6 Hz, 1H), 6.03 (s, 2H), 4.01 (s, 2H), 2.82 (t, <em>J</em> = 7.4 Hz, 2H), 2.53 (d, <em>J</em> = 7.4 Hz, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 168.5, 166.4, 158.9, 152.0, 145.8, 140.7, 132.0, 131.6, 130.3, 129.3, 128.4, 127.1, 127.1, 127.0, 126.6, 117.2, 114.5, 98.7, 41.1, 31.5. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>23</sub>H<sub>22</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 432.1666, found 432.1657.</p></div><div id="S110" class="sec"><p></p><h4 id="S110title" class="inline">4.7.6.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)-N-methylbenzamido) benzoic acid</em> (9) </h4><p id="P125" class="p p-first-last">(27 mg, 0.065 mmol, 56% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 13.10 (s, 1H), 10.67 (s, 1H), 10.09 (s, 1H), 7.70 (d, <em>J</em> = 7.7 Hz, 1H), 7.50 (t, <em>J</em> = 7.5 Hz, 1H), 7.35 (d, <em>J</em> = 7.9 Hz, 1H), 7.29 (t, <em>J</em> = 7.6 Hz, 1H), 7.11 &#x02013; 6.95 (m, 4H), 6.11 (s, 1H), 5.98 (s, 2H), 3.80 (s, 2H), 3.26 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 169.2, 166.6, 159.2, 152.2, 151.1, 144.3, 143.3, 133.5, 133.0, 131.1, 130.2, 12.9, 127.8, 127.6, 127.4, 117.0, 114.0, 98.6, 37.8, 31.4. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 418.1510, found 418.1522.</p></div><div id="S111" class="sec"><p></p><h4 id="S111title" class="inline">4.7.7.  <em>2-((4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)methyl) benzoic acid</em> (11) </h4><p id="P126" class="p p-first-last">(39 mg, 0.093 mmol, 44% yield) as a yellow pale solid. <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 13.00 (bs, 1H), 10.88 (d, <em>J</em> = 1.9 Hz, 1H), 10.40 (s, 1H), 8.85 (t, <em>J</em> = 6.0 Hz, 1H), 7.87 (dd, <em>J</em> = 7.7, 1.5 Hz, 1H), 7.81 &#x02013; 7.77 (m, 2H), 7.51 (td, <em>J</em> = 7.6, 1.5 Hz, 1H), 7.40 &#x02013; 7.32 (m, 4H), 6.39 (d, <em>J</em> = 2.2 Hz, 1H), 6.35 (s, 2H), 4.80 (d, <em>J</em> = 6.0 Hz, 2H), 3.99 (s, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 168.5, 166.4, 158.9, 152.0, 145.8, 140.7, 132.0, 131.6, 130.3, 129.3, 128.4, 127.1, 127.1, 127.0, 126.6, 117.2, 114.5, 98.7, 41.1, 31.5. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 418.1510, found 418.1517.</p></div><div id="S112" class="sec"><p></p><h4 id="S112title" class="inline">4.7.8.  <em>1-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzoyl) piperidine-2-carboxylic acid</em> (12) </h4><p id="P127" class="p p-first-last">(60 mg, 0.147 mmol, 20% yield) as a white-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 11.89 (s, 1H), 10.72 (d, <em>J</em> = 2.1 Hz, 1H), 10.11 (s, 1H), 7.39 &#x02013; 7.32 (m, 2H), 7.28 &#x02013; 7.21 (m, 2H), 6.35 (d, <em>J</em> = 2.2 Hz, 1H), 5.99 (s, 2H), 4.47 &#x02013; 4.36 (m, 1H), 3.96 (s, 2H), 3.59 &#x02013; 3.50 (m, 1H), 3.13 &#x02013; 3.02 (m, 1H), 2.20 &#x02013; 2.12 (m, 1H), 1.71 &#x02013; 1.63 (m, 1H), 1.58 &#x02013; 1.48 (m, 1H), 1.44 &#x02013; 1.36 (m, 1H), 1.30 &#x02013; 1.23 (m, 1H), 1.20 &#x02013; 1.13 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 172.3, 170.4, 159.3, 152.2, 151.2, 144.0, 133.1, 128.5, 126.6, 117.0, 114.1, 98.7, 57.8, 51.7, 45.3, 31.5, 26.3, 24.8, 20.9. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>20</sub>H<sub>22</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 396.1666, found 396.1675.</p></div><div id="S113" class="sec"><p></p><h4 id="S113title" class="inline">4.7.9.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)cyclohexan-1-carboxylic acid</em> (13) </h4><p id="P128" class="p p-first-last">(4.1 mg, 0.010 mmol, 5% yield) as a white-green solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.17 (s, 1H), 10.73 (s, 1H), 10.16 (s, 1H), 7.85 (d, <em>J</em> = 8.3 Hz, 1H), 7.66 &#x02013; 7.60 (m, 2H), 7.37 &#x02013; 7.31 (m, 2H), 6.31 (s, 1H), 6.04 (s, 2H), 4.28 (s, 1H), 3.96 (s, 2H), 2.78 &#x02013; 2.68 (m, 2H), 1.99 (s, 1H), 1.82 &#x02013; 1.71 (m, 2H), 1.66 &#x02013; 1.45 (m, 2H), 1.36 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 173.6, 166.0, 162.9, 153.6, 150.5, 132.9, 132.7, 126.2, 125.9, 119.1, 116.7, 111.3, 53.5, 47.9, 31.8, 25.8, 25.0, 23.6, 23.5. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>24</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 410.1823, found 410.1828.</p></div><div id="S114" class="sec"><p></p><h4 id="S114title" class="inline">4.7.10.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-chloro benzoic acid</em> (14) </h4><p id="P129" class="p p-first-last">(92.4 mg, 0.21 mmol, 68% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.36 (s, 1H), 10.76 (s, 1H), 10.14 (s, 1H), 8.82 (d, <em>J</em> = 2.0 Hz, 1H), 8.05 (d, <em>J</em> = 8.5 Hz, 1H), 7.85 &#x02013; 7.79 (m, 2H), 7.52 &#x02013; 7.46 (m, 2H), 7.25 (dd, <em>J</em> = 8.7, 2.0 Hz, 1H), 6.38 (d, <em>J</em> = 1.4 Hz, 1H), 6.02 (s, 2H), 4.02 (s, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub><em>6</em></sub>) <em>&#x003b4;</em> 169.3, 165.0, 159.3, 152.3, 151.3, 147.3, 142.3, 138.4, 133.0, 131.4, 130.1, 129.1, 127.0, 122.6, 119.0, 116.6, 114.3, 98.6, 31.7. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>17</sub>ClN<sub>5</sub>O<sub>4</sub><sup>+</sup> 438.0964, found 438.0955.</p></div><div id="S115" class="sec"><p></p><h4 id="S115title" class="inline">4.7.11.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido) terephthalic acid</em> (15) </h4><p id="P130" class="p p-first-last">(10 mg, 0.022 mmol, 57% yield) as a white-green solid. <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) &#x003b4; 13.25 (s, 2H), 10.76 (d, <em>J</em> = 2.3 Hz, 1H), 10.21 (s, 1H), 9.27 (d, <em>J</em> = 1.7 Hz, 1H), 8.12 (d, <em>J</em> = 8.2 Hz, 1H), 7.87 &#x02013; 7.84 (m, 2H), 7.67 (d, <em>J</em> = 8.2 Hz, 1H), 7.50 &#x02013; 7.47 (m, 2H), 6.37 (d, <em>J</em> = 2.1 Hz, 1H), 6.09 (s, 2H), 4.02 (s, 2H).<sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 169.3, 166.7, 164.8, 159.3, 152.3, 151.3, 147.1, 141.0, 135.0, 131.7, 131.5, 131.4, 129.1, 127.0, 123.1, 120.6, 116.7, 114.2, 98.6, 31.7. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>22</sub>H<sub>18</sub>N<sub>5</sub>O<sub>6</sub><sup>+</sup> 448.1252, found 448.1257.</p></div><div id="S116" class="sec"><p></p><h4 id="S116title" class="inline">4.7.12.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-methoxy benzoic acid</em> (16) </h4><p id="P131" class="p p-first-last">(40 mg, 0.092 mmol, 69% yield) as a white-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 13.48 (s, 1H), 12.38 (s, 1H), 10.77 (d, <em>J</em> = 1.9 Hz, 1H), 10.16 (s, 1H), 8.42 (d, <em>J</em> = 2.7 Hz, 1H), 8.00 (d, <em>J</em> = 8.9 Hz, 1H), 7.86 &#x02013; 7.81 (m, 2H), 7.52 &#x02013; 7.46 (m, 2H), 6.76 (dd, <em>J</em> = 8.9, 2.7 Hz, 1H), 6.38 (d, <em>J</em> = 2.2 Hz, 1H), 6.04 (s, 2H), 4.02 (s, 2H), 3.85 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 167.2, 166.0, 163.9, 158.3, 152.6, 159.0, 138.7, 133.1, 131.8, 128.7, 126.5, 127.1, 119.1, 116.9, 112.4, 111.3, 109.7, 101.2, 56.5, 31.8. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>O<sub>5</sub><sup>+</sup> 434.1459, found 434.1446.</p></div><div id="S117" class="sec"><p></p><h4 id="S117title" class="inline">4.7.13.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-cyanobenzoic acid</em> (17) </h4><p id="P132" class="p p-first-last">(50 mg, 0.117 mmol, yield 86% yield) as a white-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.09 (s, 1H), 10.77 (s, 1H), 10.16 (s, 1H), 9.09 (s, 1H), 8.16 &#x02013; 8.05 (m, 3H), 7.87 &#x02013; 7.82 (m, 2H), 7.65 &#x02013; 7.54 (m, 1H), 7.49 (d, <em>J</em> = 8.0 Hz, 1H), 6.38 (s, 1H), 6.04 (s, 2H), 4.02 (s, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 168.2, 166.0, 163.9, 153.8, 150.5, 138.3, 134.1, 132.4, 130.5, 127.8, 127.3, 127.1, 121.3, 120.1, 119.7, 117.4, 112.6, 112.3, 111.8, 31.8. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>22</sub>H<sub>17</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 429.1306, found 429.1302.</p></div><div id="S118" class="sec"><p></p><h4 id="S118title" class="inline">4.7.14.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-(hydroxymethyl)benzoic acid</em> (18) </h4><p id="P133" class="p p-first-last">(40 mg, 0.092 mmol, 54% yield) as a white-green solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.27 (s, 1H), 10.77 (s, 1H), 10.15 (s, 1H), 8.72 (s, 1H), 8.12 &#x02013; 7.96 (m, 3H), 7.92 &#x02013; 7.79 (m, 3H), 7.51 &#x02013; 7.46 (m, 1H), 7.16 &#x02013; 7.09 (m, 1H) 6.37 (d, <em>J</em> = 2.2 Hz, 1H), 6.03 (s, 2H), 4.57 (s, 2H), 4.02 (s, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 168.2, 166.0, 163.9, 153.6, 150.2, 141.8, 137.5, 134.3, 131.3, 128.8, 127.5, 127.1, 125.5, 123.7, 120.3, 118.6, 117.5, 111.3, 61.5, 30.9. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>O<sub>5</sub><sup>+</sup> 434.1459, found 434.1446.</p></div><div id="S119" class="sec"><p></p><h4 id="S119title" class="inline">4.7.15.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-(methoxymethyl)benzoic acid</em> (19) </h4><p id="P134" class="p p-first-last">(62 mg, 0.143 mmol, 83% yield) as a white-pink solid. <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 13.74 (s, 1H), 12.19 (s, 1H), 10.76 (d, <em>J</em> = 2.3 Hz, 1H), 10.14 (s, 1H), 8.72 (d, <em>J</em> = 1.5 Hz, 1H), 8.02 (d, <em>J</em> = 8.1 Hz, 1H), 7.84 &#x02013; 7.81 (m, 2H), 7.50 &#x02013; 7.47 (m, 2H), 7.12 (dd, <em>J</em> = 8.1, 1.6 Hz, 1H), 6.38 (d, <em>J</em> = 2.1 Hz, 1H), 6.02 (s, 2H), 4.50 (s, 2H), 4.02 (s, 2H), 3.34 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 169.9, 164.7, 159.3, 152.3, 151.3, 147.0, 145.2, 141.4, 131.8, 131.3, 129.1, 126.9, 121.2, 118.0, 116.6, 115.3, 114.2, 98.6, 73.1, 57.9, 31.6. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>23</sub>H<sub>22</sub>N<sub>5</sub>O<sub>5</sub><sup>+</sup> 448.1615, found 448.1622.</p></div><div id="S120" class="sec"><p></p><h4 id="S120title" class="inline">4.7.16.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-carbamoylbenzoic acid</em> (20) </h4><p id="P135" class="p p-first-last">(10 mg, 0.022 mmol, 46% yield) as a white-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.20 (bs, 1H), 10.73 (s, 1H), 10.12 (s, 1H), 9.06 (d, <em>J</em> = 1.7 Hz, 1H), 8.09 &#x02013; 8.01 (m, 2H), 7.83 &#x02013; 7.79 (m, 2H), 7.56 (d, J = 8.1 Hz, 2H), 7.50 (bs, 1H), 7.47 &#x02013; 7.44 (m, 2H), 6.35 (d, <em>J</em> = 2.1 Hz, 1H), 5.99 (s, 2H), 3.99 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 168.5, 167.8, 166.0, 165.9, 155.6, 152.0, 138.2, 134.9, 133.8, 132.6, 128.1, 127.5, 127.3, 127.1, 120.2, 117.5, 117.6, 115.8, 111.3, 31.8. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>22</sub>H<sub>19</sub>N<sub>6</sub>O<sub>5</sub><sup>+</sup> 447.1411, found 447.1416.</p></div><div id="S121" class="sec"><p></p><h4 id="S121title" class="inline">4.7.17.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-3-(methoxymethyl)benzoic acid</em> (21) </h4><p id="P136" class="p p-first-last">(43 mg, 0.096 mmol, 56% yield) as a white-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.88 (s, 1H), 10.76 (d, <em>J</em> = 2.0 Hz, 1H), 10.14 (s, 1H), 9.99 (s, 1H), 7.88 &#x02013; 7.82 (m, 2H), 7.78 (dd, <em>J</em> = 7.8, 1.6 Hz, 1H), 7.66 (d, <em>J</em> = 7.6 Hz, 1H), 7.45 &#x02013; 7.36 (m, 3H), 6.38 (d, <em>J</em> = 2.2 Hz, 1H), 6.03 (s, 2H), 4.41 (s, 2H), 4.00 (s, 2H), 3.28 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 168.4, 166.7, 162.9, 152.6, 151.4, 145.5, 137.1, 136.7, 135.4, 134.7, 132.5, 130.5, 130.1, 126.9, 123.1, 120.7, 111.6, 111.3, 68.6, 56.0, 31.8. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>23</sub>H<sub>22</sub>N<sub>5</sub>O<sub>5</sub><sup>+</sup> 448.1615, found 448.1611.</p></div><div id="S122" class="sec"><p></p><h4 id="S122title" class="inline">4.7.18.  <em>2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-5-methoxybenzoic acid</em> (22) </h4><p id="P137" class="p p-first-last">(121 mg, 0.279 mmol, 65% yield) as a white-green solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 13.77 (s, 1H), 11.80 (s, 1H), 10.76 (d, <em>J</em> = 2.3 Hz, 1H), 10.15 (s, 1H), 8.59 (d, <em>J</em> = 9.2 Hz, 1H), 7.83 &#x02013; 7.79 (m, 2H), 7.51 (d, <em>J</em> = 3.2 Hz, 1H), 7.49 &#x02013; 7.45 (m, 2H), 7.26 (dd, <em>J</em> = 9.2, 3.2 Hz, 1H), 6.37 (d, <em>J</em> = 2.2 Hz, 1H), 6.03 (s, 2H), 4.01 (s, 2H), 3.79 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 169.5, 164.3, 159.3, 154.3, 152.3, 151.2, 146.8, 134.6, 132.0, 129.0, 126.8, 121.8, 120.3, 118.1, 116.7, 114.9, 114.2, 98.6, 55.4, 31.6. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>O<sub>5</sub><sup>+</sup> 434.1459, found 434.1465.</p></div><div id="S123" class="sec"><p></p><h4 id="S123title" class="inline">4.7.19.  <em>2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-methoxyphenyl)acetic acid</em> (23) </h4><p id="P138" class="p p-first-last">(27 mg, 0.061 mmol, 68% yield) as a white-pink solid. <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.32 (s, 1H), 10.75 (s, 1H), 10.15 (s, 1H), 9.82 (s, 1H), 7.86 &#x02013; 7.76 (m, 2H), 7.46 &#x02013; 7.37 (m, 2H), 7.20 (d, <em>J</em> = 8.5 Hz, 1H), 7.14 (d, <em>J</em> = 2.2 Hz, 1H), 6.77 (dd, <em>J</em> = 8.5, 2.4 Hz, 1H), 6.36 (s, 1H), 6.03 (s, 2H), 4.00 (s, 2H), 3.74 (s, 3H), 3.57 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 171.6, 168.0, 162.9, 158.7, 152.6, 151.3, 142.8, 137.1, 135.4, 132.3, 129.5, 128.7, 123.1, 119.7, 118.1, 115.3, 110.5, 104.9, 56.5, 39.9, 31.8. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>23</sub>H<sub>22</sub>N<sub>5</sub>O<sub>5</sub><sup>+</sup> 448.1615, found 448.1624.</p></div><div id="S124" class="sec"><p></p><h4 id="S124title" class="inline">4.7.20.  <em>2-(2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-cyanophenyl)acetic acid</em> (24) </h4><p id="P139" class="p p-first-last">(106 mg, 0.239 mmol, 38% yield) as a green pale solid. <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.51 (bs, 1H), 10.82 (d, <em>J</em> = 2.3 Hz, 1H), 10.27 (s, 1H), 10.06 (s, 1H), 7.93 (d, <em>J</em> = 1.7 Hz, 1H), 7.84 &#x02013; 7.79 (m, 2H), 7.67 (dd, <em>J</em> = 7.9, 1.8 Hz, 1H), 7.54 (d, <em>J</em> = 8.0 Hz, 1H), 7.46 &#x02013; 7.40 (m, 2H), 6.39 (d, <em>J</em> = 2.1 Hz, 1H), 6.18 (s, 2H), 4.01 (s, 2H), 3.80 (s, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 171.8, 165.6, 159.1, 158.1, 152.1, 146.6, 137.8, 136.3, 132.5, 131.3, 129.4, 129.0, 128.5, 127.6, 118.5, 117.0, 114.3, 109.9, 98.6, 37.5, 31.6. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>23</sub>H<sub>19</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 443.1462, found 443.1464.</p></div><div id="S125" class="sec sec-last"><p></p><h4 id="S125title" class="inline">4.7.21.  <em>3-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)-4-(carboxymethyl)benzoic acid</em> (25) </h4><p id="P140" class="p p-first-last">(89 mg, 0.193 mmol, 38% yield) as a orange solid. <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.85 (bs, 2H), 10.75 (d, <em>J</em> = 2.3 Hz, 1H), 10.15 (s, 1H), 10.03 (s, 1H), 8.05 (s, 1H), 7.84 &#x02013; 7.81 (m, 2H), 7.76 (dd, <em>J</em> = 8.0, 1.7 Hz, 1H), 7.46 &#x02013; 7.41 (m, 3H), 6.37 (d, <em>J</em> = 2.2 Hz, 1H), 6.03 (s, 2H), 4.01 (s, 2H), 3.74 (s, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 172.2, 166.9, 165.4, 159.3, 152.3, 151.2, 146.5, 137.0, 135.5, 131.6, 131.3, 129.8, 128.5, 127.5, 126.9, 126.3, 116.9, 114.1, 98.6, 37.7, 31.7. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>23</sub>H<sub>20</sub>N<sub>5</sub>O<sub>6</sub><sup>+</sup> 462.1408, found 462.1414.</p></div></div><div id="S126" class="sec"><h3 id="S126title">4.8. General procedure for the synthesis of final compound 8. Method g.</h3><p id="P141" class="p p-first">The synthesis of compound <strong>8</strong> has been carried out following for general method <em>g.</em> NaN<sub>3</sub> (76 mg, 1.16 mmol) was added to a solution of 4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)-N-(2-cyanophenyl)benza-mide(<strong>7</strong>) (50 mg, 0.13 mmol) in DMSO (0.57 mL) and water (0.57 mL) and the reaction mixture stirred at 100 &#x000b0;C overnight. After solvent evaporation under reduced pressure the desired final compound was purified by flash column cromatography eluted initially with dichloromethane followed by 20% methanol in dichloromethane and finally 50% methanol in dichloromethane to give <em>N-(2-(1H-tetrazol-5-yl)phenyl)-4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamide</em> (<strong>8</strong>) as a pale brown powder.</p><div id="S127" class="sec sec-last"><p></p><h4 id="S127title" class="inline">4.8.1.  <em>N-(2-(1H-tetrazol-5-yl)phenyl)-4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamide</em> (8) </h4><p id="P142" class="p p-first-last">(27 mg, 0.061 mmol, 49% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 13.30 (s, 1H), 10.72 (s, 1H), 10.29 (s, 1H), 8.77 &#x02013; 8.73 (m, 1H), 8.22 (dd, <em>J</em> = 7.8, 1.7 Hz, 1H), 8.07 &#x02013; 8.02 (m, 2H), 7.50 &#x02013; 7.44 (m, 2H), 7.29 &#x02013; 7.25 (m, 1H), 7.10 (td, <em>J</em> = 7.5, 1.3 Hz, 1H), 6.35 (d, <em>J</em> = 2.1 Hz, 1H), 6.06 (s, 2H), 4.00 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 164.4, 159.9, 159.1, 152.2, 150.3, 137.7, 136.5, 130.1, 129.1, 127.7, 127.3, 127.0, 126.8, 126.5, 123.9, 122.8, 122.7, 119.2, 48.6. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>18</sub>N<sub>9</sub>O<sub>2</sub><sup>+</sup> 428.1578, found 428.1570.</p></div></div><div id="S128" class="sec"><h3 id="S128title">4.9. Procedure for the synthesis of final compound 10.</h3><div id="S129" class="sec sec-first"><p></p><h4 id="S129title" class="inline">4.9.1.  Synthesis of intermediate 33 </h4><p id="P143" class="p p-first-last">4,4,5,5-tetramethyl-2-vinyl-1,2,3-dioxoborolane (1.23 g, 8 mmol), K<sub>2</sub>CO<sub>3</sub> (1.1 g, 8 mmol) and Pd(dppf)Cl<sub>2</sub> (293 mg, 0.4 mmol) were added to a solution of methyl 2-bromobenzoate (0.86 g, 4 mmol) in dioxane/water (11 mL/0.5 mL) and the resulting mixture was stirred at 100 &#x000b0;C overnight. The mixture was diluted with water (15 mL) and extracted with ethyl acetate (3 &#x000d7; 25 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure.[<a href="#R24" rid="R24" class=" bibr popnode">24</a>] The residue was purified by flash column chromatography (hexanes to ethyl acetate) to provide <em>methyl 2-vinylbenzoate</em>
<strong>(33)</strong> as transparent oil.</p></div><div id="S130" class="sec"><p></p><h4 id="S130title" class="inline">4.9.2.  Synthesis of intermediate 37 </h4><p id="P144" class="p p-first"><em>4-iodophenyl trifluoromethanesulfonate</em> (<strong>34</strong>) Trifluoromethanesulfonic anhydride (34 mL, 5.64 g, 20 mmol) was slowly added at 0 &#x000b0;C to a solution of 4-iodophenol (4 g, 18.17 mmol) in dry pyridine (9.3 mL). The resulting mixture was stirred at the same temperature for 5 minutes and then allowed to warm to 25 &#x000b0;C and stirred for overnight. The recation was poured into water and extracted with ethyl ether (50 mL). The organic layer was washed sequentially with water, 10% HCl (2x), water and brine, dried over anhydrous MgSO<sub>4</sub> and concentrated under reduced pressure. The crude was purified by flash column chromatography (hexanes to ethyl acetate) to provide <em>4-iodophenyl trifluoromethanesulfonate</em>
<strong>(34)</strong> as transparent oil.</p><div id="S131" class="sec"><p></p><h5 id="S131title" class="inline">4.9.2.1.  <em>4-(3-oxopropyl)phenyl trifluoromethanesulfonate</em> (35). </h5><p id="P145" class="p p-first-last">Synthesized following Method <em>c.</em></p></div><div id="S132" class="sec"><p></p><h5 id="S132title" class="inline">4.9.2.2.  <em>4-(2-bromo-3-oxopropyl)phenyl trifluoromethanesulfonate</em> (36). </h5><p id="P146" class="p p-first-last">Synthesized following Method <em>d</em>.</p></div><div id="S133" class="sec sec-last"><p></p><h5 id="S133title" class="inline">4.9.2.3.  <em>4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)phenyl trifluoromethane sulfonate</em> (37). </h5><p id="P147" class="p p-first-last">Synthesized following Method <em>e</em>.</p></div></div><div id="S134" class="sec"><p></p><h4 id="S134title" class="inline">4.9.3.  Synthesis of intermediate 38 </h4><p id="P148" class="p p-first-last">Dry DMF (16 mL/eq), intermediates <strong>37</strong> (1eq) and <strong>33</strong> (1.25 eq), Pd(OAc)<sub>2</sub> (0.01 eq), PPh<sub>3</sub> (0.02 eq) and dry trimethylamine (4 eq) were added to a pressure vial. The reaction mixture was stirred at 100 &#x000b0;C for 16h. The crude reaction mixure was filtered through silica pad and washed with EtOAc.[<a href="#R25" rid="R25" class=" bibr popnode">25</a>] The solvent was evaporated and the product was was purified by flash column cromatography eluted initially with dichloromethane followed by 20% methanol in dichloromethane to give <em>(E)-2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)styryl) benzoate</em>
<strong>(38)</strong>.</p></div><div id="S135" class="sec"><p></p><h4 id="S135title" class="inline">4.9.4.  Synthesis of final compound 10 </h4><p id="P149" class="p p-first-last">Synthesized following Method <em>f.</em></p></div><div id="S136" class="sec"><p></p><h4 id="S136title" class="inline">4.9.5.  <em>methyl 2-vinylbenzoate</em> (33) </h4><p id="P150" class="p p-first-last">(286 mg, 1.76 mmol, 44% yield) <sup>1</sup>H NMR (400 MHz, Methanol-<em>d</em><sub>4</sub>) <em>&#x003b4;</em> 7.87 (d, <em>J</em> = 7.6 Hz, 1H), 7.28&#x02013;7.57 (m, 4H), 5.61 (d, <em>J</em> = 7.6 Hz, 1H), 5.35 (d, <em>J</em> = 1.2 Hz, 1H), 3.88 (s, 3H). LC-MS (ESI) m/z 163.1 [M+H]<sup>+</sup>.</p></div><div id="S137" class="sec"><p></p><h4 id="S137title" class="inline">4.9.6.  <em>4-iodophenyl trifluoromethanesulfonate</em> (34) </h4><p id="P151" class="p p-first-last">(2.47 g, 7.02 mmol, 39% yield) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 7.81 &#x02013; 7.75 (m, 2H), 7.07 &#x02013; 7.00 (m, 2H). LC- MS (ESI) m/z 353.1 [M+H]<sup>+</sup>.</p></div><div id="S138" class="sec"><p></p><h4 id="S138title" class="inline">4.9.7.  <em>4-(3-oxopropyl)phenyl trifluoromethanesulfonate</em> (35). </h4><p id="P152" class="p p-first-last">(1.86 g, 6.69 mmol, 55% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 9.82 (t, J = 1.6 Hz, 1H), 7.30 &#x02013; 7.24 (m, 2H), 7.21 &#x02013; 7.17 (m, 2H), 3.02 &#x02013; 2.94 (m, 2H), 2.84 &#x02013; 2.77 (m, 2H). LC-MS (ESI) m/z 283.1 [M+H]<sup>+</sup>.</p></div><div id="S139" class="sec"><p></p><h4 id="S139title" class="inline">4.9.8.  <em>4-(2-bromo-3-oxopropyl)phenyl trifluoromethanesulfonate</em> (36). </h4><p id="P153" class="p p-first-last">(1.05 g, 4.02 mmol, 61% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 9.51 (d, <em>J</em> = 1.7 Hz, 1H), 7.37 &#x02013; 7.31 (m, 2H), 7.29 &#x02013; 7.21 (m, 2H), 4.44 (ddt, <em>J</em> = 8.0, 6.4, 1.7 Hz, 1H), 3.56 &#x02013; 3.50 (m, 1H), 3.18 (ddd, <em>J</em> = 14.8, 8.0, 1.5 Hz, 1H). LC-MS (ESI) m/z 262.1 [M+H]<sup>+</sup>.</p></div><div id="S140" class="sec"><p></p><h4 id="S140title" class="inline">4.9.9.  <em>4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)phenyl trifluoromethane sulfonate</em> (37). </h4><p id="P154" class="p p-first-last">(704 mg, 1.81 mmol, 45% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.76 (d, <em>J</em> = 2.1 Hz, 1H), 10.13 (s, 1H), 7.48 &#x02013; 7.42 (m, 2H), 7.37 &#x02013; 7.31 (m, 2H), 6.39 (d, <em>J</em> = 2.1 Hz, 1H), 6.01 (s, 2H), 3.97 (s, 2H). LC-MS (ESI) m/z 389.1 [M+H]<sup>+</sup>.</p></div><div id="S141" class="sec"><p></p><h4 id="S141title" class="inline">4.9.10.  <em>(E)-2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)styryl) benzoate</em> (38) </h4><p id="P155" class="p p-first-last">(34.7 mg, 0.082 mmol, 62% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 10.73(s, 1H), 10.13 (s, 1H), 7.98 &#x02013; 7.64 (m, 3H), 7.62 &#x02013; 7.00 (m, 6H), 6.36 &#x02013; 6.23 (m, 2H), 6.03 (s, 2H), 3.97 (s, 2H), 3.88 (s, 3H). LC-MS (ESI) m/z 401.1 [M+H]<sup>+</sup>.</p></div><div id="S142" class="sec sec-last"><p></p><h4 id="S142title" class="inline">4.9.11.  (<em>E)-2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)styryl)benzoic acid</em> (10). </h4><p id="P156" class="p p-first-last">(13.6 mg, 0.035 mmol, 41% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.96 (bs, 1H), 11.03 (s, 1H), 10.69 (s, 1H), 7.84 &#x02013; 7.74 (m, 3H), 7.59 &#x02013; 7.25 (m, 4H), 7.16 &#x02013; 7.03 (m, 2H), 6.81 &#x02013; 6.68 (m, 2H), 6.38 (s, 2H), 3.94 (s, 2H).<sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 168.7, 158.5, 151.8, 149.0, 141.9, 137.9, 134.6, 131.9, 130.7, 130.3, 129.6, 129.0, 127.2, 126.5, 126.4, 126.3, 126.0, 114.6, 98.8, 31.3. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>19</sub>N<sub>4</sub>O<sub>4</sub><sup>+</sup> 387.1452, found 387,1448.</p></div></div><div id="S143" class="sec"><h3 id="S143title">4.10. General procedure for the synthesis of final compounds 26&#x02013;27</h3><div id="S144" class="sec sec-first"><p></p><h4 id="S144title" class="inline">4.10.1.  Synthesis of intermediate 39 </h4><p id="P157" class="p p-first-last">1-bromo-2-methoxyethane (205 &#x003bc;L, 2.21 mmol) was added to a solution of 3-bromo-5-methoxyphenol (373 mg, 1.84 mmol), K<sub>2</sub>CO<sub>3</sub> (381 mg, 2.76 mmol) and anhydrous DMF (10 mL) and the reaction mixture was stirred overnight at 85 &#x000b0;C. The resulting mixyure was then diluted in EtOAc and washed with water (3 &#x000d7; 50 mL). The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give <em>1-bromo-3-methoxy-5-(2-methoxyethoxy)benzene</em>
<strong>(41)</strong> as a white powder. n-BuLi (0.63 mL, 1.58 mmol) was added under nitrogen atmosphere to a solution of <strong>41</strong> (411 mg, 1.58 mmol) in dry THF (5 ml) at &#x02212;78&#x000b0; C. and the reaction stirred for 30 minutes. Trimethoxyborane (0.21 mL, 1.9 mmol) in a THF solution was slowly added dropwise at 70&#x000b0; C, and the mixture warmed to room temperature and stirred for 16 hours. After the completion of the reaction, 20% HCl (2.7 mL) was added and stirred for 3 hours. The mixture was extracted with ethyl acetate, washed with water and brine, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> to provide <em>(3-methoxy-5-(2-methoxyethoxy)phenyl)boronic acid</em>
<strong>(39)</strong> as pale brown solid.</p></div><div id="S145" class="sec"><p></p><h4 id="S145title" class="inline">4.10.2.  Synthesis of intermediate 40 </h4><p id="P158" class="p p-first-last">PdCl<sub>2</sub>(dppf) (0.03eq), KOAc (2.9 eq) and bis(pinacolato)diboron (1.1 eq) were added to a solution of methyl 3-bromo-5-methoxybenzoate (1 eq) in dry dioxane (5.6 mL/mmol) under nitrogen. The solution was stirred at 80 &#x000b0;C for 2 hours and then was diluted with dichloromethane (25 mL) and washed with water (25 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was eliminated under reduced pressure to give <em>methyl 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate</em>
<strong>(42)</strong>. Crude arylboronic acid pinacol ester (1 eq) and sodium periodate (3 eq) were stirred in 8 mL/mmol of a 4:1 mixture of acetone and water for 30 min, at which time aqueous NH<sub>4</sub>OAc (1eq) was added to the suspension. The reaction mixture was stirred at room temperature for 17 h and then diluted with water (30 ml) and extracted with ethyl acetate (2 &#x000d7; 60 ml). The combined extracts were washed with water (2 &#x000d7; 30 ml) and brine (30 ml), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness by rotary evaporation to give a colourless solid, <em>(3-methoxy-5-(methoxycarbonyl)phenyl)boronic acid</em>
<strong>(40)</strong>.</p></div><div id="S146" class="sec"><p></p><h4 id="S146title" class="inline">4.10.3.  Synthesis of final compounds 26 and 27 </h4><p id="P159" class="p p-first-last">Compounds <strong>26</strong> and <strong>27</strong> have been synthesized through the reaction between trifluoromethane sulfonate derivate <strong>37</strong> (1 eq) and the corresponding boronic acid <strong>39</strong> or <strong>40</strong> following general method <em>h</em> or <em>i</em>, respectively. Method h: A mixture of <strong>39</strong> (1.5 eq), <strong>37</strong> (1.0 eq), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.01 eq) and TEA (2.6 eq) in dioxane (10 mL/mmol) was stirred overnight at 90 &#x000b0;C The solvent was evaporated under reduced pressure and the residue purified by flash column cromatography eluted initially with dichloromethane followed by 20% methanol in dichloromethane to give <em>2-amino-5-((3&#x02019;-methoxy-5&#x02019;-(2-methoxyethoxy)-[1,1&#x02019;-biphenyl]-4-yl)methyl)-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one</em>
<strong>(26)</strong>. Pale pink powder. General method <em>i</em>: A solution of <strong>40</strong> (2 eq), <strong>37</strong> (1.0 eq), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.05 eq) and (2M) Na<sub>2</sub>CO<sub>3</sub> (4 eq) in DMF (1 mL/mmol) was stirred for 2h at 100 &#x000b0;C. The solvent was evaporated under reduced pressure and the residue purified by flash column cromatography eluted initially with dichloromethane followed by 20% methanol in dichloromethane to give <em>4&#x02019;-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)-5-methoxy-[1,1&#x02019;-biphenyl]-3-carboxylic acid</em>
<strong>(27)</strong>. Pale green powder.</p></div><div id="S147" class="sec"><p></p><h4 id="S147title" class="inline">4.10.4.  <em>1-bromo-3-methoxy-5-(2-methoxyethoxy)benzene</em> (41) </h4><p id="P160" class="p p-first-last">(411 mg, 1.58 mmol, 86% yield) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 6.73 &#x02013; 6.64 (m, 2H), 6.45 &#x02013; 6.39 (m, 1H), 4.07 (t, <em>J</em> = 4.7 Hz, 2H), 3.76 (s, 3H), 3.73 (t, <em>J</em> = 4.6 Hz, 2H), 3.44 (s, 3H). LC-MS (ESI) m/z 262,1 [M+H]<sup>+</sup>.</p></div><div id="S148" class="sec"><p></p><h4 id="S148title" class="inline">4.10.5.  <em>(3-methoxy-5-(2-methoxyethoxy)phenyl)boronic acid</em> (39) </h4><p id="P161" class="p p-first-last">(223 mg, 0.99 mmol, 63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <em>&#x003b4;</em> 7.38 &#x02013; 7.32 (m, 1H), 6.76 &#x02013; 6.67 (m, 1H), 6.52 &#x02013; 6.48 (m, 1H), 4.12 (t, <em>J</em> = 4.7 Hz, 2H), 3.78 (s, 3H), 3.75 (t, <em>J</em> = 4.6 Hz, 2H), 3.45 (s, 3H). LC-MS (ESI) m/z 227,0 [M+H]<sup>+</sup>.</p></div><div id="S149" class="sec"><p></p><h4 id="S149title" class="inline">4.10.6.  <em>methyl 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate</em> (42) </h4><p id="P162" class="p p-first-last">(651 mg, 2.23 mmol, 89% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 7.86 &#x02013; 7.84 (m, 1H), 7.54 (dd, <em>J</em> = 2.7, 1.5 Hz, 1H), 7.38 (dd, <em>J</em> = 2.7, 0.9 Hz, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 1.31 (s, 12H). LC-MS (ESI) m/z 293,0 [M+H]<sup>+</sup>.</p></div><div id="S150" class="sec"><p></p><h4 id="S150title" class="inline">4.10.7.  <em>(3-methoxy-5-(methoxycarbonyl)phenyl)boronic acid</em> (40) </h4><p id="P163" class="p p-first-last">(453 mg, 2.16 mmol, 97% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 7.56 (t, <em>J</em> = 2.4, 1H), 7.51 (t, <em>J</em> = 2.4, 1H), 7.46 (t, <em>J</em> = 2.3 Hz, 1H), 3.89 (s, 3H), 3.88 (s, 3H). LC-MS (ESI) m/z 211,1 [M+H]<sup>+</sup>.</p></div><div id="S151" class="sec"><p></p><h4 id="S151title" class="inline">4.10.8.  <em>2-amino-5-((3&#x02019;-methoxy-5&#x02019;-(2-methoxyethoxy)-[1,1&#x02019;-biphenyl]-4-yl)methyl)-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one</em> (26). </h4><p id="P164" class="p p-first-last">(49 mg, 0.117 mmol, 39% yield). <sup>1</sup>H NMR (600 MHz, Methanol-<em>d</em><sub>4</sub>) <em>&#x003b4;</em> 7.48 (d, <em>J</em> = 7.7 Hz, 2H), 7.34 (d, <em>J</em> = 7.7 Hz, 2H), 6.73 (d, <em>J</em> = 6.2 Hz, 2H), 6.47 (s, 1H), 6.31 (s, 1H), 4.14 (t, <em>J</em> = 4.5 Hz, 2H), 4.08 (s, 2H), 3.81 (s, 3H), 3.75 (t, <em>J</em> = 4.6 Hz, 2H), 3.43 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 164.9, 161.7, 160.5, 153.7, 150.6, 142.1, 136.3, 134.3, 126.9, 126.3, 122.1, 117.9, 113.3, 109.1, 107.9, 102.5, 70.6, 67.5, 59.0, 55.8, 31.5. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>4</sub><sup>+</sup> 421.1870, found 421.1886.</p></div><div id="S152" class="sec sec-last"><p></p><h4 id="S152title" class="inline">4.10.9.  <em>4&#x02019;-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)-5-methoxy-[1,1&#x02019;-biphenyl]-3-carboxylic acid</em> (27). </h4><p id="P165" class="p p-first-last">(32 mg, 0.082 mmol, 96% yield) <sup>1</sup>H NMR (600 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 12.85 (bs, 1H), 10.64 (<em>d</em>, <em>J</em> = 2.3 Hz, 1H), 10.09 (s, 1H), 7.07 &#x02013; 7.04 (m, 2H), 6.96 &#x02013; 6.95 (m, 1H), 6.91 &#x02013; 6.90 (m, 1H), 6.62 &#x02013; 6.60 (m, 2H), 6.54 (t, <em>J</em> = 2.3 Hz, 1H), 6.20 (s, <em>J</em> = 2.1 Hz, 1H), 5.98 (s, 2H), 3.80 (s, 2H), 3.74 (s, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<em>d</em><sub>6</sub>) <em>&#x003b4;</em> 167.6, 160.8, 158.9, 155.5, 152.6, 151.5, 132.8, 129.8, 122.2, 120.0, 119.0, 115.2, 114.0, 109.3, 106.1, 105.6, 99.1, 55.6, 31.3. HRMS (ESI): calc. for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>19</sub>N<sub>4</sub>O<sub>4</sub><sup>+</sup> 391.1401, found 391,1393.</p></div></div><div id="S153" class="sec"><h3 id="S153title">4.11. Protein Preparation</h3><p id="P166" class="p p-first-last"><em>Ch</em>TS-DHFR was expressed, purified and estimation of protein concentration was determined as reported in previous study.[<a href="#R13" rid="R13" class=" bibr popnode">13</a>] His6-human TS was expressed, purified and estimation of protein concentration was determined as previously described.[<a href="#R26" rid="R26" class=" bibr popnode">26</a>] &#x00394;7&#x02013;29 human TS deletion mutant (mhTS) was expressed, and an estimation of protein concentration was determined as previously reported.[<a href="#R19" rid="R19" class=" bibr popnode">19</a>]</p></div><div id="S154" class="sec"><h3 id="S154title">4.12. Enzyme assay, and data analysis</h3><p id="P167" class="p p-first-last">TS activity was determined by following the conversion of substrates dUMP and 5,10-methylenetetrahydrofolate to products dTMP and dihydrofolate at 340 nm (&#x00394; &#x003b5; = 6400 M<sup>&#x02212;1</sup> cm<sup>&#x02212;1</sup>) at 25&#x000b0;C.[<a href="#R13" rid="R13" class=" bibr popnode">13</a>] Reaction conditions used to determining IC<sub>50</sub> values for TS are as described in a previous study.[<a href="#R12" rid="R12" class=" bibr popnode">12</a>] Compound 1 was utilized as a positive antifolate control. Changes in absorption were determined on a SpectroMax M5 plate reader (Molecular Devices). Data were fitted to an [Inhibitor] vs normalized response with variable slope equation using GraphPad Prism software (version 7.01).</p></div><div id="S155" class="sec"><h3 id="S155title">4.13. Protein crystallography</h3><p id="P168" class="p p-first">The purified ChTS-DHFR enzyme was co-crystalized with inhibitor compounds by hanging drop vaporization with a protein:well solution ratio of 2:1 to screen crystallization conditions. Reservoir conditions for crystallization included 16&#x02013;22 % (v/v) PEG 6000, 200 mM ammonium sulfate, 60 mM lithium sulfate, and 100 mM Tris, pH 8.0. ChTS-DHFR enzyme (approximately 24 mg/ml) was incubated with 100 mM Tris, pH 8.0, 1.5 mM NADPH, 1.5 mM FdUMP, 0.5 mM methotrexate, and 5 mM inhibitor compounds on ice for 1 h before setting up drops. Crystals grew in approximately 2 days at 18&#x000b0;C. All crystals were frozen with a cryosolution containing 25 % (v/v) ethylene glycol and 5 mM of the appropriate inhibitor compounds and flash cooled with liquid nitrogen.</p><p id="P169">The purified mhTS enzyme was co-crystalized with <strong>14</strong> or <strong>23</strong> by hanging drop vaporization with a protein:well solution ratio of 1:1 to screen crystallization conditions. Reservoir conditions included 16&#x02013;18 % (v/v) PEG monomethyl ether 5000, and 100 mM Bis-Tris, pH 7.0. mhTS enzyme was co-crystalized with <strong>5</strong> by hanging drop vaporization with a protein:well solution ratio of 1:1 to screen crystallization conditions. Reservoir conditions included 28 % (v/v) PEG 4000, 200 mM lithium sulfate, and 100 mM Tris, pH 7.5. mhTS enzyme was co-crystalized with <strong>15</strong> by hanging drop vaporization with a protein:well solution ratio of 1:1 to screen crystallization conditions. Reservoir conditions included 40 % (v/v) PEG 400, and 100 mM imidazole, pH 8.0. mhTS enzyme (approximately 13 mg/ml) was incubated with 20 mM Bis-Tris, pH 7.0, 2 mM DTT, 2 mM dUMP, and 5 mM of inhibitor compounds on ice for 1 h before setting up drops. Crystals grew in approximately 1 week at 22 &#x000b0;C. All crystals were frozen with a cryosolution containing 25 % (v/v) ethylene glycol and 5 mM of the appropriate inhibitor compound and flash cooled with liquid nitrogen.</p><p id="P170" class="p p-last">Diffraction data for <em>Ch</em>TS-DHFR with <strong>2</strong>, <strong>5</strong>, <strong>11</strong>, <strong>14</strong>, <strong>15</strong>, <strong>17</strong>, <strong>20</strong>, and <strong>23</strong> and mhTS with <strong>5</strong>, <strong>14</strong>, <strong>15</strong>, and <strong>23</strong> were collected on beam line 24-ID-E, while diffraction data for <em>Ch</em>TS-DHFR with <strong>6</strong>, <strong>16</strong>, and <strong>25</strong> was collected on beam line 24-ID-C through NE-CAT, using wavelength 0.979 &#x000c5;. Diffraction data for <em>Ch</em>TS-DHFR with <strong>24</strong> was collected on beam line 17-ID-FMX at NSLSII, using wavelength 0.979 &#x000c5;. Data sets for best diffracting crystals were processed by XDS.[<a href="#R27" rid="R27" class=" bibr popnode">27</a>] Phases were solved via molecular replacement using the program phaser.[<a href="#R28" rid="R28" class=" bibr popnode">28</a>, <a href="#R29" rid="R29" class=" bibr popnode">29</a>] For <em>Ch</em>TS-DHFR:compound a <em>Ch</em>TS-DHFR structure in complex with four ligands (PDB ID 4Q0E) was used as the search model for molecular replacement. For mhTS:compound an apo mhTS structure (PDB ID 1HZW) was used as the search model for molecular replacement. The program COOT[<a href="#R30" rid="R30" class=" bibr popnode">30</a>] was used for model building of the ligands into the electron density as well as residues 307&#x02013;313 of mhTS. Structures were refined using Phenix[<a href="#R31" rid="R31" class=" bibr popnode">31</a>] until acceptable R factors, geometry statistics (RMSDs for ideal bond lengths and angles), and Ramachandran statistics were achieved for the respective structures. Iterative build omit <em>&#x003c3;</em><sub><em>A</em></sub>&#x02212; weighted <em>2mFo-Fc</em> electron density maps were generated using Phenix Autobuild.[<a href="#R32" rid="R32" class=" bibr popnode">32</a>] Refinement statistics and PDB codes for structures are listed in <a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Table S2</a>.</p></div><div id="S156" class="sec sec-last"><h3 id="S156title">4.14. Molecular modeling</h3><p id="P171" class="p p-first-last">The computational procedures that were utilized are exactly the same as in earlier studies.[<a href="#R33" rid="R33" class=" bibr popnode">33</a>&#x02013;<a href="#R35" rid="R35" class=" bibr popnode">35</a>] Starting from a crystal structure of the protein, the BOMB program[<a href="#R36" rid="R36" class=" bibr popnode">36</a>] was used to build initial structures for the desired protein-ligand complex. Conjugate-gradient energy minimizations were performed to relax the structure, and Monte Carlo free-energy perturbation (MC/FEP) was carried out to compute relative free energies of binding. The calculations were performed with the MCPRO program[<a href="#R37" rid="R37" class=" bibr popnode">37</a>] using the OPLS-AA force field for the protein,[<a href="#R38" rid="R38" class=" bibr popnode">38</a>] OPLS/CM1A for the ligands,[<a href="#R39" rid="R39" class=" bibr popnode">39</a>] and the TIP4P water model.[<a href="#R40" rid="R40" class=" bibr popnode">40</a>]</p></div></div><div id="unreferenced-ft" class="tsec sec"><div class="unreferenced">​
                    <!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F12" co-legend-rid="lgnd_F12"><a href="/pmc/articles/PMC6829050/figure/F12/" target="figure" rid-figpopup="F12" rid-ob="ob-F12"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140246371075792"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6829050_nihms-1051114-f0021.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is nihms-1051114-f0021.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC6829050/bin/nihms-1051114-f0021.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140246371075792"><a target="object" rel="noopener" href="/pmc/articles/PMC6829050/figure/F12/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F12"><div><a class="figpopup" href="/pmc/articles/PMC6829050/figure/F12/" target="figure" rid-figpopup="F12" rid-ob="ob-F12">Scheme 2.</a></div><!--caption a7--><div class="caption"><p id="P186">General scheme for the synthesis of compound <strong>10</strong>.</p></div></div></div><div class="boxed-text-box whole_rhythm hide-overflow" id="BX1"><div class="caption"><h3 id="caption-a.af.p.atitle">Highlights</h3></div><p id="P190">Twenty-six novel antifolate analogues were synthesized</p><p id="P191">Biochemical and X-ray studies were performed to determine <em>Ch</em>TS inhibition</p><p id="P192">2-phenylacetate methylene linker important for optimal position in <em>Ch</em>TS active site</p><p id="P193">Active site rigidity driving force of inhibitor selectivity</p></div></div></div><div id="SM1" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="SM1title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>Supp</h4><div class="sup-box half_rhythm" id="d36e6742"><a href="/pmc/articles/PMC6829050/bin/NIHMS1051114-supplement-Supp.pdf" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(3.5M, pdf)</sup></div></div></div><div id="S157" class="tsec sec"><h2 class="head no_bottom_margin" id="S157title">Acknowledgments</h2><div class="sec"><p id="P172">This work us supported by the National Institutes of Health under Award Numbers (AI083146) to K.S.A., and (GM32136) to W.L.J. and Training Grant (5T32AI007404&#x02013;23) to D.J.C. This work is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences (NIGMS) from the NIH [P41 GM103403]. Crystals screening was conducted with supports in the Yale Macromolecular X-ray Core Facility [1S10OD018007&#x02013;01]. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02&#x02013;06CH11357. This research used FMX beamline of the National Synchrotron Light Source II, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Brookhaven National Laboratory under Contract No. DE-SC0012704. The Life Science Biomedical Technology Research resource is primarily supported by the NIH, NIGMS through a Biomedical Technology Research Resource P41 grant (P41 GM111244), and by the DOE Office of Biological and Environmental Research (KP1605010).</p></div></div><div id="ref-list-a.ae.b" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.ae.btitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">[1] <span class="mixed-citation">Checkley W, White AC Jr., Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, Fayer R, Griffiths JK, Guerrant RL, Hedstrom L, Huston CD, Kotloff KL, Kang G, Mead JR, Miller M, Petri WA Jr., Priest JW, Roos DS, Striepen B, Thompson RC, Ward HD, Van Voorhis WA, Xiao L, Zhu G, Houpt ER, <span class="ref-title">A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium</span>, <span class="ref-journal">Lancet Infect Dis</span>, <span class="ref-vol">15</span> (2015) 85&#x02013;94. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4401121/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25278220" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Infect+Dis&amp;title=A+review+of+the+global+burden,+novel+diagnostics,+therapeutics,+and+vaccine+targets+for+cryptosporidium&amp;author=W+Checkley&amp;author=AC+White&amp;author=D+Jaganath&amp;author=MJ+Arrowood&amp;author=RM+Chalmers&amp;volume=15&amp;publication_year=2015&amp;pages=85-94&amp;pmid=25278220&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">[2] <span class="mixed-citation">Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acacio S, Biswas K, O&#x02019;Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM, <span class="ref-title">Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study</span>, <span class="ref-journal">Lancet</span>, <span class="ref-vol">382</span> (2013) 209&#x02013;222. [<a href="https://pubmed.ncbi.nlm.nih.gov/23680352" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Burden+and+aetiology+of+diarrhoeal+disease+in+infants+and+young+children+in+developing+countries+(the+Global+Enteric+Multicenter+Study,+GEMS):+a+prospective,+case-control+study&amp;author=KL+Kotloff&amp;author=JP+Nataro&amp;author=WC+Blackwelder&amp;author=D+Nasrin&amp;author=TH+Farag&amp;volume=382&amp;publication_year=2013&amp;pages=209-222&amp;pmid=23680352&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">[3] <span class="mixed-citation">Miller CN, Panagos CG, Mosedale WRT, Kvac M, Howard MJ, Tsaousis AD, <span class="ref-title">NMR metabolomics reveals effects of Cryptosporidium infections on host cell metabolome</span>, <span class="ref-journal">Gut Pathog</span>, <span class="ref-vol">11</span> (2019) 13. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6446323/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30984292" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gut+Pathog&amp;title=NMR+metabolomics+reveals+effects+of+Cryptosporidium+infections+on+host+cell+metabolome&amp;author=CN+Miller&amp;author=CG+Panagos&amp;author=WRT+Mosedale&amp;author=M+Kvac&amp;author=MJ+Howard&amp;volume=11&amp;publication_year=2019&amp;pages=13&amp;pmid=30984292&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">[4] <span class="mixed-citation">Kissinger JC, <span class="ref-title">Evolution of Cryptosporidium</span>, <span class="ref-journal">Nat Microbiol</span>, <span class="ref-vol">4</span> (2019) 730&#x02013;731. [<a href="https://pubmed.ncbi.nlm.nih.gov/31015741" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Microbiol&amp;title=Evolution+of+Cryptosporidium&amp;author=JC+Kissinger&amp;volume=4&amp;publication_year=2019&amp;pages=730-731&amp;pmid=31015741&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">[5] <span class="mixed-citation">Martucci WE, Udier-Blagovic M, Atreya C, Babatunde O, Vargo MA, Jorgensen WL, Anderson KS, <span class="ref-title">Novel non-active site inhibitor of Cryptosporidium hominis TS-DHFR identified by a virtual screen</span>, <span class="ref-journal">Bioorg Med Chem Lett</span>, <span class="ref-vol">19</span> (2009) 418&#x02013;423. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2651159/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19059777" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg+Med+Chem+Lett&amp;title=Novel+non-active+site+inhibitor+of+Cryptosporidium+hominis+TS-DHFR+identified+by+a+virtual+screen&amp;author=WE+Martucci&amp;author=M+Udier-Blagovic&amp;author=C+Atreya&amp;author=O+Babatunde&amp;author=MA+Vargo&amp;volume=19&amp;publication_year=2009&amp;pages=418-423&amp;pmid=19059777&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">[6] <span class="mixed-citation">Mazurie AJ, Alves JM, Ozaki LS, Zhou S, Schwartz DC, Buck GA, <span class="ref-title">Comparative genomics of cryptosporidium</span>, <span class="ref-journal">Int J Genomics</span>, <span class="ref-vol">2013</span> (2013) 832756. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3659464/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23738321" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Genomics&amp;title=Comparative+genomics+of+cryptosporidium&amp;author=AJ+Mazurie&amp;author=JM+Alves&amp;author=LS+Ozaki&amp;author=S+Zhou&amp;author=DC+Schwartz&amp;volume=2013&amp;publication_year=2013&amp;pages=832756&amp;pmid=23738321&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">[7] <span class="mixed-citation">Laurent F, Lacroix-Lamande S, <span class="ref-title">Innate immune responses play a key role in controlling infection of the intestinal epithelium by Cryptosporidium</span>, <span class="ref-journal">Int J Parasitol</span>, <span class="ref-vol">47</span> (2017) 711&#x02013;721. [<a href="https://pubmed.ncbi.nlm.nih.gov/28893638" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Parasitol&amp;title=Innate+immune+responses+play+a+key+role+in+controlling+infection+of+the+intestinal+epithelium+by+Cryptosporidium&amp;author=F+Laurent&amp;author=S+Lacroix-Lamande&amp;volume=47&amp;publication_year=2017&amp;pages=711-721&amp;pmid=28893638&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">[8] <span class="mixed-citation">Lee S, Ginese M, Girouard D, Beamer G, Huston CD, Osbourn D, Griggs DW, Tzipori S, <span class="ref-title">Piperazine-Derivative MMV665917: an effective drug in the diarrheic piglet model of Cryptosporidium hominis</span>, <span class="ref-journal">The Journal of infectious diseases</span>, (2019). <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7368243/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30893435" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Journal+of+infectious+diseases&amp;title=Piperazine-Derivative+MMV665917:+an+effective+drug+in+the+diarrheic+piglet+model+of+Cryptosporidium+hominis&amp;author=S+Lee&amp;author=M+Ginese&amp;author=D+Girouard&amp;author=G+Beamer&amp;author=CD+Huston&amp;publication_year=2019&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">[9] <span class="mixed-citation">Ruiz V, Czyzyk DJ, Valhondo M, Jorgensen WL, Anderson KS, <span class="ref-title">Novel allosteric covalent inhibitors of bifunctional Cryptosporidium hominis TS-DHFR from parasitic protozoa identified by virtual screening</span>, <span class="ref-journal">Bioorg Med Chem Lett</span>, <span class="ref-vol">29</span> (2019) 1413&#x02013;1418. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6624847/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30929953" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg+Med+Chem+Lett&amp;title=Novel+allosteric+covalent+inhibitors+of+bifunctional+Cryptosporidium+hominis+TS-DHFR+from+parasitic+protozoa+identified+by+virtual+screening&amp;author=V+Ruiz&amp;author=DJ+Czyzyk&amp;author=M+Valhondo&amp;author=WL+Jorgensen&amp;author=KS+Anderson&amp;volume=29&amp;publication_year=2019&amp;pages=1413-1418&amp;pmid=30929953&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">[10] <span class="mixed-citation">Borad A, Ward H, <span class="ref-title">Human immune responses in cryptosporidiosis</span>, <span class="ref-journal">Future Microbiol</span>, <span class="ref-vol">5</span> (2010) 507&#x02013;519. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2856646/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20210556" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Future+Microbiol&amp;title=Human+immune+responses+in+cryptosporidiosis&amp;author=A+Borad&amp;author=H+Ward&amp;volume=5&amp;publication_year=2010&amp;pages=507-519&amp;pmid=20210556&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">[11] <span class="mixed-citation">Martucci WE, Vargo MA, Anderson KS, <span class="ref-title">Explaining an unusually fast parasitic enzyme: folate tail-binding residues dictate substrate positioning and catalysis in Cryptosporidium hominis thymidylate synthase</span>, <span class="ref-journal">Biochemistry</span>, <span class="ref-vol">47</span> (2008) 8902&#x02013;8911. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2613286/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18672899" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Explaining+an+unusually+fast+parasitic+enzyme:+folate+tail-binding+residues+dictate+substrate+positioning+and+catalysis+in+Cryptosporidium+hominis+thymidylate+synthase&amp;author=WE+Martucci&amp;author=MA+Vargo&amp;author=KS+Anderson&amp;volume=47&amp;publication_year=2008&amp;pages=8902-8911&amp;pmid=18672899&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">[12] <span class="mixed-citation">Kumar VP, Cisneros JA, Frey KM, Castellanos-Gonzalez A, Wang Y, Gangjee A, White AC Jr., Jorgensen WL, Anderson KS, <span class="ref-title">Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase</span>, <span class="ref-journal">Bioorg Med Chem Lett</span>, <span class="ref-vol">24</span> (2014) 4158&#x02013;4161. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4427026/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25127103" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg+Med+Chem+Lett&amp;title=Structural+studies+provide+clues+for+analog+design+of+specific+inhibitors+of+Cryptosporidium+hominis+thymidylate+synthase-dihydrofolate+reductase&amp;author=VP+Kumar&amp;author=JA+Cisneros&amp;author=KM+Frey&amp;author=A+Castellanos-Gonzalez&amp;author=Y+Wang&amp;volume=24&amp;publication_year=2014&amp;pages=4158-4161&amp;pmid=25127103&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">[13] <span class="mixed-citation">Atreya CE, Anderson KS, <span class="ref-title">Kinetic characterization of bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) from Cryptosporidium hominis: a paradigm shift for ts activity and channeling behavior</span>, <span class="ref-journal">J Biol Chem</span>, <span class="ref-vol">279</span> (2004) 18314&#x02013;18322. [<a href="https://pubmed.ncbi.nlm.nih.gov/14966126" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Kinetic+characterization+of+bifunctional+thymidylate+synthase-dihydrofolate+reductase+(TS-DHFR)+from+Cryptosporidium+hominis:+a+paradigm+shift+for+ts+activity+and+channeling+behavior&amp;author=CE+Atreya&amp;author=KS+Anderson&amp;volume=279&amp;publication_year=2004&amp;pages=18314-18322&amp;pmid=14966126&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">[14] <span class="mixed-citation">Martucci WE, Rodriguez JM, Vargo MA, Marr M, Hamilton AD, Anderson KS, <span class="ref-title">Exploring novel strategies for AIDS protozoal pathogens: alpha-helix mimetics targeting a key allosteric protein-protein interaction in C. hominis TS-DHFR</span>, <span class="ref-journal">Medchemcomm</span>, <span class="ref-vol">4</span> (2013). <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3855065/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24324854" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Medchemcomm&amp;title=Exploring+novel+strategies+for+AIDS+protozoal+pathogens:+alpha-helix+mimetics+targeting+a+key+allosteric+protein-protein+interaction+in+C.+hominis+TS-DHFR&amp;author=WE+Martucci&amp;author=JM+Rodriguez&amp;author=MA+Vargo&amp;author=M+Marr&amp;author=AD+Hamilton&amp;volume=4&amp;publication_year=2013&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">[15] <span class="mixed-citation">Yuthavong Y, Kamchonwongpaisan S, Leartsakulpanich U, Chitnumsub P, <span class="ref-title">Folate metabolism as a source of molecular targets for antimalarials</span>, <span class="ref-journal">Future Microbiology</span>, <span class="ref-vol">1</span> (2006) 113&#x02013;125. [<a href="https://pubmed.ncbi.nlm.nih.gov/17661690" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Future+Microbiology&amp;title=Folate+metabolism+as+a+source+of+molecular+targets+for+antimalarials&amp;author=Y+Yuthavong&amp;author=S+Kamchonwongpaisan&amp;author=U+Leartsakulpanich&amp;author=P+Chitnumsub&amp;volume=1&amp;publication_year=2006&amp;pages=113-125&amp;pmid=17661690&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">[16] <span class="mixed-citation">Kumar VP, Frey KM, Wang Y, Jain HK, Gangjee A, Anderson KS, <span class="ref-title">Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors</span>, <span class="ref-journal">Bioorg Med Chem Lett</span>, <span class="ref-vol">23</span> (2013) 5426&#x02013;5428. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3853131/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23927969" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg+Med+Chem+Lett&amp;title=Substituted+pyrrolo[2,3-d]pyrimidines+as+Cryptosporidium+hominis+thymidylate+synthase+inhibitors&amp;author=VP+Kumar&amp;author=KM+Frey&amp;author=Y+Wang&amp;author=HK+Jain&amp;author=A+Gangjee&amp;volume=23&amp;publication_year=2013&amp;pages=5426-5428&amp;pmid=23927969&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">[17] <span class="mixed-citation">Carreras CW, Santi DV, <span class="ref-title">The catalytic mechanism and structure of thymidylate synthase</span>, <span class="ref-journal">Annu Rev Biochem</span>, <span class="ref-vol">64</span> (1995) 721&#x02013;762. [<a href="https://pubmed.ncbi.nlm.nih.gov/7574499" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annu+Rev+Biochem&amp;title=The+catalytic+mechanism+and+structure+of+thymidylate+synthase&amp;author=CW+Carreras&amp;author=DV+Santi&amp;volume=64&amp;publication_year=1995&amp;pages=721-762&amp;pmid=7574499&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">[18] <span class="mixed-citation">Benkovic SJ, Hammes-Schiffer S, <span class="ref-title">A perspective on enzyme catalysis</span>, <span class="ref-journal">Science</span>, <span class="ref-vol">301</span> (2003) 1196&#x02013;1202. [<a href="https://pubmed.ncbi.nlm.nih.gov/12947189" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=A+perspective+on+enzyme+catalysis&amp;author=SJ+Benkovic&amp;author=S+Hammes-Schiffer&amp;volume=301&amp;publication_year=2003&amp;pages=1196-1202&amp;pmid=12947189&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">[19] <span class="mixed-citation">Czyzyk DJ, Valhondo M, Jorgensen WL, Anderson KS, <span class="ref-title">Understanding the Structural Basis of Species Selective, Stereospecific Inhibition for Cryptosporidium and Human Thymidylate Synthase</span>, <span class="ref-journal">FEBS Lett</span>, (2019). <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6690774/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31172516" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FEBS+Lett&amp;title=Understanding+the+Structural+Basis+of+Species+Selective,+Stereospecific+Inhibition+for+Cryptosporidium+and+Human+Thymidylate+Synthase&amp;author=DJ+Czyzyk&amp;author=M+Valhondo&amp;author=WL+Jorgensen&amp;author=KS+Anderson&amp;publication_year=2019&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">[20] <span class="mixed-citation">Doan LT, Martucci WE, Vargo MA, Atreya CE, Anderson KS, <span class="ref-title">Nonconserved residues Ala287 and Ser290 of the Cryptosporidium hominis thymidylate synthase domain facilitate its rapid rate of catalysis</span>, <span class="ref-journal">Biochemistry</span>, <span class="ref-vol">46</span> (2007) 8379&#x02013;8391. [<a href="https://pubmed.ncbi.nlm.nih.gov/17580969" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Nonconserved+residues+Ala287+and+Ser290+of+the+Cryptosporidium+hominis+thymidylate+synthase+domain+facilitate+its+rapid+rate+of+catalysis&amp;author=LT+Doan&amp;author=WE+Martucci&amp;author=MA+Vargo&amp;author=CE+Atreya&amp;author=KS+Anderson&amp;volume=46&amp;publication_year=2007&amp;pages=8379-8391&amp;pmid=17580969&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">[21] <span class="mixed-citation">Aso K, Imai Y, Yukishige K, Ootsu K, Akimoto H, <span class="ref-title">Pyrrolo[2,3-d]pyrimidine thymidylate synthase inhibitors: design and synthesis of one-carbon bridge derivatives</span>, <span class="ref-journal">Chem Pharm Bull (Tokyo)</span>, <span class="ref-vol">49</span> (2001) 1280&#x02013;1287. [<a href="https://pubmed.ncbi.nlm.nih.gov/11605654" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Chem+Pharm+Bull+(Tokyo)&amp;title=Pyrrolo[2,3-d]pyrimidine+thymidylate+synthase+inhibitors:+design+and+synthesis+of+one-carbon+bridge+derivatives&amp;author=K+Aso&amp;author=Y+Imai&amp;author=K+Yukishige&amp;author=K+Ootsu&amp;author=H+Akimoto&amp;volume=49&amp;publication_year=2001&amp;pages=1280-1287&amp;pmid=11605654&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">[22] <span class="mixed-citation">Dahlgren MK, Schyman P, Tirado-Rives J, Jorgensen WL, <span class="ref-title">Characterization of biaryl torsional energetics and its treatment in OPLS all-atom force fields</span>, <span class="ref-journal">J Chem Inf Model</span>, <span class="ref-vol">53</span> (2013) 1191&#x02013;1199. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3707137/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23621692" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Chem+Inf+Model&amp;title=Characterization+of+biaryl+torsional+energetics+and+its+treatment+in+OPLS+all-atom+force+fields&amp;author=MK+Dahlgren&amp;author=P+Schyman&amp;author=J+Tirado-Rives&amp;author=WL+Jorgensen&amp;volume=53&amp;publication_year=2013&amp;pages=1191-1199&amp;pmid=23621692&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">[23] <span class="mixed-citation">Zhang G, Liu C, Yi H, Meng Q, Bian C, Chen H, Jian JX, Wu LZ, Lei A, <span class="ref-title">External Oxidant-Free Oxidative Cross-Coupling: A Photoredox Cobalt-Catalyzed Aromatic C-H Thiolation for Constructing C-S Bonds</span>, <span class="ref-journal">J Am Chem Soc</span>, <span class="ref-vol">137</span> (2015) 9273&#x02013;9280. [<a href="https://pubmed.ncbi.nlm.nih.gov/26158688" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Am+Chem+Soc&amp;title=External+Oxidant-Free+Oxidative+Cross-Coupling:+A+Photoredox+Cobalt-Catalyzed+Aromatic+C-H+Thiolation+for+Constructing+C-S+Bonds&amp;author=G+Zhang&amp;author=C+Liu&amp;author=H+Yi&amp;author=Q+Meng&amp;author=C+Bian&amp;volume=137&amp;publication_year=2015&amp;pages=9273-9280&amp;pmid=26158688&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">[24] <span class="mixed-citation">Kim R, Kuduk SD, Liverton N, Zhuo G, <span class="ref-title">N-Heteroarylethyldiamines as orexin receptor antagonists and their preparation</span>, in, <span class="ref-journal">Merck Sharp &#x00026; Dohme Corp., USA</span>. 2016, pp. 116pp. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Merck+Sharp+&#x00026;+Dohme+Corp.,+USA&amp;title=N-Heteroarylethyldiamines+as+orexin+receptor+antagonists+and+their+preparation&amp;author=R+Kim&amp;author=SD+Kuduk&amp;author=N+Liverton&amp;author=G+Zhuo&amp;publication_year=2016&amp;pages=116pp&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">[25] <span class="mixed-citation">Demmer CS, Rombach D, Liu N, Nielsen B, Pickering DS, Bunch L, <span class="ref-title">Revisiting the Quinoxalinedione Scaffold in the Construction of New Ligands for the Ionotropic Glutamate Receptors</span>, <span class="ref-journal">ACS Chem. Neurosci</span>, <span class="ref-vol">8</span> (2017) 2477&#x02013;2495. [<a href="https://pubmed.ncbi.nlm.nih.gov/28872835" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=ACS+Chem.+Neurosci&amp;title=Revisiting+the+Quinoxalinedione+Scaffold+in+the+Construction+of+New+Ligands+for+the+Ionotropic+Glutamate+Receptors&amp;author=CS+Demmer&amp;author=D+Rombach&amp;author=N+Liu&amp;author=B+Nielsen&amp;author=DS+Pickering&amp;volume=8&amp;publication_year=2017&amp;pages=2477-2495&amp;pmid=28872835&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">[26] <span class="mixed-citation">Pedersen-Lane J, Maley GF, Chu E, Maley F, <span class="ref-title">High-level expression of human thymidylate synthase</span>, <span class="ref-journal">Protein Expr Purif</span>, <span class="ref-vol">10</span> (1997) 256&#x02013;262. [<a href="https://pubmed.ncbi.nlm.nih.gov/9226722" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Protein+Expr+Purif&amp;title=High-level+expression+of+human+thymidylate+synthase&amp;author=J+Pedersen-Lane&amp;author=GF+Maley&amp;author=E+Chu&amp;author=F+Maley&amp;volume=10&amp;publication_year=1997&amp;pages=256-262&amp;pmid=9226722&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">[27] <span class="mixed-citation">Kabsch W, <span class="ref-journal">Xds, Acta Crystallogr D Biol Crystallogr</span>, <span class="ref-vol">66</span> (2010) 125&#x02013;132. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2815665/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20124692" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Xds,+Acta+Crystallogr+D+Biol+Crystallogr&amp;author=W+Kabsch&amp;volume=66&amp;publication_year=2010&amp;pages=125-132&amp;pmid=20124692&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">[28] <span class="mixed-citation">McCoy AJ, <span class="ref-title">Solving structures of protein complexes by molecular replacement with Phaser</span>, <span class="ref-journal">Acta Crystallogr D Biol Crystallogr</span>, <span class="ref-vol">63</span> (2007) 32&#x02013;41. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2483468/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17164524" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acta+Crystallogr+D+Biol+Crystallogr&amp;title=Solving+structures+of+protein+complexes+by+molecular+replacement+with+Phaser&amp;author=AJ+McCoy&amp;volume=63&amp;publication_year=2007&amp;pages=32-41&amp;pmid=17164524&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">[29] <span class="mixed-citation">McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ, Phaser crystallographic software J
<span class="ref-journal">Appl Crystallogr</span>, <span class="ref-vol">40</span> (2007) 658&#x02013;674. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2483472/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19461840" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Appl+Crystallogr&amp;author=AJ+McCoy&amp;author=RW+Grosse-Kunstleve&amp;author=PD+Adams&amp;author=MD+Winn&amp;author=LC+Storoni&amp;volume=40&amp;publication_year=2007&amp;pages=658-674&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">[30] <span class="mixed-citation">Emsley P, Cowtan K, <span class="ref-title">Coot: model-building tools for molecular graphics</span>, <span class="ref-journal">Acta Crystallogr D Biol Crystallogr</span>, <span class="ref-vol">60</span> (2004) 2126&#x02013;2132. [<a href="https://pubmed.ncbi.nlm.nih.gov/15572765" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acta+Crystallogr+D+Biol+Crystallogr&amp;title=Coot:+model-building+tools+for+molecular+graphics&amp;author=P+Emsley&amp;author=K+Cowtan&amp;volume=60&amp;publication_year=2004&amp;pages=2126-2132&amp;pmid=15572765&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">[31] <span class="mixed-citation">Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH, <span class="ref-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>, <span class="ref-journal">Acta Crystallogr D Biol Crystallogr</span>, <span class="ref-vol">66</span> (2010) 213&#x02013;221. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2815670/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20124702" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acta+Crystallogr+D+Biol+Crystallogr&amp;title=PHENIX:+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&amp;author=PD+Adams&amp;author=PV+Afonine&amp;author=G+Bunkoczi&amp;author=VB+Chen&amp;author=IW+Davis&amp;volume=66&amp;publication_year=2010&amp;pages=213-221&amp;pmid=20124702&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">[32] <span class="mixed-citation">Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Moriarty NW, Adams PD, Read RJ, Zwart PH, Hung LW, <span class="ref-title">Iterative-build OMIT maps: map improvement by iterative model building and refinement without model bias</span>, <span class="ref-journal">Acta Crystallogr D Biol Crystallogr</span>, <span class="ref-vol">64</span> (2008) 515&#x02013;524. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2424225/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18453687" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acta+Crystallogr+D+Biol+Crystallogr&amp;title=Iterative-build+OMIT+maps:+map+improvement+by+iterative+model+building+and+refinement+without+model+bias&amp;author=TC+Terwilliger&amp;author=RW+Grosse-Kunstleve&amp;author=PV+Afonine&amp;author=NW+Moriarty&amp;author=PD+Adams&amp;volume=64&amp;publication_year=2008&amp;pages=515-524&amp;pmid=18453687&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">[33] <span class="mixed-citation">Lee WG, Gallardo-Macias R, Frey KM, Spasov KA, Bollini M, Anderson KS, Jorgensen WL, <span class="ref-title">Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group</span>, <span class="ref-journal">J Am Chem Soc</span>, <span class="ref-vol">135</span> (2013) 16705&#x02013;16713. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3877923/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24151856" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Am+Chem+Soc&amp;title=Picomolar+inhibitors+of+HIV+reverse+transcriptase+featuring+bicyclic+replacement+of+a+cyanovinylphenyl+group&amp;author=WG+Lee&amp;author=R+Gallardo-Macias&amp;author=KM+Frey&amp;author=KA+Spasov&amp;author=M+Bollini&amp;volume=135&amp;publication_year=2013&amp;pages=16705-16713&amp;pmid=24151856&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">[34] <span class="mixed-citation">Bollini M, Domaoal RA, Thakur VV, Gallardo-Macias R, Spasov KA, Anderson KS, Jorgensen WL, <span class="ref-title">Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents</span>, <span class="ref-journal">J Med Chem</span>, <span class="ref-vol">54</span> (2011) 8582&#x02013;8591. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3258498/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22081993" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;title=Computationally-guided+optimization+of+a+docking+hit+to+yield+catechol+diethers+as+potent+anti-HIV+agents&amp;author=M+Bollini&amp;author=RA+Domaoal&amp;author=VV+Thakur&amp;author=R+Gallardo-Macias&amp;author=KA+Spasov&amp;volume=54&amp;publication_year=2011&amp;pages=8582-8591&amp;pmid=22081993&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">[35] <span class="mixed-citation">Jorgensen WL, Bollini M, Thakur VV, Domaoal RA, Spasov KA, Anderson KS, <span class="ref-title">Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase</span>, <span class="ref-journal">J Am Chem Soc</span>, <span class="ref-vol">133</span> (2011) 15686&#x02013;15696. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3183387/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21853995" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Am+Chem+Soc&amp;title=Efficient+discovery+of+potent+anti-HIV+agents+targeting+the+Tyr181Cys+variant+of+HIV+reverse+transcriptase&amp;author=WL+Jorgensen&amp;author=M+Bollini&amp;author=VV+Thakur&amp;author=RA+Domaoal&amp;author=KA+Spasov&amp;volume=133&amp;publication_year=2011&amp;pages=15686-15696&amp;pmid=21853995&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">[36] <span class="mixed-citation">Jorgensen WL, <span class="ref-title">Efficient drug lead discovery and optimization</span>, <span class="ref-journal">Acc Chem Res</span>, <span class="ref-vol">42</span> (2009) 724&#x02013;733. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2727934/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19317443" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acc+Chem+Res&amp;title=Efficient+drug+lead+discovery+and+optimization&amp;author=WL+Jorgensen&amp;volume=42&amp;publication_year=2009&amp;pages=724-733&amp;pmid=19317443&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">[37] <span class="mixed-citation">Jorgensen WL, Tirado-Rives J, <span class="ref-title">Molecular modeling of organic and biomolecular systems using BOSS and MCPRO</span>, <span class="ref-journal">J Comput Chem</span>, <span class="ref-vol">26</span> (2005) 1689&#x02013;1700. [<a href="https://pubmed.ncbi.nlm.nih.gov/16200637" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Comput+Chem&amp;title=Molecular+modeling+of+organic+and+biomolecular+systems+using+BOSS+and+MCPRO&amp;author=WL+Jorgensen&amp;author=J+Tirado-Rives&amp;volume=26&amp;publication_year=2005&amp;pages=1689-1700&amp;pmid=16200637&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">[38] <span class="mixed-citation">Jorgensen WL, Maxwell DS, TiradoRives J, <span class="ref-title">Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids</span>, <span class="ref-journal">Journal of the American Chemical Society</span>, <span class="ref-vol">118</span> (1996) 11225&#x02013;11236. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+the+American+Chemical+Society&amp;title=Development+and+testing+of+the+OPLS+all-atom+force+field+on+conformational+energetics+and+properties+of+organic+liquids&amp;author=WL+Jorgensen&amp;author=DS+Maxwell&amp;author=J+TiradoRives&amp;volume=118&amp;publication_year=1996&amp;pages=11225-11236&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">[39] <span class="mixed-citation">Jorgensen WL, Tirado-Rives J, <span class="ref-title">Potential energy functions for atomic-level simulations of water and organic and biomolecular systems</span>, <span class="ref-journal">Proc Natl Acad Sci U S A</span>, <span class="ref-vol">102</span> (2005) 6665&#x02013;6670. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1100738/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15870211" ref="reftype=pubmed&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Potential+energy+functions+for+atomic-level+simulations+of+water+and+organic+and+biomolecular+systems&amp;author=WL+Jorgensen&amp;author=J+Tirado-Rives&amp;volume=102&amp;publication_year=2005&amp;pages=6665-6670&amp;pmid=15870211&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">[40] <span class="mixed-citation">Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, <span class="ref-title">Comparison of Simple Potential Functions for Simulating Liquid Water</span>, <span class="ref-journal">J Chem Phys</span>, <span class="ref-vol">79</span> (1983) 926&#x02013;935. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Chem+Phys&amp;title=Comparison+of+Simple+Potential+Functions+for+Simulating+Liquid+Water&amp;author=WL+Jorgensen&amp;author=J+Chandrasekhar&amp;author=JD+Madura&amp;author=RW+Impey&amp;author=ML+Klein&amp;volume=79&amp;publication_year=1983&amp;pages=926-935&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=6829050&amp;issue-id=344982&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC6829050/pdf/nihms-1051114.pdf" class="int-view">PDF (3.3M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/6829050/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/6829050/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="6829050" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6829050%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="5THP198bdnnoCitBIC56tRGDRe3AuE3nHxs3ENclSebpM8CkBA8RTiAAqIUHtaYm">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6829050%2F&amp;text=Structure%20Activity%20Relationship%20Towards%20Design%20of%20Cryptosporidium%20Specific%20Thymidylate%20Synthase%20Inhibitors" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6829050%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829050/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC6829050/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/31536894/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC6829050/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/31536894/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC6829050/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/6829050/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC6829050/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
